



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/00	A2	(11) International Publication Number: WO 98/58953	(43) International Publication Date: 30 December 1998 (30.12.98)
(21) International Application Number: PCT/DK98/00266 (22) International Filing Date: 19 June 1998 (19.06.98) (30) Priority Data: 0744/97 23 June 1997 (23.06.97) DK (71)(72) Applicants and Inventors: BIRKELUND, Svend [DK/DK]; Søjtoften 26, DK-8250 Egå (DK). CHRIS- TIANSEN, Gunna [DK/DK]; Søjtoften 26, DK-8250 Egå (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): KNUDSEN, Katrine [DK/DK]; Lundingsgade 33, Lejlighed 407, DK-8000 Århus C (DK). MADSEN, Anna-Sofie [DK/DK]; Ramsh- erred 51 b, 1.tv., DK-6200 Aabenraa (DK). MYGIND, Per [DK/DK]; Falstersgade 5, 3.tv., DK-8000 Århus C (DK). (74) Agent: PLOUGMANN, VINGTOFT & PARTNERS A/S; Sankt Annæ Plads 11, P.O. Box 3007, DK-1021 Copen- hagen K (DK).		(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI- patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published Without international search report and to be republished upon receipt of that report.	
(54) Title: NOVEL SURFACE EXPOSED PROTEINS FROM CHLAMYDIA PNEUMONIAE			
(57) Abstract			
<p>The invention relates to the identification of members of a gene family from the human respiratory pathogen <i>Chlamydia pneumoniae</i>, encoding surface exposed membrane proteins of a size of approximately 89–101 kDa and of 56–57 kDa, preferably about 89.6–100.3 kDa and about 56.1 kDa. The invention relates to the novel DNA sequences, the deduced amino acid sequences of the corresponding proteins and the use of the DNA sequences and the proteins in diagnosis of infections caused by <i>C. pneumoniae</i>, in pathology, in epidemiology, and as vaccine components.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NOVEL SURFACE EXPOSED PROTEINS FROM CHLAMYDIA PNEUMONIAE

The present invention relates to the identification of members of a gene family from the human respiratory pathogen *Chlamydia pneumoniae*, encoding surface exposed membrane proteins of a size of approximately 89-101 kDa and of 56-57 kDa, preferably about 89.6-100.3 kDa and about 56.1 kDa. The invention relates to the novel DNA sequences, the deduced amino acid sequences of the corresponding proteins and the use of the DNA sequences and the proteins in diagnosis of infections caused by *C. pneumoniae*, in pathology, in epidemiology, and as vaccine components.

GENERAL BACKGROUND

C. pneumoniae is an obligate intracellular bacteria (Christiansen and Birkelund (1992); Grayston et al. (1986)). It has a cell wall structure as Gram negative bacteria with an outer membrane, a periplasmic space, and a cytoplasmic membrane. It is possible to purify the outer membrane from Gram negative bacteria with the detergent sarkosyl. This fraction is named the 'outer membrane complex (OMC)' (Caldwell et al. (1981)). The COMC (*Chlamydia* outer membrane complex) of *C. pneumoniae* contains four groups of proteins: A high molecular weight protein 98 kDa as determined by SDS-PAGE, a double band of the cysteine rich outer membrane protein 2 (Omp2) protein of 62/60 kDa, the major outer membrane protein (MOMP) of 38 kDa, and the low-molecular weight lipo-protein Omp3 of 12 kDa. The Omp2/Omp3 and MOMP proteins are present in COMC from all *Chlamydia* species, and these genes have been cloned from both *C. trachomatis*, *C. psittaci* and *C. pneumoniae*. However, the gene encoding 98 kDa protein from *C. pneumoniae* COMC have not been characterized or cloned.

The current state of *C. pneumoniae* serology and detection

C. pneumoniae is an obligate intra-cellular bacteria belonging to the genus *Chlamydia* which can be divided into

four species: *C. trachomatis*, *C. pneumoniae*, *C. psittaci* and *C. pecorum*. Common for the four species is their obligate intra cellular growth, and that they have a biphasic life cycle, with an extracellular infectious particle (the elementary body, EB), and an intercellular replicating form (the reticulate body, RB). In addition the Chlamydia species are characterized by a common lipopolysaccharide (LPS) epitope that is highly immunogenic in human infection. *C. trachomatis* is causing the human ocular infection (trachoma) and genital infections. *C. psittaci* is a variable group of animal pathogens where the avian strains can occasionally infect humans and give rise to a severe pneumonia (ornithosis). The first *C. pneumoniae* isolate was obtained from an eye infection, but it was classified as a non-typable Chlamydia. Under an epidemic outbreak of pneumonia in Finland it was realized that the patients had a positive reaction in the Chlamydia genus specific test, (the lygranum test), and the patients showed a titre increase to the untyped Chlamydia isolates. Similar isolates were obtained in an outbreak of upper respiratory tract infections in Seattle, and the Chlamydia isolates were classified as a new species, *Chlamydia pneumoniae* (Grayston et al. (1989)). In addition, *C. pneumoniae* is suggested to be involved in the development of atherosclerotic lesions and for initiating bronchial asthma (Kuo et al. (1995)). These two conditions are thought to be caused by either chronic infections, by a hypersensitivity reaction, or both.

Diagnosis of *Chlamydia pneumoniae* infections

Diagnosis of acute respiratory tract infection with *C. pneumoniae* is difficult. Cultivation of *C. pneumoniae* from patient samples is insensitive, even when proper tissue culture cells are selected for the isolation. A *C. pneumoniae* specific polymerase chain reaction (PCR) has been developed by Campbell et al. (1992).

Even though *Chlamydia pneumoniae* has in several studies been detected by this PCR it is debated whether this method is suitable for detection under all clinical situations. The reason for this is, that the cells carrying *Chlamydia pneumoniae* in acute respiratory infections have not been determined, and that a chronic carrier state is expected but it is unknown in which organs and cells they are present. Furthermore, the PCR test is difficult to perform due to the low yield of these bacteria and due to the presence of inhibitory substances in the patient samples. Therefore, it will be of great value to develop sensitive and specific sero-diagnostics for detecting both acute and chronic infections. Sero-diagnosis of *Chlamydia* infections is currently based on either genus specific tests as the Lygranum test and ELISA, measuring the antibodies to LPS, or the more species specific tests where antibodies to purified EBs are measured by microimmuno fluorescence (Micro-IF) (Wang et al. (1970)). However, the micro-IF method is read by microscopy, and in order to ensure correct readings the result must be compared to the results with *C. trachomatis* used as antigen due to the cross-reacting antibodies to the common LPS epitope. Thus, there exists in the art an urgent need for development of reliable methods for species specific diagnosis of *Chlamydia pneumoniae*, as has been expressed in Kuo et al. (1995); "...a rapid reliable laboratory test of infection for the clinical laboratory is a major need in the field". Furthermore, the possible involvement of *C. pneumoniae* in atherosclerosis and bronchial asthma clearly warrants the development of an effective vaccine.

DETAILED DISCLOSURE OF THE INVENTION

The present invention aims at providing means for efficient diagnosis of infections with *Chlamydia pneumoniae* as well as the development of effective vaccines against infection with this microorganism. The invention thus relates to species specific diagnostic tests for infection in a mammal, such as a human, with *Chlamydia pneumoniae*, said tests being based on

the detection of antibodies against surface exposed membrane proteins of a size of approximately 89-101 kDa and of 56-57 kDa, preferably of about 89.6-100.3 kDa and about 56.1 kDa (the range in size of the deduced amino acid sequences was from 100.3 to 89.6 except for Omp13 with the size of 56.1 kDa), or the detection of nucleic acid fragments encoding such proteins or variants or subsequences thereof. The invention further relates to the amino acid sequences of proteins according to the invention, to variants and subsequences thereof, and to nucleic acid fragments encoding these proteins or variants or subsequences thereof. The present invention further relates to antibodies against proteins according to the invention. The invention also relates to the use of nucleic acid fragments and proteins according to the invention in diagnosis of *Chlamydia pneumoniae* and vaccines against *Chlamydia pneumoniae*.

Prior to the disclosure of the present invention only a very limited number of genes from *C. pneumoniae* had been sequenced. These were primarily the genes encoding known *C. trachomatis* homologues: MOMP, Omp2, Omp3, Kdo-transferase, the heat shock protein genes GroEl/Es and DnaK, a ribonuclease P homologue and a gene encoding a 76 kDa protein of unknown function. The reason why so few genes have been cloned to date is the very low yield of *C. pneumoniae* which can be obtained after purification from the host cells. After such purification the DNA must be purified from the EBs, and at this step the *C. pneumoniae* DNA can easily be contaminated with host cell DNA. In addition to these inherent difficulties, it is exceedingly difficult to cultivate *C. pneumoniae* and use DNA technology to produce expression libraries with very low amounts (few μ g) of DNA. It has been known since 1993 (Melgosa et al., 1993) that a 98 kDa protein is present in OMC from *C. pneumoniae*. Even though the protein bands of 98 kDa was mentioned to be part of the OMC of *C. pneumoniae* by Melgosa, the gene sequences and thus the deduced amino acid sequences have not been determined. Only

bands originating from *Chlamydia pneumoniae* proteins in general separated by SDS-PAGE are describe therein. However, the gene encoding this protein has not been determined before the present invention. Only a very weak or no reaction with patient sera can be observed to the 98 kDa protein (Campbell et al. 1990) and prior to the work of the present inventors it has not been recognized that the 89-101 kDa proteins are surface exposed or that they in fact is immunogenic. In this report it is described that a number of human serum samples reacts with a *C. pneumoniae* protein that in SDS-PAGE migrate as 98 kDa. The protein was not further characterized and it is therefore not in conflict with the present application.

Halme et al. (1997) described the presence of human T-cell epitopes in *C. pneumoniae* proteins of 92-98 kDa. The proteins were eluted from SDS-PAGE of total chlamydia proteins but the identity of the proteins were not determined.

Use of antibodies to screen expression libraries is a well known method to clone fragments of genes encoding antigenic parts of proteins. However, since patient sera do not show a significant reaction with the 98 kDa protein it has not been possible to use patient serum to clone the proteins.

It was known that monoclonal antibodies generated by the inventors reacted with conformational epitopes on the surface of *C. pneumoniae* and that they also reacted with *C. pneumoniae* OMC by immuno-electron microscopy (Christiansen et al. 1994). Furthermore, the 98 kDa protein is the only unknown protein from the *C. pneumoniae* OMC (Melgosa et al. 1993). The present inventors chose to take an unconventional step in order to clone the gene encoding the hitherto unknown 98 kDa protein: *C. pneumoniae* OMC was purified and the highly immunogenic conformational epitopes were destroyed by SDS-treatment of the antigen before immunization. Thereby an antibody (PAB 150) to less immunogenic linear epitopes was obtained. This provided the possibility to obtain an

antiserum which could detect the protein, and it was shown that a gene family encoding the 89-101 kDa and 56 proteins according to the invention could be detected in colony blotting of recombinant *E. coli*.

- 5 Mice infected with *C. pneumoniae* generate antibodies to the proteins identified by the inventors and named Omp4-15, but do not recognize the SDS treated heat denatured antigens normally used for SDS-PAGE and immunoblotting. However, a strong reaction was seen if the antigen was not heat
10 denatured. It is therefore highly likely that if a similar reaction is seen in connection with human infections the antigens of the present invention will be of invaluable use in sero-diagnostic tests and may very likely be used as a vaccine for the prevention of infections.

- 15 By generating antibodies against COMC from *C. pneumoniae* a polyclonal antibody (PAB 150) was obtained which reacted with all the proteins. This antibody was used to identify the genes encoding the 89.6-101.3 kDa and 56.1 kDa proteins in an
20 expression library of *C. pneumoniae* DNA. A problem in connection with the present invention was that a family comprising a number of similar genes were found in *C. pneumoniae*. Therefore, a large number of different clones were required to identify clusters of fragments. Only because
25 the rabbit antibody generated by the use of SDS-denatured antigens contained antibodies to a high number of different epitopes positioned on different members of the protein family did the inventors succeed in cloning and sequencing four of the genes. One gene was fully sequenced, a second was
30 sequenced except for the distal part and shorter fragments of two additional genes were obtained by this procedure. To obtain the DNA sequence of the additional genes and to search for more members of the gene family long range PCR with primers derived from the sequenced genes, and primers from
35 the genes already published in the database were used. This approach gave rise to the detection of additional eight genes belonging to this family. The genes were situated in two gene

clusters: Omp12,11,10,5,4,13 and 14 in one cluster and Omp6,7,8,9 and 15 in the second. Full sequence was obtained from Omp4,5,6,7,8,9,10,11 and 13, and partial sequence of Omp12,14. Omp13 was a truncated gene of 1545 nucleotides. The
5 rest of the full length genes were from 2526 (Omp7) to 2838 (Omp15) nucleotides. The deduced amino acid sequences revealed putative polypeptides of 89.6 to 100.3 kDa, except for Omp13 of 56.1 kDa. Alignment of the deduced amino acid
10 sequences showed a maximum identity of 49% (Omp5/Omp9) when all the sequences were compared. Except for Omp13, the lowest homology was to Omp7 with no more than 34% identity to any of the other amino acid sequences. The scores for Omp13 was from 29-32% to all the other sequences.

In the present context SEQ ID Nos. 1 and 2 correspond to
15 Omp4, SEQ ID Nos 3 and 4 correspond to Omp5, SEQ ID Nos 5 and 6 correspond to Omp6, SEQ ID Nos 7 and 8 correspond to Omp7, SEQ ID Nos 9 and 10 correspond to Omp8, SEQ ID Nos 11 and 12 correspond to Omp9, SEQ ID Nos 13 and 14 corresponds to Omp10, SEQ ID Nos 15 and 16 corresponds to Omp11, SEQ ID Nos
20 17 and 18 corresponds to Omp12, SEQ ID Nos 19 and 20 corresponds to Omp13, SEQ ID Nos 21 and 22 corresponds to Omp14, and SEQ ID Nos 23 and 24 corresponds to Omp15.

The estimated size of the Omp proteins of the of the present invention are listed in the following. Omp 4 has a size of
25 98.9 kDa, Omp5 has an estimated size of 97.2 kDa, Omp6 has an estimated size of 100.3 kDa, Omp7 has an estimated size of 89.7 kDa, Omp8 has an estimated size of 90.0 kDa, Omp9 has an estimated size of 96.7 kDa, Omp10 has an estimated size of 98.4 kDa, Omp11 has an estimated size of 97.6 kDa, Omp13 has
30 an estimated size of 56.1 kDa, Omp 12 and 14 being partial.

Furthermore, SEQ ID No 25 is a subsequence of SEQ ID No 3, SEQ ID No 26 is a subsequence of SEQ ID No 4, SEQ ID No 27 is a subsequence of SEQ ID No 5, SEQ ID No 28 is a subsequence of SEQ ID No 6, SEQ ID No 29 is a subsequence of SEQ ID No 7,
35 and SEQ ID No 30 is a subsequence of SEQ ID No 8.

Part of the omp proteins were expressed as fusion proteins, and mice polyclonal monospecific antibodies against the proteins were produced. The antibodies reacted with the surface of *C. pneumoniae* in both immunofluorescence and immunoelectron microscopy. This shows for the first time that the 89-101 kDa and 56-57 kDa protein family in *C. pneumoniae* comprises surface exposed outer membrane proteins. This important finding leads to the realization that members of the 89-101 kDa and 56-57 kDa *C. pneumoniae* protein family are good candidates for the development of a sero diagnostic test for *C. pneumoniae*, as well as the development of a vaccine against infections with *C. pneumoniae* based on using these proteins. Furthermore, the proteins may be used as epidemiological markers, and polyclonal monospecific sera against the proteins can be used to detect *C. pneumoniae* in human tissue or detect *C. pneumoniae* isolates in tissue culture. Also, the genes encoding the 89-101 kDa and 56-57 kDa such as the 89.6-100.3 kDa and 56.1 protein family may be used for the development of a species specific diagnostic test based on nucleic acid detection/amplification.

The full length Omp4 was cloned into an expression vector system that allowed expression of the Omp4 polypeptide. This polypeptide was used as antigen for immunization of a rabbit. Since the protein was purified under denaturing condition the antibody did not react with the native surface of *C. pneumoniae*, but it reacted with a 98 kDa protein in immunoblotting where purified *C. pneumoniae* EB was used as antigen. Furthermore, the antibody reacted in paraffin embedded sections of lung tissue from experimentally infected mice.

A broad aspect of the present invention relates to a species specific diagnostic test for infection of a mammal, such as a human, with *Chlamydia pneumoniae*, said test comprising detecting in a patient or preferable in a patient sample the presence of antibodies against proteins from the outer membrane of *Chlamydia pneumoniae*, said proteins being of a

molecular weight of 89-101 kDa or 56-57 kDa, or detecting the presence of nucleic acid fragments encoding said outer membrane proteins or fragments thereof.

5 In the context of the present application, the term "patient sample" should be taken to mean an amount of serum from a patient, such as a human patient, or an amount of plasma from said patient, or an amount of mucosa from said patient, or an amount of tissue from said patient, or an amount of
10 expectorate, forced sputum or a bronchial aspirate, an amount of urine from said patient, or an amount of cerebrospinal fluid from said patient, or an amount of atherosclerotic lesion from said patient, or an amount of mucosal swaps from said patient, or an amount of cells from a tissue culture
15 originating from said patient, or an amount of material which in any way originates from said patient. The in vivo test in a human according to the present invention includes a skin test known in the art such as an intradermal test, e.g. similar to a Mantoux test. In certain patients being very
20 sensitive to the test, such as is often the case with children, the test could be non-invasive, such as a superficial test on the skin, e.g. by use of a plaster

In the present context, the term 89-101 kDa protein means proteins normally present in the outer membrane of *Chlamydia*
25 *pneumoniae*, which in SDS-PAGE can be observed as one or more bands with an apparent molecular weight substantially in the range of 89-101 kDa. From the deduced amino acid sequences the molecular size varies from 89.6 to 100.3 kDa.

Within the scope of the present invention are species
30 specific sero-diagnostic tests based on the usage of the genes belonging to the gene family disclosed in the present application.

Preferred embodiments of the present invention relate to species specific diagnostic tests according to the invention,
35 wherein the outer membrane proteins have sequences selected

from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, and SEQ ID NO: 24.

- 5 When used in connection with proteins according to the present invention the term "variant" should be understood as a sequence of amino acids which shows a sequence similarity of less than 100% to one of the proteins of the invention. A variant sequence can be of the same size or it can be of a
10 different size as the sequence it is compared to. A variant will typically show a sequence similarity of preferably at least 50%, preferably at least 60%, more preferably at least 70%, such as at least 80%, e.g. at least 90%, 95% or 98%.

- The term "sequence similarity" in connection with sequences
15 of proteins of the invention means the percentage of identical and conservatively changed amino acid residues (with respect to both position and type) in the proteins of the invention and an aligned protein of equal or different length. The term "sequence identity" in connection with
20 sequences of proteins of the invention means the percentage of identical amino acid with respect to both position and type in the proteins of the invention and an aligned protein of equal or different length.

- Within the scope of the present invention are subsequences of
25 one of the proteins of the invention, meaning a consecutive stretch of amino acid residues taken from SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22 , or SEQ ID NO: 24. A subsequence will
30 typically comprise at least 100 amino acids, preferably at least 80 amino acids, more preferably at least 70 amino acids, such as 50 amino acids. It might even be as small as 10-50 amino acids, such as 20-40 amino acids, e.g. about 30 amino acids. A subsequence will typically show a sequence
35 homology of at least 50%, preferably at least 60%, more

preferably at least 70%, such as at least 80%, e.g. at least 90%, 95% or 98%.

Diagnostic tests according to the invention include immunoassays selected from the group consisting of a direct
5 or indirect EIA such as an ELISA, an immunoblot technique such as a Western blot, a radio immuno assay, and any other non-enzyme linked antibody binding assay or procedure such as a fluorescence, agglutination or precipitation reaction, and nephelometry.

- 10 A preferred embodiment of the present invention relates to species specific diagnostic tests according to the invention, said test comprising an ELISA, wherein antibodies against the proteins of the invention or fragments thereof are detected in samples.
- 15 A preferred embodiment of the invention, is an ELISA based on detection in samples of antibodies against proteins of the invention. The ELISA may use proteins of the invention, or variants thereof, i.e. the antigen, as coating agent. An ELISA will typically be developed according to standard
20 methods well known in the art, such as methods described in "Antibodies; a laboratory manual", Ed. David Lane Harlow, Cold Spring Habor laboratories (1988), which is hereby incorporated by reference.

- Recombinant proteins will be produced using DNA sequences
25 obtained essentially using methods described in the examples below. Such DNA sequences, comprising the entire coding region of each gene in the gene family of the invention, will be cloned into an expression vector from which the deduced protein sequence can be purified. The purified proteins will
30 be analyzed for reactivity in ELISA using both monoclonal and polyclonal antibodies as well as sera from experimentally infected mice and human patient sera.

From the experimentally infected mice sera it is known that non-linear epitopes are recognized predominantly. Thus, it is contemplated that different forms of purification schemes known in the art will be used to analyze for the presence of discontinuous epitopes, and to analyze whether the human immune response is also directed against such epitopes.

Preferred embodiments of the present invention relate to species specific diagnostic tests according to the invention, wherein the nucleic acid fragments have sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, and SEQ ID NO: 23.

In connection with nucleic acid fragments according to the present invention the term "variant" should be understood as a sequence of nucleic acids which shows a sequence homology of less than 100%. A variant sequence can be of the same size or it can be of a different size as the sequence it is compared to. A variant will typically show a sequence homology of at least 50%, preferably at least 60%, more preferably at least 70%, such as at least 80%, e.g. at least 90%, 95% or 98%.

The term "sequence homology" in connection with nucleic acid fragments of the invention means the percentage of matching nucleic acids (with respect to both position and type) in the nucleic acid fragments of the invention and an aligned nucleic acid fragment of equal or different length.

In order to obtain information concerning the general distribution of each of the genes according to the present invention, PCR will be performed for each gene on all available *C. pneumoniae* isolates. This will provide information on the general variability of the genes or nucleic acid fragments of the invention. Variable regions will be sequenced. From patient samples PCR will be used to

- amplify variable parts of the genes for epidemiology. Non-variable parts will be used for amplification by PCR and analyzed for possible use as a diagnostic test. It is contemplated that if variability is discovered, PCR of
- 5 variable regions can be used for epidemiology. PCR of non-variable regions can be used as a species specific diagnostic test. Using genes encoding proteins known to be invariable in all known isolates prepared as targets for PCR to genes encoding proteins with unknown function.
- 10 Particularly preferred embodiments of the present invention, relate to diagnostic tests according to the invention, wherein detection of nucleic acid fragments is obtained by using nucleic acid amplification, preferably polymerase chain reaction (PCR).
- 15 Within the scope of the present invention is a PCR based test directed at detecting nucleic acid fragments of the invention or variants thereof. A PCR test will typically be developed according to methods well known in the art and will typically comprise a PCR test capable of detecting and differentiating
- 20 between nucleic acid fragments of the invention. Preferred are quantitative competitive PCR tests or nested PCR tests. The PCR test according to the invention will typically be developed according to methods described in detail in EP B 540 588, EP A 586 112, EP A 643 140 OR EP A 669 401, which
- 25 are hereby incorporated by reference.

Within the scope of the present invention are variants and subsequences of one of the nucleic acid fragments of the invention, meaning a consecutive stretch of nucleic acids taken from SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID

30 NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23. A variant or subsequence will preferably comprise at least 100 nucleic acids, preferably at least 80 nucleic acids, more preferably at least 70 nucleic acids, such as at least 50 nucleic acids.

35 It might even be as small as 10-50 nucleic acids, such as

20-40 nucleic acids, e.g. about 30 nucleic acids. A subsequence will typically show a sequence homology of at least 30%, preferably at least 60%, more preferably at least 70%, such as at least 80%, e.g. at least 90%, 95% or 98%. The shorter the subsequence, the higher the required homology. Accordingly, a subsequence of 100 nucleic acids or lower must show a homology of at least 80%.

A very important aspect of the present invention relates to proteins of the invention derived from *Chlamydia pneumoniae* having amino acid sequences selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, and SEQ ID NO: 24 having a sequence similarity of at least 50%, preferably at least 60%, more preferably at least 70%, such as at least 80%, e.g. at least 90%, 95% or 98% and a similar biological function.

By the term "similar biological function" is meant that the protein shows characteristics similar with the proteins derivable from the membrane proteins of *Chlamydia pneumoniae*. Such proteins comprise repeated motifs of GGAI (at least 2, preferable at least 3 repeats) and/or conserved positions of tryptophan, (w).

Comparison of the DNA sequences from genes encoding Omp4-15 shows that the overall similarity between the individual genes ranges between 43-55%. Comparison of the amino acid sequences of Omp4-15 shows 34-49% identity and 53-64% similarity. The homology is generally scattered along the entire length of the deduced amino acids. However, as seen from figure 8 A - J there are some regions in which the homology is more pronounced. This is seen in the repeated sequence where the sequence GGAI is repeated 4-7 times in the genes. It is interesting that the DNA homology is not conserved for the sequences encoding the four amino acids GGAI. This may indicate a functional role of this part of the

protein and indicates that the repeated structure did not occur by a duplication of the gene. In addition to the four amino acid repeats GGAI a region from amino acid 400 to 490 has a higher degree of homology than the rest of the protein, with the conserved sequence FYDPI occurring in all sequences. As further indication of similarity in function the amino acid tryptophan (W) is perfectly conserved at 4-6 localizations in the C-terminal part of the protein.

Since none of the genes and deduced amino acid sequences of the invention are identical the following is within the scope of the present invention; production of monospecific antibodies, the use of said antibodies for characterizing which *C. pneumoniae* proteins are expressed, the use of said antibodies for characterizing at which time during developmental life cycle said *C. pneumoniae* proteins are expressed, and the use of said antibodies for characterizing the precise cellular localization of said *C. pneumoniae* proteins. Also within the scope of the present invention is the use of monospecific antibodies against proteins of the invention for determining which part of said proteins is surface exposed and how proteins in the *C. pneumoniae* COMC interact with each other.

Preferred embodiments of the present invention relate to polypeptides which comprise subsequences of the proteins of the invention, said subsequences comprising the sequence GGAI. Further preferred embodiments of the present invention relate to polypeptides which comprise subsequences of the proteins of the invention, said subsequences comprising the sequence FSGE.

Polypeptides according to the invention will typically be of a length of at least 6 amino acids, preferably at least 15 amino acids, preferably at least 20 amino acids, preferably at least 25 amino acids, preferably at least 30 amino acids, preferably at least 35 amino acids, preferably at least 40 amino acids, preferably at least 45 amino acids, preferably

at least 50 amino acids, preferably at least 55 amino acids, preferably at least 100 amino acids.

A very important aspect of the present invention relates to nucleic acid fragments of the invention derived from

5 *Chlamydia pneumoniae*, variants and subsequences thereof.

Another important aspect of the present invention relates to antibodies against the proteins according to the invention, such antibodies including polyclonal monospecific antibodies and monoclonal antibodies against proteins with sequences

10 selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, and SEQ ID NO: 24.

A very important aspect of the present invention relates to

15 diagnostic kits for the diagnosis of infection of a mammal, such as a human, with *Chlamydia pneumoniae*, said kits comprising one or more proteins with amino acid sequences selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, and SEQ ID NO: 24.

Another very important aspect of the present invention relates to diagnostic kits for the diagnosis of infection of a mammal, such as a human, with *Chlamydia pneumoniae*, said

25 kits comprising antibodies against a protein with an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, and SEQ ID NO: 24.

30 Antibodies included in a diagnostic kit according to the invention can be polyclonal or monoclonal or a mixture hereof.

Still another very important aspect of the present invention relates to diagnostic kits for the diagnosis of infection of a mammal, such as a human, with *Chlamydia pneumoniae*, said kits comprising one or more nucleic acid fragments with

5 sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, and SEQ ID NO: 23.

An aspect of the present invention relates to a composition

10 for immunizing a mammal, such as a human, against *Chlamydia pneumoniae*, said composition comprising one or more proteins with amino acid sequences selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16,

15 SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, and SEQ ID NO: 24.

An important role for the proteins of the invention in prevention of infection of a mammal, such as a human, with *C. pneumoniae* is expected. Thus proteins of the invention,

20 including variants and subsequences will be produced, typically by using recombinant techniques, and will then be used as an antigen in immunization of mammals, such as rabbits. Subsequently, the hyper immune sera obtained by the immunization will be analyzed for protection against *C.*

25 *pneumoniae* infection using a tissue culture assay. In addition it is contemplated that monoclonal antibodies will be produced, typically using standard hybridoma techniques, and analyzed for protection against infection with *C. pneumoniae*.

30 It is envisioned that particularly interesting and immunogenic epitopes will be found in connection with the proteins of the invention, which will comprise subsequences of said proteins. It is preferred to use polypeptides comprising such subsequences of the proteins of the invention

in immunizing a mammal, such as a human, against *Chlamydia pneumoniae*.

An important aspect of the present invention relates to the use of proteins with sequences selected from the group

- 5 consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, and SEQ ID NO: 24 in diagnosis of infection of a mammal, such as a human, with *Chlamydia pneumoniae*.

- 10 A preferred embodiment of the present invention relates to the use of proteins according to the invention in an undenatured form, in diagnosis of infection of a mammal, such as a human, with *Chlamydia pneumoniae*.

- A very important aspect of the present invention relates to
15 the use of proteins with sequences selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, and SEQ ID NO: 24, for immunizing a mammal, such as a human, against
20 *Chlamydia pneumoniae*.

A preferred embodiment of the present invention relates to the use of proteins according to the invention in an undenatured form, for immunizing a mammal, such as a human, against *Chlamydia pneumoniae*.

- 25 A very important aspect of the present invention relates to the use of nucleic acid fragments with nucleotide sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO:
30 19, SEQ ID NO: 21, and SEQ ID NO: 23 for immunizing a mammal, such as a human, against *Chlamydia pneumoniae*.

It is envisioned that one type of vaccine against *C. pneumoniae* will be developed by using gene-gun vaccination of mice. Typically, different genetic constructs containing nucleic acid fragments, combinations of nucleic acid fragments according to the invention will be used in the gene-gun approach. The mice will then subsequently be analyzed for production of both humoral and cellular immune response and for protection against infection with *C. pneumoniae* after challenge herewith.

- 10 In line with this, the invention also relates to the uses of the proteins of the invention as a pharmaceutical (a vaccine) as well as to the uses thereof for the preparation of a vaccine against infections with *Chlamydia pneumoniae*.

- Preparation of vaccines which contain protein sequences as active ingredients is generally well understood in the art, as exemplified by U.S. Patents 4,608,251; 4,601,903; 4,599,231; 4,599,230; 4,596,792; and 4,578,770, all incorporated herein by reference. Typically, such vaccines are prepared as injectables either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified. The active immunogenic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or adjuvants which enhance the effectiveness of the vaccines.

- The vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscularly. Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations. These compositions take the form of

solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10-95% of active ingredient, preferably 25-70%, and optionally a suitable carrier.

- 5 The protein sequences may be formulated into the vaccine as neutral or salt forms known in the art. The vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective and immunogenic. The quantity to be administered
10 depends on the subject to be treated. Suitable dosage ranges are of the order of several hundred micrograms active ingredient per vaccination with a preferred range from about 0.1 μ g to 1000 μ g. The immune response may be enhanced if the vaccine further comprises an adjuvant substance as known in
15 the art. Other possibilities involve the use of immunomodulating substances such as lymphokines (e.g. IFN- γ , IL-2 and IL-12) or synthetic IFN- γ inducers such as poly I:C in combination with the above-mentioned adjuvants.

- It is also possible to produce a living vaccine by introducing, into a non-pathogenic microorganism, at least one
20 nucleic acid fragment encoding a protein fragment or protein of the invention, and effecting expression of the protein fragment or the protein on the surface of the microorganism (e.g. in the form of a fusion protein including a membrane
25 anchoring part or in the form of a slightly modified protein or protein fragment carrying a lipidation signal which allows anchoring in the membrane). The skilled person will know how to adapt relevant expression systems for this purpose.

- Another part of the invention is based on the fact that
30 recent research have revealed that a DNA fragment cloned in a vector, which is non-replicative in eukaryotic cells may be introduced into an animal (including a human being) by e.g. intramuscular injection or percutaneous administration (the so-called "gene gun" approach). The DNA is taken up by e.g.
35 muscle cells and the gene of interest is expressed by a

promoter which is functioning in eukaryotes, e.g. a viral promoter, and the gene product thereafter stimulates the immune system. These newly discovered methods are reviewed in Ulmer et al., 1993, which hereby is included by reference.

- 5 Thus, a nucleic acid fragment encoding a protein or protein of the invention may be used for effecting *in vivo* expression of antigens, i.e. the nucleic acid fragments may be used in so-called DNA vaccines. Hence, the invention also relates to a vaccine comprising a nucleic acid fragment encoding a
10 protein fragment or a protein of the invention, the vaccine effecting *in vivo* expression of antigen by an mammal, such as a human, to whom the vaccine has been administered, the amount of expressed antigen being effective to confer substantially increased resistance to infections with
15 *Chlamydia pneumoniae* in an mammal, such as a human.

- The efficacy of such a "DNA vaccine" can possibly be enhanced by administering the gene encoding the expression product together with a DNA fragment encoding a protein which has the capability of modulating an immune response. For instance, a
20 gene encoding lymphokine precursors or lymphokines (e.g. IFN- γ , IL-2, or IL-12) could be administered together with the gene encoding the immunogenic protein fragment or protein, either by administering two separate DNA fragments or by administering both DNA fragments included in the same vector.
25 It is also a possibility to administer DNA fragments comprising a multitude of nucleotide sequences which each encode relevant epitopes of the protein fragments and proteins disclosed herein so as to effect a continuous sensitization of the immune system with a broad spectrum of these epitopes.
30 The following experimental non-limiting examples are intended to illustrate certain features and embodiments of the invention.

LEGENDS TO FIGURES

Figure 1. The figure shows electron microscopy of negative stained purified *C. pneumoniae* EB (A) and purified OMC (B).

5 Figure 2. The figure shows silver stained 15% SDS-PAGE of purified EB and OMC. Lane 1, purified *C. pneumoniae* EB; lane 2, *C. pneumoniae* OMC; lane 3, purified *C. trachomatis* EB; and lane 4 *C. trachomatis* OMC.

Figure 3. The figure shows immunoblotting of *C. pneumoniae* EB separated by 10% SDS-PAGE, transferred to nitrocellulose and
10 reacted with rabbit anti *C. pneumoniae* OMC.

Figure 4. The figure shows coomassie blue stained 7.5% SDS-PAGE of recombinant pEX that were detected by the rabbit anti *C. pneumoniae* serum. Arrow indicated the localization of the 117 kDa b-galactosidase protein.

15 Figure 5. The figure shows immunoblotting of recombinant pEX clones detected by colony blotting separated by 7.5% SDS-PAGE and transferred to nitrocellulose and reacted with rabbit anti *C. pneumoniae* OMC. Lane 1, seablue molecular weight standard. Lane 2-6 pEX clones cultivated at 42°C to
20 induce the production of the b-galactosidase fusion proteins.

Figure 6. The figure shows sequence strategy for Omp4 and Omp5. Arrows indicates primers used for sequencing.

Figure 7. *C. pneumoniae* omp genes. The genes are arranged in two clusters. In cluster 1 Omp12, 11, 10, 5, 4, 13, and 14
25 are found. In cluster 2 are found Omp6, 7, 8, 9, and 15.

Figure 8 A - J. The figure shows alignment of *C. pneumoniae* Omp4-15, using the program pileup in the GCG package.

Figure 9. The figure shows immunofluorescence of *C. pneumoniae* infected HeLa, 72 hrs. after infection, reacted

with mouse monospecific anti-serum against pEX3-36 fusion protein. pEX3-36 is a part of the Omp5 gene.

Figure 10. The figure shows immunoblotting of *C. pneumoniae* EB, lane 1-3 heated to 100°C in SDS-sample buffer, lane 4-6 unheated. Lane 1 reacted with rabbit anti *C. pneumoniae* OMC; lane 2 and 4 pre-serum; lane 3 and 5 polyclonal rabbit anti pEX1-1 fusion protein; lane 6 MAb 26.1.

Figure 11. The figure shows immunoblotting of *C. pneumoniae* EB, lane 1-4 heated to 100°C in SDS-sample buffer, lane 5-6 unheated. Reacted with serum from C57-black mice 14 days after infection with 10^7 CFU of *C. pneumoniae*. Lane 1 and 5 mouse 1; lane 2 and 6 mouse 2; lane 3 and 5 mouse 3; and lane 4 and 8 mouse 4.

Figure 12. The figure shows immunohistochemistry analysis of mouse lung tissue with *C. pneumoniae* inclusions present both in the bronchial epithelium and in the lung parenchyma (arrows).

EXAMPLE 1

Cloning of the genes encoding the 98/95 kDa *C. pneumoniae* COMC proteinsPurification of *C. pneumoniae* EBs and COMC

5 *C. pneumoniae* was cultivated in HeLa cells. Cultivation was done according to the specifications of Miyashita and Matsumoto (1992), with the modification that centrifugation of supernatant and of the later precipitate and turbid bottom layer was carried out at 100,000 X g. The microorganism
10 attached to the HeLa cells by 30 minutes of centrifugation at 1000 x g, after which the cells were incubated in RPMI 1640 medium (Gibco BRL, Germany cat No. 51800-27), containing 5% foetal calf serum (FCS, Gibco BRL, Germany Cat No. 10106.169) gentamicin for two hours at 37°C in 5% CO₂ atmosphere. The
15 medium was changed to medium that in addition contained 1 mg per ml of cycloheximide. After 48 hours of incubation a coverslip was removed from the cultures and the inclusion was tested with an antibody specific for *C. pneumoniae* (MAb 26.1) (Christiansen et al. 1994) and a monoclonal antibody specific
20 for the species *C. trachomatis* (MAb 32.3, Loke diagnostics, Århus Denmark) to ensure that no contamination with *C. trachomatis* had occurred. The HeLa cells were tested by Hoechst stain for Mycoplasma contamination as well as by culture in BEa and BEg medium (Freund et al., 1979). Also the
25 *C. pneumoniae* stocks were also tested for Mycoplasma contamination by cultivation in BEa and BEg medium. No contamination with *C. trachomatis*, Mycoplasmas or bacteria were detected in cultures or cells. 72 hours post-infection the monolayer was washed in PBS, the cells were loosened in
30 PBS with a rubber policeman, and the Chlamydia were liberated from the host cell by sonication. The *C. pneumoniae* EBs and RBs were purified on discontinuous density gradients (Miyashita et al. (1992)). The purity of the Chlamydia EBs were verified by negative staining and electronmicroscopy
35 (Figure 1), only particles of a size of 0.3 to 0.5 µm were

detected in agreement with the structure of *C. pneumonia* EBs. The purified Chlamydia EBs were subjected to sarkosyl extraction as described by Caldwell et al (1981) with the modification that a brief sonication was used to suspend the COMC. The purified COMC was tested by electronmicroscopy and negative staining (Figure 1), where a folded outer membrane complex was seen.

SDS-PAGE analysis of purified EBs and COMC

The proteins from purified EBs and *C. pneumoniae* OMC were separated on 15% SDS-polyacrylamide gel, and the gel was silver stained (Figure 2), in lane 1 it is seen that the purified EBs contain major proteins of 100/95 kDa and a protein of 38 kDa, in the purified COMC (lane 2) these two protein groups are also dominant. In addition, proteins with a molecular weight of 62/60 kDa, 55 kDa, and 12 kDa have been enriched in the COMC preparation. When the purified *C. pneumoniae* EBs are compared to purified *C. trachomatis* EB (lane 3) it is seen that predominant protein in the *C. trachomatis* EB is the major outer membrane protein (MOMP), and it is also the dominant band in the COMC preparation of *C. trachomatis* (lane 4), and Omp2 of 60/62 kDa as well as Omp3 at 12 kDa are seen in the preparation. However, no major bands with a size of 100/95 kDa are detected as in the *C. pneumoniae* COMC preparation.

Production of rabbit polyclonal antibodies against *C. pneumoniae* COMC

To ensure production of rabbit antibodies that would recognize all the *C. pneumoniae* proteins in immuno-blotting and colony-blotting 10 µg of COMC antigen was dissolved in 20 µl of SDS sample buffer and thereafter divided into 5 vials. The dissolved antigen was further diluted in one ml of PBS and one ml of Freund incomplete adjuvant (Difco laboratories, USA cat. No. 0639-60-6) and injected into the quadriceps muscle of a New Zealand white rabbit. The rabbit was given

three times intramuscular injections at an interval of one week, and after further three weeks the dissolved COMC protein, diluted in one ml PBS was injected intravenously, and the procedure was repeated two weeks later. Eleven weeks
5 after the beginning of the immunization, the serum was obtained from the rabbit. Purified *C. pneumoniae* EBs were separated by SDS-PAGE, and the proteins were electrotransferred to nitrocellulose membrane. The membrane was blocked and immunostained with the polyclonal COMC
10 antibody (Figure 3). The serum recognized proteins with a size of 100/95, 60 and 38 kDa in the EB preparation. This is in agreement with the sizes of the outer membrane proteins.

Cloning of the COMC proteins

Due to the cultivation of *C. pneumoniae* in HeLa cells,
15 contaminating host cell DNA could be present in the EB preparations. Therefore, the purified EB preparations were treated with DNase to remove contaminating DNA. The *C. pneumoniae* DNA was then purified by CsCl gradient centrifugation. The *C. pneumoniae* DNA was partially digested
20 with Sau3A and the fractions containing DNA fragments with a size of approx. 0.5 to 4.0 kb were cloned into the expression vector system pEX (Boehringer, Germany cat. No. 1034 766, 1034 774, 1034 782). The pEX vector system has a β -galactosidase gene with multiple cloning sites in the 3' end
25 of the β -galactosidase gene. Expression of the gene is regulated by the PR promoter, so the protein expression can be induced by elevating the temperature from 32 to 42°C. The colonies of recombinant bacteria were transferred to nitrocellulose membranes, and the temperature was increased
30 to 42°C for two hours. The bacteria were lysed by placing the nitrocellulose membranes on filters soaked in 5% SDS. The colonies expressing outer membrane proteins were detected with the polyclonal antibody raised against *C. pneumoniae* COMC. The positive clones were cultivated in suspension and
35 induced at 42°C for two hours. The protein profile of the clones were analysed by SDS-PAGE, and increases in the size

of the induced b-galactosidase were observed (Figure 4). In addition, the proteins were electrotransferred to nitrocellulose membranes, and the reaction with the polyclonal serum against COMC was confirmed (Figure 5).

5 Sequencing of positive COMC clones

To characterize the pEX clones, the inserted *C. pneumoniae* DNA was sequenced. The resulting DNA sequences were searched against the prokaryotic sequences in the GenEmbl database. The search identified 6 clones as part of the Omp2 gene, and 10 2 clones as part of the Omp3 gene, and 2 clones as part of the MOMP gene, indicating that COMC proteins had been successfully cloned. Furthermore, 32 clones were obtained, containing DNA sequences not found in the GenEmbl database. These sequences could, however, be clustered in two contigs 15 of 6 and 4 clones, and three clones were identical. In addition 19 clones were found with no overlap to the contigs (Figure 7). To obtain more sequence data for the genes, *C. pneumoniae* DNA was totally digested with BamHI restriction enzyme, and the fragments were cloned into the vector 20 pBluescript. The ligated DNA was electrotransformed into *E. coli* XL1-Blue and selected on plates containing Ampicillin. The recombinant bacterial colonies were transferred to a nitrocellulose membrane, and colony hybridisation was performed using the inserts of pEX 1-1 clone as a probe. A 25 clone containing a single BamHI fragment of 4.5 kb was found, and the hybridisation to the probe was confirmed by Southern blotting. The insert of the clone was sequenced bi-directionally using synthetic primers for approx. each 300 bp. The sequence of the BamHI fragment made it possible to 30 join the two contigs of pEX clones. Totally, together with the pEX clones it was possible to assemble 6.5 kb DNA sequence, encoding two new COMC proteins. (Figure 6)

Additional sequences were obtained by PCR performed on purified *C. pneumoniae* DNA with primers both from the known 35 Omp genes and from other known genes. The obtained PCR

products were sequenced, The sequence organisation is shown in Fig. 7. Additional 8 Omp genes were detected. The alignment of the deduced amino acid sequences are shown in Fig. 8 A and B.

5 Analysis of DNA sequence

The DNA sequence encoding the Omp4-15 proteins with a size of 89.6-100.3 kDa (and for Omp13: 56.1 kDa). Omp4 and Omp5 were transcribed in opposite directions. Downstream Omp4 a possible termination structure was located. The 3' end of the Omp5 gene was not cloned due to the presence of the BamHI restriction enzyme site positioned within the gene. The translated DNA sequence of Omp4 and Omp5 was compared by use of the gap programme in the GCG package (Wisconsin package, version 8.1-UNIX, August 1995, sequence analysis software package). The two genes had an amino acid identity of 41% (similarity 61%), and a possible cleavage site for signal peptidase 1 was present at amino acid 17 in Omp4 and amino acid 25 in Omp5. When the amino acid sequence encoded by two other pEX clones were compared to the sequence of Omp4 and Omp5 they also had amino acid homology to the genes. It is seen that the two clones have homology to the same area in the Omp4 and Omp5 proteins. Consequently, the pEX clones must have originated from two additional genes. Therefore these genes were named Omp6 and Omp7. Similar analyses were performed with the other genes. In contrast to what was seen for Omp4 and 5 none of the other putative omp proteins had a cleavage site for signal peptides.

EXAMPLE 2

Polyclonal monospecific antibodies against pEX fusion proteins and full length recombination + Omp4

To investigate the topology of the Omp4-7 proteins, representative pEX clones, were selected from each gene. The fusion proteins of β -galactosidase/omp were induced, and the

proteins were partially purified as inclusion bodies. Balb/c mice were immunized three times intramuscular with the antigens at an interval of one week, and after six weeks the serum was obtained from the mice. HeLa cells were infected with the *C. pneumoniae*. 72 hours after the infection the mono-layers were fixed with 3.7% formaldehyde. This treatment makes the outer membrane of the Chlamydia impermeable for antibodies due to the extensive cross-linking of the outer membrane proteins by the formaldehyde. The HeLa cells were permeabilized with 0.2% Triton X100, the monolayers were washed in PBS, then incubated with 20% (v/v) FCS to inactivate free radicals of the formaldehyde. The mice sera were diluted 1:100 PBS with 20% (v/v) FCS and incubated with the monolayers for half an hour. The monolayers were washed in PBS and secondary FITCH conjugated rabbit anti mouse serum was added for half an hour, and the monolayers were washed and mounted. Several of the antibodies reacted strongly with the EBs in the inclusions (Figure 9). In spite of the formaldehyde fixation it could not be excluded that the surface of the EB was changed by the treatments, so that the antibodies could get access to the Omp4-7. Therefore, the reaction was confirmed by immuno-electron microscopy with the antibody raised against clone pEX3-36. Purified EB of *C. pneumoniae* were absorbed to carbon coated nickel grids. After the absorption the grids were washed with PBS and blocked in 0.5% Ovalbumin dissolved in PBS. The antibodies were diluted 1:100 in the same buffer and incubated for 30 minutes. The grids were washed in PBS. Rabbit anti mouse Ig conjugated with 10nm colloidal gold diluted in PBS containing 1% gelatin was added to the grids for half an hour. The grids were washed in 3 x PBS with 1% gelatin and 3 times in PBS, the grids were contrastained with 0.7% phospho tungstic acid. The grids were analysed in a Jeol 1010 electron microscope at 40 kV. It was seen that the gold particles were covering the surface of the purified EB. Because the *C. pneumoniae* EBs were not exposed to any detergent or fixation under either the purification or the reaction with antibodies, these

results show that the cloned proteins have surface exposed epitopes.

Polyclonal monospecific antibodies against Omp4

The Omp4 gene was amplified by PCR with primers that
5 contained LIC-sites, and the PCR product was cloned into the
pET-30 LIC vector (Novagen). The histidine tagged fusion
protein was expressed by induction of the synthesis by IPTG
and purified over a nickel column. The purified Omp4 protein
was used for immunization of a rabbit (six times, 8 µg each
10 time).

Use of rabbit polyclonal antibodies to recombinant Omp4 for detection of *Chlamydia pneumoniae* in paraffin embedded sections

The lungs of *C. pneumoniae* infected mice were obtained three
15 days after intranasal infection. The tissue samples were
fixed in 4% formaldehyde, paraffin embedded, sectioned and
deparaffinized prior to staining. The sections were incubated
with the rabbit serum diluted 1:200 in TBS (150 mM NaCl,
20mM Tris pH 7.5) for 30 min at room temperature. After wash
20 two times in TBS the sections were incubated with the
secondary antibody (biotinylated goat anti-rabbit antibodies)
diluted 1:300 in TBS, followed by two times wash in TBS. The
sections were stained with streptavidin-biotin complex
(streptABComplex/AP, Dako) for 30 min washed and developed
25 under microscopic inspection with chromagen + new fuchsin
(Vector laboratories). The sections were counter stained with
Hematoxylin and analyzed ny microscopy.

Immuno blotting analysis with hyperimmune monospecific rabbit anti-serum

30 The insert of pEX1-1 clone was amplified by PCR using primers
containing LIC sites. The PCR product could therefore be
inserted in the pET-32 LIC vector (Novagen, UK cat No. 69076-

1). Thereby the insert sequence of the pEX1-1 clone was expressed in the new vector as a fusion protein, the part of the fusion protein encoded by the pET-32 LIC vector had 6 histidine residues in a row. The expression of the fusion protein was induced in this vector, and the fusion protein could be purified under denaturing condition on a Ni²⁺ column due to the high affinity of the histidine residues to divalent cations. The purified protein was used for immunization of a New Zealand white rabbit. After 6 times intramuscular and 2 times intravenous immunization the serum was obtained from the rabbit. Purified *C. pneumoniae* EB was dissolved in SDS-sample buffer. Half of the sample was heated to 100°C in the sample buffer, whereas the other half of the sample was not heated. The samples were separated by SDS-PAGE, and the proteins were transferred to nitrocellulose, the serum was reacted with the strips. With the samples heated to 100°C the serum recognized a high molecular weight band of approximately 98 kDa. This is in agreement with the predicted size of Omp5, of which the pEX1-1 clone is a part, however, when the antibody was reacted to the strip with unheated EB, the pattern was different. Now a band was seen with a size of 75 kDa, in addition weaker bands were observed above the band (Figure 10). These data demonstrate that Omp5 needs boiling in SDS-sample buffer to be fully denatured and migrate with a size as predicted from the gene product. When the samples were not boiled, the protein was not fully denatured and less SDS binds to the protein and it has a more globular structure that will migrate faster in the acrylamide gel. The band pattern looked identical to what was obtained with a monoclonal antibody (MAb 26.1) (lane 6), we earlier have described (Christiansen et al., 1994), reacting with the surface of *C. pneumoniae* EB, but the antibody do not react with the fully SDS denatured *C. pneumoniae* EB in immunoblotting.

Experimental infection of C57 black mice

Due to the realization of the altered migration of the Omp4-7 proteins without boiling, we chose to analyse antibodies against *C. pneumoniae* EBs after an experimental infection of mice. To obtain antibodies from an infection caused by *C. pneumoniae*, C57 black mice were inoculated intranasally with 10^7 CFI of *C. pneumoniae* under a light ether anaesthesia. After 14 days of infection the serum samples were obtained and the lungs were analysed for pathological changes. In two of the mice a severe pneumonia was observed in the lung sections, and in the third mouse only minor changes were observed. The serum from the mice was diluted 1:100 and reacted with purified EBs dissolved in sample buffer with and without boiling. In the preparations that had been heated to 100°C the sera from two of the mice reacted strongly with bands of 60/62 kDa and weaker bands of 55 kDa, but no reaction was observed with proteins of the size of Omp4-7 (Figure 11). However, when the sera were reacted with the preparation that had not been heated they all had a strong reaction with a broad band of an approximate size of 75 kDa. This is in agreement with the size of the Omp4-7 proteins in the unheated preparation. Therefore, it could be concluded that the epitopes of the Omp4-7 proteins recognized by the antibodies after a *C. pneumoniae* infection were discontinuous epitopes because the full denaturation of the antigen completely destroyed the epitopes. The 75 kDa protein observed in unheated samples is not Omp2 (Shown in immunoblotting with an Omp2 specific antibody)

EXAMPLE 3

Comparison of Omp4-7 of *C. pneumoniae* with putative outer membrane proteins (POMP) of *C. psittaci*

Longbottom et al. (1996) have published partial sequence from 98 to 90 kDa proteins from *C. psittaci*. They have entered the full sequence of 5 genes in this family in the EMBL database.

They have named the genes "putative outer membrane proteins" (POMP) since their precise location was not determined. The family is composed of two genes that are completely identical, and two genes with high homology to these genes.

5 They calculated a molecular size of 90 and 91 kDa. The 5th encode a protein of 98 kDa. The sequence of the Omp4-7 proteins of *C. pneumoniae* were compared to the sequences of the *C. Psittaci* POMP proteins with the programme pileup in the GCG package. The amino acid homologies were in the range

10 of 51-63%. It is seen that the *C. pneumoniae* Omp4-5 proteins are most related to the 98 kDa POMP protein of *C. psittaci*. Interestingly, the 98 kDa *C. psittaci* POMP protein is more related to the *C. pneumoniae* genes than to the other *C. psittaci* genes. The repeated sequences of GGAI were conserved

15 in the 98 kDa POMP protein, but only three GGAI repeats were present in the 90 and 91 kDa *C. psittaci* POMP proteins. For *C. psittaci* it has been shown that antibodies to these proteins seem to be protective for the infection.

REFERENCES

20

1. Caldwell, H.D., J. Kromhout and J. Schachter, Infect. Immun. 31, 1161-1176 (1981).
2. Campbell, L.A., M.P. Melgosa, D.J. Hamilton, C.-C. Kuo and J.T. Grayston, J. Clinical Microbiol., 30, 434-439 (1992).
- 25 3. Christiansen, G., and S. Birkelund. Eur. Microbiol. 1:24-29 (1992).
4. Christiansen, G., L. Østergaard, and S. Birkelund. Proceedings of the eight International symposium on Human Infections, Eds. Orfila et al., pp 173-176, (1994).
- 30 5. Grayston, J.T., Kuo, C.-C., Campbell, L.A., and Vang, S.-P. Int. J. Syst. Bacteriol. 39, 88-90 (1989).
6. Grayston, J.T., C.-C. Kuo, S.-P. Wang and J. Altman. 1986. N. Engl. J. Med. 315, 161-168 (1986).
- 35 7. Kuo, C.C., L.A. Jackson, L.A. Campbell and J.T. Graystone. Clin. Microbiol. Rev. 8, 451-461 (1995).

8. Longbottom, D., M. Russell, G.E Jones, A. Lainson, and A.J. Herring. FEMS Microbiol. Lett. 142, 277-281 (1996).
- 5 9. Melgosa, M.P., C.-C. Kuo and L.A. Campbell, FEMS Microbiol. Lett. 112, 199-204 (1993).
10. Campbell, L.A., C.-C kuo, S.P. Wang amd J.T. Grayston. J. Clin. Microbiol. 28, 1261-1264 (1990).
11. Halme, S., P. Saikku and H.-M. Surcel. Scand. J. Immunol. 45, 378-384 (1997).
- 10 12. Miyashita, N. and A. Matsumoto. J. Clin. Microbiol. 30, 2911-2916 (1992).
13. Wang, S.P., and J.T. Grayston, Am. J. Ophtalmol. 70, 367-374 (1970).
- 15 14. Freund, E.A., H. Ernø and R.M. Lemcke. Identification of mycoplasma, P377-443 in I. Norris and J.R. Bergen; Methods in Microbiology vol 13, A.P. Inc. London 1979)

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT

- (A) NAME: Svend Birkelund
 (B) STREET: Dept. of Medical Microbiology and Immunology,
 University of Århus
 (C) CITY: Århus C
 (D) STATE OR PROVINCE:
 (E) COUNTRY: Denmark
 (F) POSTAL CODE: 8000

(ii) TITLE OF THE INVENTION: Chlamydia pneumoniae anti
 gens

(iii) NUMBER OF SEQUENCES: 30

(iv) COMPUTER-READABLE FORM:

- (A) MEDIUM TYPE: Diskette
 (B) COMPUTER: IBM Compatible
 (C) OPERATING SYSTEM: DOS
 (D) SOFTWARE: FastSEQ for Windows Version 2.0

(v) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER:

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3200 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
 (B) LOCATION: 205...2987
 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CAATGTCGAA GAGAGCTACTA ACCAGGAAAA TTGCGATTTC ATAAACCCAC TTTATTATTA	60
AATTCTTACT TGCATCATAT AAAATAGAAA ACTCAGAGAG TCAAGATAAA AATTCTTGAC	120
AGCTGTTTGT TCATCTTTAA CTTGATTAC TTATTTTGT TCTATATTGA TGCGAATAGT	180
TCTCTAAAAA ACAAAGCAT TACC ATG AAG ACT TCG ATT CCT TGG GTT TTA	231
Met Lys Thr Ser Ile Pro Trp Val Leu	
1 5	
GTT TCC TCC GTG TTA GCT TTC TCA TGT CAC CTA CAG TCA CTA GCT AAC	279
Val Ser Ser Val Leu Ala Phe Ser Cys His Leu Gln Ser Leu Ala Asn	
10 15 20 25	

GAG GAA CTT TTA TCA CCT GAT GAT AGC TTT AAT GGA AAT ATC GAT TCA Glu Glu Leu Leu Ser Pro Asp Asp Ser Phe Asn Gly Asn Ile Asp Ser 30 35 40	327
GGA ACG TTT ACT CCA AAA ACT TCA GCC ACA ACA TAT TCT CTA ACA GGA Gly Thr Phe Thr Pro Lys Thr Ser Ala Thr Thr Tyr Ser Leu Thr Gly 45 50 55	375
GAT GTC TTC TTT TAC GAG CCT GGA AAA GGC ACT CCC TTA TCT GAC AGT Asp Val Phe Phe Tyr Glu Pro Gly Lys Gly Thr Pro Leu Ser Asp Ser 60 65 70	423
TGT TTT AAG CAA ACC ACG GAC AAT CTT ACC TTC TTG GGG AAC GGT CAT Cys Phe Lys Gln Thr Thr Asp Asn Leu Thr Phe Leu Gly Asn Gly His 75 80 85	471
AGC TTA ACG TTT GGC TTT ATA GAT GCT GGC ACT CAT GCA GGT GCT GCT Ser Leu Thr Phe Gly Phe Ile Asp Ala Gly Thr His Ala Gly Ala Ala 90 95 100 105	519
GCA TCT ACA ACA GCA AAT AAG AAT CTT ACC TTC TCA GGG TTT TCC TTA Ala Ser Thr Thr Ala Asn Lys Asn Leu Thr Phe Ser Gly Phe Ser Leu 110 115 120	567
CTG AGT TTT GAT TCC TCT CCT AGC ACA ACG GTT ACT ACA GGT CAG GGA Leu Ser Phe Asp Ser Ser Pro Ser Thr Thr Val Thr Thr Gly Gln Gly 125 130 135	615
ACG CTT TCC TCA GCA GGA GGC GTA AAT TTA GAA AAT ATT CGT AAA CTT Thr Leu Ser Ser Ala Gly Gly Val Asn Leu Glu Asn Ile Arg Lys Leu 140 145 150	663
GTA GTT GCT GGG AAT TTT TCT ACT GCA GAT GGT GGA GCT ATC AAA GGA Val Val Ala Gly Asn Phe Ser Thr Ala Asp Gly Gly Ala Ile Lys Gly 155 160 165	711
GCG TCT TTC CTT TTA ACT GGC ACT TCT GGA GAT GCT CTT TTT AGT AAC Ala Ser Phe Leu Leu Thr Gly Thr Ser Gly Asp Ala Leu Phe Ser Asn 170 175 180 185	759
AAC TCT TCA TCA ACA AAG GGA GGA GCA ATT GCT ACT ACA GCA GGC GCT Asn Ser Ser Ser Thr Lys Gly Gly Ala Ile Ala Thr Thr Ala Gly Ala 190 195 200	807
CGC ATA GCA AAT AAC ACA GGT TAT GTT AGA TTC CTA TCT AAC ATA GCG Arg Ile Ala Asn Asn Thr Gly Tyr Val Arg Phe Leu Ser Asn Ile Ala 205 210 215	855
TCT ACG TCA GGA GGC GCT ATC GAT GAT GAA GGC ACG TCG ATA CTA TCG Ser Thr Ser Gly Gly Ala Ile Asp Asp Glu Gly Thr Ser Ile Leu Ser 220 225 230	903
AAC AAC AAA TTT CTA TAT TTT GAA GGG AAT GCA GCG AAA ACT ACT GGC Asn Asn Lys Phe Leu Tyr Phe Glu Gly Asn Ala Ala Lys Thr Thr Gly 235 240 245	951
GGT GCG ATC TGC AAC ACC AAG GCG AGT GGA TCT CCT GAA CTG ATA ATC	999

Gly	Ala	Ile	Cys	Asn	Thr	Lys	Ala	Ser	Gly	Ser	Pro	Glu	Leu	Ile	Ile	
250					255				260						265	
TCT	AAC	AAT	AAG	ACT	CTG	ATC	TTT	GCT	TCA	AAC	GTA	GCA	GAA	ACA	AGC	1047
Ser	Asn	Asn	Lys	Thr	Leu	Ile	Phe	Ala	Ser	Asn	Val	Ala	Glu	Thr	Ser	
				270				275						280		
GGT	GGC	GCC	ATC	CAT	GCT	AAA	AAG	CTA	GCC	CTT	TCC	TCT	GGA	GGC	TTT	1095
Gly	Gly	Ala	Ile	His	Ala	Lys	Lys	Leu	Ala	Leu	Ser	Ser	Gly	Gly	Phe	
			285					290					295			
ACA	GAG	TTT	CTA	CGA	AAT	AAT	GTC	TCA	TCA	GCA	ACT	CCT	AAG	GGG	GGT	1143
Thr	Glu	Phe	Leu	Arg	Asn	Asn	Val	Ser	Ser	Ala	Thr	Pro	Lys	Gly	Gly	
		300					305					310				
GCT	ATC	AGC	ATC	GAT	GCC	TCA	GGA	GAG	CTC	AGT	CTT	TCT	GCA	GAG	ACA	1191
Ala	Ile	Ser	Ile	Asp	Ala	Ser	Gly	Glu	Leu	Ser	Leu	Ser	Ala	Glu	Thr	
	315					320					325					
GGA	AAC	ATT	ACC	TTT	GTA	AGA	AAT	ACC	CTT	ACA	ACA	ACC	GGA	AGT	ACC	1239
Gly	Asn	Ile	Thr	Phe	Val	Arg	Asn	Thr	Leu	Thr	Thr	Thr	Gly	Ser	Thr	
	330				335				340						345	
GAT	ACT	CCT	AAA	CGT	AAT	GCG	ATC	AAC	ATA	GGA	AGT	AAC	GGG	AAA	TTC	1287
Asp	Thr	Pro	Lys	Arg	Asn	Ala	Ile	Asn	Ile	Gly	Ser	Asn	Gly	Lys	Phe	
				350				355						360		
ACG	GAA	TTA	CGG	GCT	GCT	AAA	AAT	CAT	ACA	ATT	TTC	TTC	TAT	GAT	CCC	1335
Thr	Glu	Leu	Arg	Ala	Ala	Lys	Asn	His	Thr	Ile	Phe	Phe	Tyr	Asp	Pro	
			365					370					375			
ATC	ACT	TCA	GAA	GGA	ACC	TCA	TCA	GAC	GTA	TTG	AAG	ATA	AAT	AAC	GGC	1383
Ile	Thr	Ser	Glu	Gly	Thr	Ser	Ser	Asp	Val	Leu	Lys	Ile	Asn	Asn	Gly	
		380					385					390				
TCT	GCG	GGA	GCT	CTC	AAT	CCA	TAT	CAA	GGA	ACG	ATT	CTA	TTT	TCT	GGA	1431
Ser	Ala	Gly	Ala	Leu	Asn	Pro	Tyr	Gln	Gly	Thr	Ile	Leu	Phe	Ser	Gly	
	395					400					405					
GAA	ACC	CTA	ACA	GCA	GAT	GAA	CTT	AAA	GTT	GCT	GAC	AAT	TTA	AAA	TCT	1479
Glu	Thr	Leu	Thr	Ala	Asp	Glu	Leu	Lys	Val	Ala	Asp	Asn	Leu	Lys	Ser	
	410				415					420				425		
TCA	TTC	ACG	CAG	CCA	GTC	TCC	CTA	TCC	GGA	GGA	AAG	TTA	TTG	CTA	CAA	1527
Ser	Phe	Thr	Gln	Pro	Val	Ser	Leu	Ser	Gly	Gly	Lys	Leu	Leu	Leu	Gln	
				430					435					440		
AAG	GGA	GTC	ACT	TTA	GAG	AGC	ACG	AGC	TTC	TCT	CAA	GAG	GCC	GGT	TCT	1575
Lys	Gly	Val	Thr	Leu	Glu	Ser	Thr	Ser	Phe	Ser	Gln	Glu	Ala	Gly	Ser	
			445					450					455			
CTC	CTC	GGC	ATG	GAT	TCA	GGA	ACG	ACA	TTA	TCA	ACT	ACA	GCT	GGG	AGT	1623
Leu	Leu	Gly	Met	Asp	Ser	Gly	Thr	Thr	Leu	Ser	Thr	Thr	Ala	Gly	Ser	
		460					465					470				
ATT	ACA	ATC	ACG	AAC	CTA	GGA	ATC	AAT	GTT	GAC	TCC	TTA	GGT	CTT	AAG	1671
Ile	Thr	Ile	Thr	Asn	Leu	Gly	Ile	Asn	Val	Asp	Ser	Leu	Gly	Leu	Lys	

475	480	485	
CAG CCC GTC AGC CTA ACA GCA AAA GGT GCT TCA AAT AAA GTG ATC GTA Gln Pro Val Ser Leu Thr Ala Lys Gly Ala Ser Asn Lys Val Ile Val 490 495 500 505			1719
TCT GGG AAG CTC AAC CTG ATT GAT ATT GAA GGG AAC ATT TAT GAA AGT Ser Gly Lys Leu Asn Leu Ile Asp Ile Glu Gly Asn Ile Tyr Glu Ser 510 515 520			1767
CAT ATG TTC AGC CAT GAC CAG CTC TTC TCT CTA TTA AAA ATC ACG GTT His Met Phe Ser His Asp Gln Leu Phe Ser Leu Leu Lys Ile Thr Val 525 530 535			1815
GAT GCT GAT GTT GAT ACT AAC GTT GAC ATC AGC AGC CTT ATC CCT GTT Asp Ala Asp Val Asp Thr Asn Val Asp Ile Ser Ser Leu Ile Pro Val 540 545 550			1863
CCT GCT GAG GAT CCT AAT TCA GAA TAC GGA TTC CAA GGA CAA TGG AAT Pro Ala Glu Asp Pro Asn Ser Glu Tyr Gly Phe Gln Gly Gln Trp Asn 555 560 565			1911
GTT AAT TGG ACT ACG GAT ACA GCT ACA AAT ACA AAA GAG GCC ACG GCA Val Asn Trp Thr Thr Asp Thr Ala Thr Asn Thr Lys Glu Ala Thr Ala 570 575 580 585			1959
ACT TGG ACC AAA ACA GGA TTT GTT CCC AGC CCC GAA AGA AAA TCT GCG Thr Trp Thr Lys Thr Gly Phe Val Pro Ser Pro Glu Arg Lys Ser Ala 590 595 600			2007
TTA GTA TGC AAT ACC CTA TGG GGA GTC TTT ACT GAC ATT CGC TCT CTG Leu Val Cys Asn Thr Leu Trp Gly Val Phe Thr Asp Ile Arg Ser Leu 605 610 615			2055
CAA CAG CTT GTA GAG ATC GGC GCA ACT GGT ATG GAA CAC AAA CAA GGT Gln Gln Leu Val Glu Ile Gly Ala Thr Gly Met Glu His Lys Gln Gly 620 625 630			2103
TTC TGG GTT TCC TCC ATG ACG AAC TTC CTG CAT AAG ACT GGA GAT GAA Phe Trp Val Ser Ser Met Thr Asn Phe Leu His Lys Thr Gly Asp Glu 635 640 645			2151
AAT CGC AAA GGC TTC CGT CAT ACC TCT GGA GGC TAC GTC ATC GGT GGA Asn Arg Lys Gly Phe Arg His Thr Ser Gly Gly Tyr Val Ile Gly Gly 650 655 660 665			2199
AGT GCT CAC ACT CCT AAA GAC GAC CTA TTT ACC TTT GCG TTC TGC CAT Ser Ala His Thr Pro Lys Asp Asp Leu Phe Thr Phe Ala Phe Cys His 670 675 680			2247
CTC TTT GCT AGA GAC AAA GAT TGT TTT ATC GCT CAC AAC AAC TCT AGA Leu Phe Ala Arg Asp Lys Asp Cys Phe Ile Ala His Asn Asn Ser Arg 685 690 695			2295
ACC TAC GGT GGA ACT TTA TTC TTC AAG CAC TCT CAT ACC CTA CAA CCC Thr Tyr Gly Gly Thr Leu Phe Phe Lys His Ser His Thr Leu Gln Pro 700 705 710			2343

CAA AAC TAT TTG AGA TTA GGA AGA GCA AAG TTT TCT GAA TCA GCT ATA	2391
Gln Asn Tyr Leu Arg Leu Gly Arg Ala Lys Phe Ser Glu Ser Ala Ile	
715 720 725	
GAA AAA TTC CCT AGG GAA ATT CCC CTA GCC TTG GAT GTC CAA GTT TCG	2439
Glu Lys Phe Pro Arg Glu Ile Pro Leu Ala Leu Asp Val Gln Val Ser	
730 735 740 745	
TTC AGC CAT TCA GAC AAC CGT ATG GAA ACG CAC TAT ACC TCA TTG CCA	2487
Phe Ser His Ser Asp Asn Arg Met Glu Thr His Tyr Thr Ser Leu Pro	
750 755 760	
GAA TCC GAA GGT TCT TGG AGC AAC GAG TGT ATA GCT GGT GGT ATC GGC	2535
Glu Ser Glu Gly Ser Trp Ser Asn Glu Cys Ile Ala Gly Gly Ile Gly	
765 770 775	
CTA GAC CTT CCT TTT GTT CTT TCC AAC CCA CAT CCT CTT TTC AAG ACC	2583
Leu Asp Leu Pro Phe Val Leu Ser Asn Pro His Pro Leu Phe Lys Thr	
780 785 790	
TTC ATT CCA CAG ATG AAA GTC GAA ATG GTT TAT GTA TCA CAA AAT AGC	2631
Phe Ile Pro Gln Met Lys Val Glu Met Val Tyr Val Ser Gln Asn Ser	
795 800 805	
TTC TTC GAA AGC TCT AGT GAT GGC CGT GGT TTT AGT ATT GGA AGG CTG	2679
Phe Phe Glu Ser Ser Ser Asp Gly Arg Gly Phe Ser Ile Gly Arg Leu	
810 815 820 825	
CTT AAC CTC TCG ATT CCT GTG GGT GCG AAA TTC GTG CAG GGG GAT ATC	2727
Leu Asn Leu Ser Ile Pro Val Gly Ala Lys Phe Val Gln Gly Asp Ile	
830 835 840	
GGA GAT TCC TAC ACC TAT GAT CTC TCA GGA TTC TTT GTT TCC GAT GTC	2775
Gly Asp Ser Tyr Thr Tyr Asp Leu Ser Gly Phe Phe Val Ser Asp Val	
845 850 855	
TAT CGT AAC AAT CCC CAA TCT ACA GCG ACT CTT GTG ATG AGC CCA GAC	2823
Tyr Arg Asn Asn Pro Gln Ser Thr Ala Thr Leu Val Met Ser Pro Asp	
860 865 870	
TCT TGG AAA ATT CGC GGT GGC AAT CTT TCA AGA CAG GCA TTT TTA CTG	2871
Ser Trp Lys Ile Arg Gly Gly Asn Leu Ser Arg Gln Ala Phe Leu Leu	
875 880 885	
AGG GGT AGC AAC AAC TAC GTC TAC AAC TCC AAT TGT GAG CTC TTC GGA	2919
Arg Gly Ser Asn Asn Tyr Val Tyr Asn Ser Asn Cys Glu Leu Phe Gly	
890 895 900 905	
CAT TAC GCT ATG GAA CTC CGT GGA TCT TCA AGG AAC TAC AAT GTA GAT	2967
His Tyr Ala Met Glu Leu Arg Gly Ser Ser Arg Asn Tyr Asn Val Asp	
910 915 920	
GTT GGT ACC AAA CTC CGA TT CTAGATTGCT AAAACTCCCT AGTTCTTCTA GGGAG	3022
Val Gly Thr Lys Leu Arg Phe	
925	
TTTTCTCATA CTTTTAGGGA AATATTTGCT ATAGGGAATG CTTTCCTTGC AAACGTGAAA	3082

AAATAACATT TGTCCCTCTT CAAAAAAGAT TTCTTTTAAT AATTTCTAGT TATAATTTTA 3142
TTTTAAAAAC AGTTAAATAA TTAATAGACA ATAATCTATT CTTATTGACT TCTTTTTT 3200

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 928 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Lys	Thr	Ser	Ile	Pro	Trp	Val	Leu	Val	Ser	Ser	Val	Leu	Ala	Phe
1				5				10					15		
Ser	Cys	His	Leu	Gln	Ser	Leu	Ala	Asn	Glu	Glu	Leu	Leu	Ser	Pro	Asp
			20					25					30		
Asp	Ser	Phe	Asn	Gly	Asn	Ile	Asp	Ser	Gly	Thr	Phe	Thr	Pro	Lys	Thr
		35					40					45			
Ser	Ala	Thr	Thr	Tyr	Ser	Leu	Thr	Gly	Asp	Val	Phe	Phe	Tyr	Glu	Pro
	50					55					60				
Gly	Lys	Gly	Thr	Pro	Leu	Ser	Asp	Ser	Cys	Phe	Lys	Gln	Thr	Thr	Asp
65					70					75					80
Asn	Leu	Thr	Phe	Leu	Gly	Asn	Gly	His	Ser	Leu	Thr	Phe	Gly	Phe	Ile
				85				90						95	
Asp	Ala	Gly	Thr	His	Ala	Gly	Ala	Ala	Ala	Ser	Thr	Thr	Ala	Asn	Lys
			100					105					110		
Asn	Leu	Thr	Phe	Ser	Gly	Phe	Ser	Leu	Leu	Ser	Phe	Asp	Ser	Ser	Pro
			115				120					125			
Ser	Thr	Thr	Val	Thr	Thr	Gly	Gln	Gly	Thr	Leu	Ser	Ser	Ala	Gly	Gly
			130			135						140			
Val	Asn	Leu	Glu	Asn	Ile	Arg	Lys	Leu	Val	Val	Ala	Gly	Asn	Phe	Ser
145					150					155					160
Thr	Ala	Asp	Gly	Gly	Ala	Ile	Lys	Gly	Ala	Ser	Phe	Leu	Leu	Thr	Gly
				165				170						175	
Thr	Ser	Gly	Asp	Ala	Leu	Phe	Ser	Asn	Asn	Ser	Ser	Ser	Thr	Lys	Gly
			180					185					190		
Gly	Ala	Ile	Ala	Thr	Thr	Ala	Gly	Ala	Arg	Ile	Ala	Asn	Asn	Thr	Gly
			195				200					205			
Tyr	Val	Arg	Phe	Leu	Ser	Asn	Ile	Ala	Ser	Thr	Ser	Gly	Gly	Ala	Ile
	210					215					220				
Asp	Asp	Glu	Gly	Thr	Ser	Ile	Leu	Ser	Asn	Asn	Lys	Phe	Leu	Tyr	Phe
225					230					235					240
Glu	Gly	Asn	Ala	Ala	Lys	Thr	Thr	Gly	Gly	Ala	Ile	Cys	Asn	Thr	Lys
				245					250					255	
Ala	Ser	Gly	Ser	Pro	Glu	Leu	Ile	Ile	Ser	Asn	Asn	Lys	Thr	Leu	Ile
			260					265					270		
Phe	Ala	Ser	Asn	Val	Ala	Glu	Thr	Ser	Gly	Gly	Ala	Ile	His	Ala	Lys
		275					280					285			
Lys	Leu	Ala	Leu	Ser	Ser	Gly	Gly	Phe	Thr	Glu	Phe	Leu	Arg	Asn	Asn
						295					300				
Val	Ser	Ser	Ala	Thr	Pro	Lys	Gly	Gly	Ala	Ile	Ser	Ile	Asp	Ala	Ser

305		310		315		320									
Gly	Glu	Leu	Ser	Leu	Ser	Ala	Glu	Thr	Gly	Asn	Ile	Thr	Phe	Val	Arg
		325							330					335	
Asn	Thr	Leu	Thr	Thr	Gly	Ser	Thr	Asp	Thr	Pro	Lys	Arg	Asn	Ala	
		340						345					350		
Ile	Asn	Ile	Gly	Ser	Asn	Gly	Lys	Phe	Thr	Glu	Leu	Arg	Ala	Ala	Lys
		355					360					365			
Asn	His	Thr	Ile	Phe	Phe	Tyr	Asp	Pro	Ile	Thr	Ser	Glu	Gly	Thr	Ser
		370				375					380				
Ser	Asp	Val	Leu	Lys	Ile	Asn	Asn	Gly	Ser	Ala	Gly	Ala	Leu	Asn	Pro
385					390					395				400	
Tyr	Gln	Gly	Thr	Ile	Leu	Phe	Ser	Gly	Glu	Thr	Leu	Thr	Ala	Asp	Glu
		405						410					415		
Leu	Lys	Val	Ala	Asp	Asn	Leu	Lys	Ser	Ser	Phe	Thr	Gln	Pro	Val	Ser
		420						425					430		
Leu	Ser	Gly	Gly	Lys	Leu	Leu	Leu	Gln	Lys	Gly	Val	Thr	Leu	Glu	Ser
		435					440					445			
Thr	Ser	Phe	Ser	Gln	Glu	Ala	Gly	Ser	Leu	Leu	Gly	Met	Asp	Ser	Gly
		450				455					460				
Thr	Thr	Leu	Ser	Thr	Thr	Ala	Gly	Ser	Ile	Thr	Ile	Thr	Asn	Leu	Gly
465					470					475				480	
Ile	Asn	Val	Asp	Ser	Leu	Gly	Leu	Lys	Gln	Pro	Val	Ser	Leu	Thr	Ala
		485						490					495		
Lys	Gly	Ala	Ser	Asn	Lys	Val	Ile	Val	Ser	Gly	Lys	Leu	Asn	Leu	Ile
		500						505					510		
Asp	Ile	Glu	Gly	Asn	Ile	Tyr	Glu	Ser	His	Met	Phe	Ser	His	Asp	Gln
		515					520					525			
Leu	Phe	Ser	Leu	Leu	Lys	Ile	Thr	Val	Asp	Ala	Asp	Val	Asp	Thr	Asn
		530				535					540				
Val	Asp	Ile	Ser	Ser	Leu	Ile	Pro	Val	Pro	Ala	Glu	Asp	Pro	Asn	Ser
545					550					555				560	
Glu	Tyr	Gly	Phe	Gln	Gly	Gln	Trp	Asn	Val	Asn	Trp	Thr	Thr	Asp	Thr
		565						570						575	
Ala	Thr	Asn	Thr	Lys	Glu	Ala	Thr	Ala	Thr	Trp	Thr	Lys	Thr	Gly	Phe
		580						585					590		
Val	Pro	Ser	Pro	Glu	Arg	Lys	Ser	Ala	Leu	Val	Cys	Asn	Thr	Leu	Trp
		595					600					605			
Gly	Val	Phe	Thr	Asp	Ile	Arg	Ser	Leu	Gln	Gln	Leu	Val	Glu	Ile	Gly
		610				615					620				
Ala	Thr	Gly	Met	Glu	His	Lys	Gln	Gly	Phe	Trp	Val	Ser	Ser	Met	Thr
625					630					635				640	
Asn	Phe	Leu	His	Lys	Thr	Gly	Asp	Glu	Asn	Arg	Lys	Gly	Phe	Arg	His
		645						650					655		
Thr	Ser	Gly	Gly	Tyr	Val	Ile	Gly	Gly	Ser	Ala	His	Thr	Pro	Lys	Asp
		660						665					670		
Asp	Leu	Phe	Thr	Phe	Ala	Phe	Cys	His	Leu	Phe	Ala	Arg	Asp	Lys	Asp
		675					680					685			
Cys	Phe	Ile	Ala	His	Asn	Asn	Ser	Arg	Thr	Tyr	Gly	Gly	Thr	Leu	Phe
		690				695					700				
Phe	Lys	His	Ser	His	Thr	Leu	Gln	Pro	Gln	Asn	Tyr	Leu	Arg	Leu	Gly
705					710					715				720	
Arg	Ala	Lys	Phe	Ser	Glu	Ser	Ala	Ile	Glu	Lys	Phe	Pro	Arg	Glu	Ile
		725						730					735		
Pro	Leu	Ala	Leu	Asp	Val	Gln	Val	Ser	Phe	Ser	His	Ser	Asp	Asn	Arg
		740						745					750		
Met	Glu	Thr	His	Tyr	Thr	Ser	Leu	Pro	Glu	Ser	Glu	Gly	Ser	Trp	Ser
		755					760					765			

Asn Glu Cys Ile Ala Gly Gly Ile Gly Leu Asp Leu Pro Phe Val Leu
 770 775 780
 Ser Asn Pro His Pro Leu Phe Lys Thr Phe Ile Pro Gln Met Lys Val
 785 790 795 800
 Glu Met Val Tyr Val Ser Gln Asn Ser Phe Phe Glu Ser Ser Ser Asp
 805 810 815
 Gly Arg Gly Phe Ser Ile Gly Arg Leu Leu Asn Leu Ser Ile Pro Val
 820 825 830
 Gly Ala Lys Phe Val Gln Gly Asp Ile Gly Asp Ser Tyr Thr Tyr Asp
 835 840 845
 Leu Ser Gly Phe Phe Val Ser Asp Val Tyr Arg Asn Asn Pro Gln Ser
 850 855 860
 Thr Ala Thr Leu Val Met Ser Pro Asp Ser Trp Lys Ile Arg Gly Gly
 865 870 875 880
 Asn Leu Ser Arg Gln Ala Phe Leu Leu Arg Gly Ser Asn Asn Tyr Val
 885 890 895
 Tyr Asn Ser Asn Cys Glu Leu Phe Gly His Tyr Ala Met Glu Leu Arg
 900 905 910
 Gly Ser Ser Arg Asn Tyr Asn Val Asp Val Gly Thr Lys Leu Arg Phe
 915 920 925

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2815 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATGAAATCGC	AATTTTCCTG	GTTAGTGCTC	TCTTCGACAT	TGGCATGTTT	TACTAGTTGT	60
TCCACTGTTT	TGCTGCAAC	TGCTGAAAAT	ATAGGCCCCCT	CTGATAGCTT	TGACGGAAGT	120
ACTAACACAG	GCACCTATAC	TCCTAAAAAT	ACGACTACTG	GAATAGACTA	TACTCTGACA	180
GGAGATATAA	CTCTGCAAAA	CCTTGGGGAT	TCGGCAGCTT	TAACGAAGGG	TGTTTTTTCT	240
GACACTACGG	AATCTTTAAG	CTTTGCCGGT	AAGGGGTACT	CACTTTCTTT	TTTAAATATT	300
AAGTCTAGTG	CTGAAGGCGC	AGCACTTTCT	GTTACAACCTG	ATAAAAATCT	GTCGCTAACA	360
GGATTTTTCGA	GTCCTTACTTT	CTTAGCGGCC	CCATCATCGG	TAATCACAAC	CCCCTCAGGA	420
AAAGGTGCAG	TTAAATGTGG	AGGGGATCTT	ACATTTGATA	ACAATGGAAC	TATTTTATTT	480
AAACAAGATT	ACTGTGAGGA	AAATGGCGGA	GCCATTTCTA	CCAAGAATCT	TTCTTTGAAA	540
AACAGCACGG	GATCGATTTC	TTTTGAAGGG	AATAAATCGA	GCGCAACAGG	GAAAAAAGGT	600
GGGGCTATTT	GTGCTACTGG	TACTGTAGAT	ATTACAAATA	ATACGGCTCC	TACCCCTCTT	660
TCGAACAATA	TTGCTGAAGC	TGCAGGTGGA	GCTATAAATA	GCACAGGAAA	CTGTACAATT	720
ACAGGGAATA	CGTCTCTTGT	ATTTTCTGAA	AATAGTGTGA	CAGCGACCGC	AGGAAATGGA	780
GGAGCTCTTT	CTGGAGATGC	CGATGTTACC	ATATCTGGGA	ATCAGAGTGT	AACTTTCTCA	840
GGAAACCAAG	CTGTAGCTAA	TGGCGGAGCC	ATTTATGCTA	AGAAGCTTAC	ACTGGCTTCC	900
GGGGGGGGGG	GGGGTATCTC	CTTTTCTAAC	AATATAGTCC	AAGGTACCAC	TGCAGGTAAT	960
GGTGGAGCCA	TTTCTATACT	GGCAGCTGGA	GAGTGTAGTC	TTTCAGCAGA	AGCAGGGGAC	1020
ATTACCTTCA	ATGGGAATGC	CATTGTTGCA	ACTACACCAC	AAACTACAAA	AAGAAATTCT	1080
ATTGACATAG	GATCTACTGC	AAAGATCACG	AATTTACGTG	CAATATCTGG	GCATAGCATC	1140
TTTTTCTACG	ATCCGATTAC	TGCTAATACG	GCTGCGGATT	CTACAGATAC	TTTAAATCTC	1200
AATAAGGCTG	ATGCAGGTAA	TAGTACAGAT	TATAGTGGGT	CGATTGTTTT	TTCTGGTGAA	1260

```

AAGCTCTCTG AAGATGAAGC AAAAGTTGCA GACAACCTCA CTTCTACGCT GAAGCAGCCT 1320
GTAACCTCTAA CTGCAGGAAA TTTAGTACTT AAACGTGGTG TCACTCTCGA TACGAAAGGC 1380
TTTACTCAGA CCGCGGGTTC CTCTGTTATT ATGGATGCGG GCACAACGTT AAAAGCAAGT 1440
ACAGAGGAGG TCACTTTAAC AGGTCTTTCC ATTCCTGTAG ACTCTTTAGG CGAGGGTAAG 1500
AAAGTTGTAA TTGCTGCTTC TGCAGCAAGT AAAAATGTAG CCCTTAGTGG TCCGATTCTT 1560
CTTTTGGATA ACCAAGGGAA TGCTTATGAA AATCACGACT TAGGAAAAAC TCAAGACTTT 1620
TCATTTGTGC AGCTCTCTGC TCTGGGTACT GCAACAAC TA CAGATGTTCC AGCGGTTCTT 1680
ACAGTAGCAA CTCCTACGCA CTATGGGTAT CAAGGTACTT GGGGAATGAC TTGGGTGTGAT 1740
GATACCGCAA GCACTCCAAA GACTAAGACA GCGACATTAG CTTGGACCAA TACAGGCTAC 1800
CTTCCGAATC CTGAGCGTCA AGGACCTTTA GTTCCTAATA GCCTTTGGGG ATCTTTTTCA 1860
GACATCCAAG CGATTCAAGG TGTCATAGAG AGAAGTGCTT TGACTCTTTG TTCAGATCGA 1920
GGCTTCTGGG CTGCGGGAGT CGCCAATTTC TTAGATAAAG ATAAGAAAGG GGAAAAACGC 1980
AAATACCGTC ATAAATCTGG TGGATATGCT ATCGGAGGTG CAGCGCAAAC TTGTTCTGAA 2040
AACTTAATTA GCTTTGCCIT TTGCCAATC TTTGGTAGCG ATAAAGATT CTTAGTCGCT 2100
AAAAATCATA CTGATACCTA TGCAGGAGCC TTCTATATCC AACACATTAC AGAATGTAGT 2160
GGGTTCATAG GTTGTCTCTT AGATAAACTT CCTGGCTCTT GGAGTCATAA ACCCCTCGTT 2220
TTAGAAGGGC AGCTCGCTTA TAGCCACGTC AGTAATGATC TGAAGACAAA GTATACTGCG 2280
TATCCTGAGG TGAAAGGTTT TTGGGGGAAT AATGCTTTTA ACATGATGTT GGGAGCTTCT 2340
TCTCATTCTT ATCCTGAATA CCTGCATTGT TTTGATACCT ATGCTCCATA CATCAAAC TG 2400
AATCTGACCT ATATACGTCA GGACAGCTTC TCGGAGAAAG GTACAGAAGG AAGATCTTTT 2460
GATGACAGCA ACCTCTTCAA TTTATCTTTG CCTATAGGGG TGAAGTTTGA GAAGTTCTCT 2520
GATTGTAATG ACTTTTCTTA TGATCTGACT TTATCCTATG TTCCTGATCT TATCCGCAAT 2580
GATCCCAAAT GCACTACAGC ACTTGTAATC AGCGGAGCCT CTTGGGAAAC TTATGCCAAT 2640
AACTTAGCAC GACAGGCCIT GCAAGTGCCT GCAGGCAGTC ACTACGCCTT CTCTCCTATG 2700
TTTGAAGTGC TCGGCCAGTT TGTCTTTGAA GTTCGTGGAT CCTCACGGAT TTATAATGTA 2760
GATCTTGGGG GTAAGTTCCA ATTCTAGGAG CGTCTCTCAT GTCTCAGAAA TTCTG 2815

```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 928 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Met Lys Ser Gln Phe Ser Trp Leu Val Leu Ser Ser Thr Leu Ala Cys
 1             5             10             15
Phe Thr Ser Cys Ser Thr Val Phe Ala Ala Thr Ala Glu Asn Ile Gly
 20             25             30
Pro Ser Asp Ser Phe Asp Gly Ser Thr Asn Thr Gly Thr Tyr Thr Pro
 35             40             45
Lys Asn Thr Thr Thr Gly Ile Asp Tyr Thr Leu Thr Gly Asp Ile Thr
 50             55             60
Leu Gln Asn Leu Gly Asp Ser Ala Ala Leu Thr Lys Gly Cys Phe Ser
 65             70             75             80
Asp Thr Thr Glu Ser Leu Ser Phe Ala Gly Lys Gly Tyr Ser Leu Ser
 85             90             95
Phe Leu Asn Ile Lys Ser Ser Ala Glu Gly Ala Ala Leu Ser Val Thr
100             105             110
Thr Asp Lys Asn Leu Ser Leu Thr Gly Phe Ser Ser Leu Thr Phe Leu
115             120             125
Ala Ala Pro Ser Ser Val Ile Thr Thr Pro Ser Gly Lys Gly Ala Val
130             135             140

```

Lys Cys Gly Gly Asp Leu Thr Phe Asp Asn Asn Gly Thr Ile Leu Phe
 145 150 155 160
 Lys Gln Asp Tyr Cys Glu Glu Asn Gly Gly Ala Ile Ser Thr Lys Asn
 165 170 175
 Leu Ser Leu Lys Asn Ser Thr Gly Ser Ile Ser Phe Glu Gly Asn Lys
 180 185 190
 Ser Ser Ala Thr Gly Lys Lys Gly Gly Ala Ile Cys Ala Thr Gly Thr
 195 200 205
 Val Asp Ile Thr Asn Asn Thr Ala Pro Thr Leu Phe Ser Asn Asn Ile
 210 215 220
 Ala Glu Ala Ala Gly Gly Ala Ile Asn Ser Thr Gly Asn Cys Thr Ile
 225 230 235 240
 Thr Gly Asn Thr Ser Leu Val Phe Ser Glu Asn Ser Val Thr Ala Thr
 245 250 255
 Ala Gly Asn Gly Gly Ala Leu Ser Gly Asp Ala Asp Val Thr Ile Ser
 260 265 270
 Gly Asn Gln Ser Val Thr Phe Ser Gly Asn Gln Ala Val Ala Asn Gly
 275 280 285
 Gly Ala Ile Tyr Ala Lys Lys Leu Thr Leu Ala Ser Gly Gly Gly Gly
 290 295 300
 Gly Ile Ser Phe Ser Asn Asn Ile Val Gln Gly Thr Thr Ala Gly Asn
 305 310 315 320
 Gly Gly Ala Ile Ser Ile Leu Ala Ala Gly Glu Cys Ser Leu Ser Ala
 325 330 335
 Glu Ala Gly Asp Ile Thr Phe Asn Gly Asn Ala Ile Val Ala Thr Thr
 340 345 350
 Pro Gln Thr Thr Lys Arg Asn Ser Ile Asp Ile Gly Ser Thr Ala Lys
 355 360 365
 Ile Thr Asn Leu Arg Ala Ile Ser Gly His Ser Ile Phe Phe Tyr Asp
 370 375 380
 Pro Ile Thr Ala Asn Thr Ala Ala Asp Ser Thr Asp Thr Leu Asn Leu
 385 390 395 400
 Asn Lys Ala Asp Ala Gly Asn Ser Thr Asp Tyr Ser Gly Ser Ile Val
 405 410 415
 Phe Ser Gly Glu Lys Leu Ser Glu Asp Glu Ala Lys Val Ala Asp Asn
 420 425 430
 Leu Thr Ser Thr Leu Lys Gln Pro Val Thr Leu Thr Ala Gly Asn Leu
 435 440 445
 Val Leu Lys Arg Gly Val Thr Leu Asp Thr Lys Gly Phe Thr Gln Thr
 450 455 460
 Ala Gly Ser Ser Val Ile Met Asp Ala Gly Thr Thr Leu Lys Ala Ser
 465 470 475 480
 Thr Glu Glu Val Thr Leu Thr Gly Leu Ser Ile Pro Val Asp Ser Leu
 485 490 495
 Gly Glu Gly Lys Lys Val Val Ile Ala Ala Ser Ala Ala Ser Lys Asn
 500 505 510
 Val Ala Leu Ser Gly Pro Ile Leu Leu Leu Asp Asn Gln Gly Asn Ala
 515 520 525
 Tyr Glu Asn His Asp Leu Gly Lys Thr Gln Asp Phe Ser Phe Val Gln
 530 535 540
 Leu Ser Ala Leu Gly Thr Ala Thr Thr Thr Asp Val Pro Ala Val Pro
 545 550 555 560
 Thr Val Ala Thr Pro Thr His Tyr Gly Tyr Gln Gly Thr Trp Gly Met
 565 570 575
 Thr Trp Val Asp Asp Thr Ala Ser Thr Pro Lys Thr Lys Thr Ala Thr
 580 585 590
 Leu Ala Trp Thr Asn Thr Gly Tyr Leu Pro Asn Pro Glu Arg Gln Gly

595	600	605
Pro Leu Val	Pro Asn Ser Leu Trp Gly Ser Phe Ser Asp Ile Gln Ala	
610	615	620
Ile Gln Gly Val	Ile Glu Arg Ser Ala Leu Thr Leu Cys Ser Asp Arg	
625	630	635
Gly Phe Trp Ala	Ala Gly Val Ala Asn Phe Leu Asp Lys Asp Lys Lys	640
	645	650
Gly Glu Lys Arg	Lys Tyr Arg His Lys Ser Gly Gly Tyr Ala Ile Gly	655
	660	665
Gly Ala Ala Gln Thr Cys Ser Glu Asn Leu Ile Ser Phe Ala Phe Cys		670
	675	680
Gln Leu Phe Gly Ser Asp Lys Asp Phe Leu Val Ala Lys Asn His Thr		685
	690	695
Asp Thr Tyr Ala Gly Ala Phe Tyr Ile Gln His Ile Thr Glu Cys Ser		700
705	710	715
Gly Phe Ile Gly Cys Leu Leu Asp Lys Leu Pro Gly Ser Trp Ser His		720
	725	730
Lys Pro Leu Val Leu Glu Gly Gln Leu Ala Tyr Ser His Val Ser Asn		735
	740	745
Asp Leu Lys Thr Lys Tyr Thr Ala Tyr Pro Glu Val Lys Gly Ser Trp		750
	755	760
Gly Asn Asn Ala Phe Asn Met Met Leu Gly Ala Ser Ser His Ser Tyr		765
	770	775
Pro Glu Tyr Leu His Cys Phe Asp Thr Tyr Ala Pro Tyr Ile Lys Leu		780
785	790	795
Asn Leu Thr Tyr Ile Arg Gln Asp Ser Phe Ser Glu Lys Gly Thr Glu		800
	805	810
Gly Arg Ser Phe Asp Asp Ser Asn Leu Phe Asn Leu Ser Leu Pro Ile		815
	820	825
Gly Val Lys Phe Glu Lys Phe Ser Asp Cys Asn Asp Phe Ser Tyr Asp		830
	835	840
Leu Thr Leu Ser Tyr Val Pro Asp Leu Ile Arg Asn Asp Pro Lys Cys		845
	850	855
Thr Thr Ala Leu Val Ile Ser Gly Ala Ser Trp Glu Thr Tyr Ala Asn		860
865	870	875
Asn Leu Ala Arg Gln Ala Leu Gln Val Arg Ala Gly Ser His Tyr Ala		880
	885	890
Phe Ser Pro Met Phe Glu Val Leu Gly Gln Phe Val Phe Glu Val Arg		895
	900	905
Gly Ser Ser Arg Ile Tyr Asn Val Asp Leu Gly Gly Lys Phe Gln Phe		910
	915	920
		925

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3052 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATGCGATTTT	CGCTCTGCGG	ATTTCCTCTA	GTTTITTTCTT	TAACATTGCT	CTCAGTCTTC	60
GACACTTCTT	TGAGTGCTAC	TACGATTTCT	TTAACCCAG	AAGATAGTTT	TCATGGAGAT	120
AGTCAGAATG	CAGAACGTTT	TTATAATGTT	CAAGCTGGGG	ATGTCTATAG	CCTTACTGGT	180

GATGTCTCAA	TATCTAACGT	CGATAACTCT	GCATTAAATA	AAGCCTGCTT	CAATGTGACC	240
TCAGGAAGTG	TGACGTTTCG	AGGAAATCAT	CATGGGTTAT	ATTTTAATAA	TATTTCTCTCA	300
GGAACTACAA	AGGAAGGGGC	TGTACTTTGT	TGCCAAGATC	CTCAAGCAAC	GGCACGTTTT	360
TCTGGGTTCT	CCACGCTCTC	TTTTATTTCAG	AGCCCCGGAG	ATATTAAAGA	ACAGGGATGT	420
CTCTATTCAA	AAAATGCACT	TATGCTCTTA	AACAATTATG	TAGTGCGTTT	TGAACAAAAC	480
CAAAGTAAGA	CTAAAGGCGG	AGCTATTAGT	GGGGCGAATG	TTACTATAGT	AGGCAACTAC	540
GATTCCGTCT	CTTCTATCA	GAATGCAGCC	ACTTTTGGAG	GTGCTATCCA	TTCTTCAGGT	600
CCCCTACAGA	TTGCAGTAAA	TCAGGCAGAG	ATAAGATTTG	CACAAAATAC	TGCCAAGAAT	660
GGTTCGGAG	GGGCTTTGTA	CTCCGATGGT	GATATTGATA	TTGATCAGAA	TGCTTATGTT	720
CTATTTGAG	AAAATGAGGC	ATTGACTACT	GCTATAGGTA	AGGGAGGGGC	TGTCTGTTGT	780
CTTCCCACTT	CAGGAAGTAG	TACTCCAGTT	CCTATTGTGA	CTTTCTCTGA	CAATAAACAG	840
TTAGTCTTTG	AAAGAAACCA	TTCCATAATG	GGTGGCGGAG	CCATTTATGC	TAGGAAACTT	900
AGCATCTCTT	CAGGAGGTCC	TACTCTATTT	ATCAATAATA	TATCATATGC	AAATTGCGAA	960
AATTTAGGTG	GAGCTATTGC	CATTGATACT	GGAGGGGAGA	TCAGTTTATC	AGCAGAGAAA	1020
GGACAAATTA	CATTCGAAGG	AAACCGGACG	AGCTTACCGT	TTTTGAATGG	CATCCATCTT	1080
TTACAAAATG	CTAAATTCCT	GAAATTACAG	GCGGAAATG	GATGCTCTAT	AGAATTTTAT	1140
GATCCCTATTA	CTTCTGAAGC	AGATGGGTCT	ACCCAATTGA	ATATCAACGG	AGATCCTAAA	1200
AATAAAGAGT	ACACAGGGAC	CATACTCTTT	TCTGGAGAAA	AGAGTCTAGC	AAACGATCCT	1260
AGGGATTTTA	AATCTACAAT	CCCTCAGAAC	GTCAACCTGT	CTGCAGGATA	CTTAGTTATT	1320
AAAGAGGGGG	CCGAAGTCAC	AGTTTCAAAA	TTCACGCAGT	CTCCAGGATC	GCATTTAGTT	1380
TTAGATTTAG	GAACCAAAT	GATAGCCTCT	AAGGAAGACA	TTGCCATCAC	AGGCCTCGCG	1440
ATAGATATAG	ATAGCTTAAG	CTCATCCTCA	ACAGCAGCTG	TTATTAAAGC	AAACACCGCA	1500
AATAAACAGA	TATCCGTGAC	GGACTCTATA	GAACCTATCT	CGCCTACTGG	CAATGCCTAT	1560
GAAGATCTCA	GAATGAGAAA	TTACAGACAG	TTCCCTCTGC	TCTCTTTAGA	GCCTGGAGCC	1620
GGGGGTAGTG	TGACTGTAAAC	TGCTGGAGAT	TTCTTACCGG	TAAGTCCCCA	TTATGGTTTT	1680
CAAGGCAATT	GGAAATTAGC	TTGGACAGGA	ACTGGAAACA	AAGTTGGAGA	ATTCTTCTGG	1740
GATAAAATAA	ATTATAAGCC	TAGACCTGAA	AAAGAAGGAA	ATTTAGTTCC	TAATATCTTG	1800
TGGGGGAATG	CTGTAAATGT	CAGATCCTTA	ATGCAGGTTT	AAGAGACCCA	TGCATCGAGC	1860
TTACAGACAG	ATCGAGGGCT	GTGGATCGAT	GGAATTGGGA	ATTTCTTTCA	TGTATCTGCC	1920
TCCGAAGACA	ATATAAGGTA	CCGTCATAAC	AGCGGTGGAT	ATGTTCTATC	TGTAAATAAT	1980
GAGATCACAC	CTAAGCACTA	TACTTCGATG	GCATTTTCCC	AACTCTTTAG	TAGAGACAAG	2040
GACTATGCGG	TTTCCAACAA	CGAATACAGA	ATGTATTTAG	GATCGTATCT	CTATCAATAT	2100
ACAACCTCCC	TAGGGAATAT	TTTCCGTTAT	GCTTCGCGTA	ACCCTAATGT	AAACGTCGGG	2160
ATTCTCTCAA	GAAGGTTTCT	TCAAAATCCT	CTTATGATTT	TTCAATTTTT	GTGTGCTTAT	2220
GGTCATGCCA	CCAATGATAT	GAAAACAGAC	TACGCAAATT	TCCCTATGGT	GAAAAACAGC	2280
TGGAGAAACA	ATTGTTGGGC	TATAGAGTGC	GGAGGGAGCA	TGCCTCTATT	GGTATTTGAG	2340
AACGGAAGAC	TTTTCCAAGG	TGCCATCCCA	TTTATGAAAC	TACAATTAGT	TTATGCTTAT	2400
CAGGGAGATT	TCAAAGAGAC	GACTGCAGAT	GGCCGTAGAT	TTAGTAATGG	GAGTTTAACA	2460
TCGATTTCTG	TACCTCTAGG	CATACGCTTT	GAGAAGCTGG	CACTTTCTCA	GGATGTACTC	2520
TATGACTTTA	GTTTCTCCTA	TATTCCTGAT	ATTTTCCGTA	AGGATCCCTC	ATGTGAAGCT	2580
GCTCTGGTGA	TTAGCGGAGA	CTCCTGGCTT	GTTCCGGCAG	CACACGPATC	AAGACATGCT	2640
TTTGTAGGGA	GTGGAACGGG	TCGGTATCAC	TTTAACGACT	ATACTGAGCT	CTTATGTGCA	2700
GGAAGTATAG	AATGCCGCCC	CCATGCTAGG	AATTATAATA	TAAACTGTGG	AAGCAAATTT	2760
CGTTTTTAGA	AGGTTTCCAT	TGCCTGTGTG	GTTCCGGATC	TTAACTATAA	ATCCTGGACT	2820
ATGGATCATA	GGCATTGGGT	TTCTCGAACT	TGTGTGGAGA	ATAACGACAT	TTTATATGCA	2880
TAACGGAATA	CTCGTATCAC	CTCAGCCCCT	AGAGACATTC	TTTAGGGGTT	CTTTATTTGT	2940
CTAAACTTCG	TATTTTATCG	AGAATCCTTT	ACGTTCTTGG	TTTGCTTGTC	TCCGAGGAGT	3000
TCTCTAACGA	ATCATAGGGA	TTCCAGGGTT	CTGTTCCCTG	AGTCCTTTGG	CA	3052

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 922 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

Met Arg Phe Ser Leu Cys Gly Phe Pro Leu Val Phe Ser Leu Thr Leu
 1           5           10           15
Leu Ser Val Phe Asp Thr Ser Leu Ser Ala Thr Thr Ile Ser Leu Thr
          20           25           30
Pro Glu Asp Ser Phe His Gly Asp Ser Gln Asn Ala Glu Arg Ser Tyr
          35           40           45
Asn Val Gln Ala Gly Asp Val Tyr Ser Leu Thr Gly Asp Val Ser Ile
 50           55           60
Ser Asn Val Asp Asn Ser Ala Leu Asn Lys Ala Cys Phe Asn Val Thr
 65           70           75           80
Ser-Gly Ser Val Thr Phe Ala Gly Asn His His Gly Leu Tyr Phe Asn
          85           90           95
Asn Ile Ser Ser Gly Thr Thr Lys Glu Gly Ala Val Leu Cys Cys Gln
          100          105          110
Asp Pro Gln Ala Thr Ala Arg Phe Ser Gly Phe Ser Thr Leu Ser Phe
          115          120          125
Ile Gln Ser Pro Gly Asp Ile Lys Glu Gln Gly Cys Leu Tyr Ser Lys
          130          135          140
Asn Ala Leu Met Leu Leu Asn Asn Tyr Val Val Arg Phe Glu Gln Asn
145          150          155          160
Gln Ser Lys Thr Lys Gly Gly Ala Ile Ser Gly Ala Asn Val Thr Ile
          165          170          175
Val Gly Asn Tyr Asp Ser Val Ser Phe Tyr Gln Asn Ala Ala Thr Phe
          180          185          190
Gly Gly Ala Ile His Ser Ser Gly Pro Leu Gln Ile Ala Val Asn Gln
          195          200          205
Ala Glu Ile Arg Phe Ala Gln Asn Thr Ala Lys Asn Gly Ser Gly Gly
          210          215          220
Ala Leu Tyr Ser Asp Gly Asp Ile Asp Ile Asp Gln Asn Ala Tyr Val
225          230          235          240
Leu Phe Arg Glu Asn Glu Ala Leu Thr Thr Ala Ile Gly Lys Gly Gly
          245          250          255
Ala Val Cys Cys Leu Pro Thr Ser Gly Ser Ser Thr Pro Val Pro Ile
          260          265          270
Val Thr Phe Ser Asp Asn Lys Gln Leu Val Phe Glu Arg Asn His Ser
          275          280          285
Ile Met Gly Gly Gly Ala Ile Tyr Ala Arg Lys Leu Ser Ile Ser Ser
          290          295          300
Gly Gly Pro Thr Leu Phe Ile Asn Asn Ile Ser Tyr Ala Asn Ser Gln
305          310          315          320
Asn Leu Gly Gly Ala Ile Ala Ile Asp Thr Gly Gly Glu Ile Ser Leu
          325          330          335
Ser Ala Glu Lys Gly Thr Ile Thr Phe Gln Gly Asn Arg Thr Ser Leu
          340          345          350
Pro Phe Leu Asn Gly Ile His Leu Leu Gln Asn Ala Lys Phe Leu Lys
          355          360          365
Leu Gln Ala Arg Asn Gly Cys Ser Ile Glu Phe Tyr Asp Pro Ile Thr
          370          375          380
Ser Glu Ala Asp Gly Ser Thr Gln Leu Asn Ile Asn Gly Asp Pro Lys
385          390          395          400
Asn Lys Glu Tyr Thr Gly Thr Ile Leu Phe Ser Gly Glu Lys Ser Leu
          405          410          415
Ala Asn Asp Pro Arg Asp Phe Lys Ser Thr Ile Pro Gln Asn Val Asn

```

420	425	430
Leu Ser Ala Gly Tyr Leu Val Ile Lys Glu Gly Ala Glu Val Thr Val		
435	440	445
Ser Lys Phe Thr Gln Ser Pro Gly Ser His Leu Val Leu Asp Leu Gly		
450	455	460
Thr Lys Leu Ile Ala Ser Lys Glu Asp Ile Ala Ile Thr Gly Leu Ala		
465	470	475
Ile Asp Ile Asp Ser Leu Ser Ser Ser Ser Thr Ala Ala Val Ile Lys		
485	490	495
Ala Asn Thr Ala Asn Lys Gln Ile Ser Val Thr Asp Ser Ile Glu Leu		
500	505	510
Ile Ser Pro Thr Gly Asn Ala Tyr Glu Asp Leu Arg Met Arg Asn Ser		
515	520	525
Gln Thr Phe Pro Leu Leu Ser Leu Glu Pro Gly Ala Gly Gly Ser Val		
530	535	540
Thr Val Thr Ala Gly Asp Phe Leu Pro Val Ser Pro His Tyr Gly Phe		
545	550	555
Gln Gly Asn Trp Lys Leu Ala Trp Thr Gly Thr Gly Asn Lys Val Gly		
565	570	575
Glu Phe Phe Trp Asp Lys Ile Asn Tyr Lys Pro Arg Pro Glu Lys Glu		
580	585	590
Gly Asn Leu Val Pro Asn Ile Leu Trp Gly Asn Ala Val Asn Val Arg		
595	600	605
Ser Leu Met Gln Val Gln Glu Thr His Ala Ser Ser Leu Gln Thr Asp		
610	615	620
Arg Gly Leu Trp Ile Asp Gly Ile Gly Asn Phe Phe His Val Ser Ala		
625	630	635
Ser Glu Asp Asn Ile Arg Tyr Arg His Asn Ser Gly Gly Tyr Val Leu		
645	650	655
Ser Val Asn Asn Glu Ile Thr Pro Lys His Tyr Thr Ser Met Ala Phe		
660	665	670
Ser Gln Leu Phe Ser Arg Asp Lys Asp Tyr Ala Val Ser Asn Asn Glu		
675	680	685
Tyr Arg Met Tyr Leu Gly Ser Tyr Leu Tyr Gln Tyr Thr Thr Ser Leu		
690	695	700
Gly Asn Ile Phe Arg Tyr Ala Ser Arg Asn Pro Asn Val Asn Val Gly		
705	710	715
Ile Leu Ser Arg Arg Phe Leu Gln Asn Pro Leu Met Ile Phe His Phe		
725	730	735
Leu Cys Ala Tyr Gly His Ala Thr Asn Asp Met Lys Thr Asp Tyr Ala		
740	745	750
Asn Phe Pro Met Val Lys Asn Ser Trp Arg Asn Asn Cys Trp Ala Ile		
755	760	765
Glu Cys Gly Gly Ser Met Pro Leu Leu Val Phe Glu Asn Gly Arg Leu		
770	775	780
Phe Gln Gly Ala Ile Pro Phe Met Lys Leu Gln Leu Val Tyr Ala Tyr		
785	790	795
Gln Gly Asp Phe Lys Glu Thr Thr Ala Asp Gly Arg Arg Phe Ser Asn		
805	810	815
Gly Ser Leu Thr Ser Ile Ser Val Pro Leu Gly Ile Arg Phe Glu Lys		
820	825	830
Leu Ala Leu Ser Gln Asp Val Leu Tyr Asp Phe Ser Phe Ser Tyr Ile		
835	840	845
Pro Asp Ile Phe Arg Lys Asp Pro Ser Cys Glu Ala Ala Leu Val Ile		
850	855	860
Ser Gly Asp Ser Trp Leu Val Pro Ala Ala His Val Ser Arg His Ala		
865	870	875
		880

Phe	Val	Gly	Ser	Gly	Thr	Gly	Arg	Tyr	His	Phe	Asn	Asp	Tyr	Thr	Gl
				885					890					895	
Leu	Leu	Cys	Arg	Gly	Ser	Ile	Glu	Cys	Arg	Pro	His	Ala	Arg	Asn	Tyr
			900					905					910		
Asn	Ile	Asn	Cys	Gly	Ser	Lys	Phe	Arg	Phe						
		915					920								

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2526 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

ATGAAGATTTC	CACTCCGCTT	TTTATTGATA	TCATTAGTAC	CTACGCTTTC	TATGTCGAAT	60
TTATTAGGAG	CTGCTACTAC	CGAAGAGCTA	TCGGCTAGCA	ATAGCTTCGA	TGGAACTACA	120
TCAACAACAA	GCTTTTCTAG	TAAAACATCA	TCGGCTACAG	ATGGCACCAA	TTATGTTTTT	180
AAAGATTCTG	TAGTTATAGA	AAATGTACCC	AAAACAGGGG	AAACTCAGTC	TACTAGTTGT	240
TTTAAAAATG	ACGCTGCAGC	TGGAGATCTA	AATTTCTTAG	GAGGGGGATT	TTCTTTTACA	300
TTTAGCAATA	TCGATGCAAC	CACGGCTTCT	GGAGCTGCTA	TTGGAAGTGA	AGCAGCTAAT	360
AAGACAGTCA	CGTTATCAGG	ATTTTCCGGC	CTTTCTTTTC	TTAAATCCCC	AGCAAGTACA	420
GTGACTAATG	GATTGGGAGC	TATCAATGTT	AAAGGGAATT	TAAGCCTATT	GGATAATGAT	480
AAGGTATTGA	TTCAGGACAA	TTTCTCAACA	GGAGATGGCG	GAGCAATTAA	TTGTGCAGGC	540
TCCTTGAAGA	TCGCAAAACAA	TAAGTCCCTT	TCTTTTATTG	GAAATAGTTC	TTCAACACGT	600
GGCGGAGCGA	TTCATACCAA	AAACCTCACA	CTATCTTCTG	GTGGGGAAAC	TCTATTTTCAG	660
GGGAATACAG	CGCCTACGGC	TGCTGGTAAA	GGAGGTGCTA	TCGCGATTGC	AGACTCTGGC	720
ACCCTATCCA	TTTCTGGAGA	CAGTGGCGAC	ATTATCTTTG	AAGGCAATAC	GATAGGAGCT	780
ACAGGAACCG	TCTCTCATAG	TGCTATTGAT	TTAGGAACCTA	GCGCTAAGAT	AACTGCGTTA	840
CGTGTCTGCG	AAGGACATAC	GATATACTTT	TATGATCCGA	TTACTGTAAC	AGGATCGACA	900
TCTGTTGCTG	ATGCTCTCAA	TATTAATAGC	CCTGATACTG	GAGATAACAA	AGAGTATACG	960
GGAAACATAG	TCPTTCTGG	AGAGAAGCTC	ACGGAGGCAG	AAGCTAAAGA	TGAGAAAGAAC	1020
CGCACTTCTA	AATTACTTCA	AAATGTTGCT	TTTAAAAATG	GGAAGTGTAGT	TTTAAAGAGT	1080
GATGTCGTTT	TAAGTGCAGG	CGGTTTCTCT	CAGGATGCAA	ACTCTAAGTT	GATTATGGAT	1140
TTAGGGACGT	CGTTGGTTGC	AAACACCGAA	AGTATCGAGT	TAACGAATTT	GGAAATTAAT	1200
ATAGACTCTC	TCAGGAACGG	GAAAAAGATA	AAACTCAGTG	CTGCCACAGC	TCAGAAAGAT	1260
ATTTCGTATAG	ATCGTCCTGT	TGTAAGTGCA	ATTAGCGATG	AGAGTTTTTA	TCAAATGGC	1320
TTTTTGAATG	AGGACCATTG	CTATGATGGG	ATTCTTGAGT	TAGATGCTGG	GAAAGACATC	1380
GTGATTTCTG	CAGATTCTCG	CAGTATAAAT	GCTGTACAAT	CTCCGTATGG	CTATCAGGGA	1440
AAGTGGACAA	TCAATTTGTC	TACTGATGAT	AAGAAAGCTA	CGGTTTCTTG	GGCAAAGCAA	1500
AGTTTAAATC	CCACTGCTGA	CGAGGAGGCT	CCGTTAGTTC	CTAATCTTCT	TTGGGGTTCT	1560
TTTATAGATG	TTCGTCCCTT	CCAAAATTTT	ATAGAGCTAG	GTACTGAAGG	TGCTCCTTAC	1620
GAAAAGAGAT	TTTGGGTTGC	AGGCATTTCC	AATGTTTTGC	ATAGGAGCGG	TCGTGAAAAT	1680
CAAAGGAAAT	TCCGTCAATG	GAGTGGAGGT	GCTGTAGTAG	GTGCTAGCAC	GAGGATGCCG	1740
GGTGGTGATA	CTTGTCTCT	GGGTTTTGCT	CAGCTCTTTG	CGCGTGACAA	AGACTACTTT	1800
ATGAATACCA	ATTCGCAAA	GACCTACGCA	GGATCTTTAC	GTTTGCAGCA	CGATGCTTCC	1860
CTATACTCTG	TGGTGAGTAT	CTTTTATAGG	GAGGGAGGAC	TCCGCGAGAT	CCTGTTGCCT	1920
TATGTTTTCCA	AGACTCTGCC	GTGCTCTTTC	TATGGGCAGC	TTAGCTACGG	CCATACGGAT	1980
CTACGCATGA	AGACCGAGTC	TCTACCCCCC	CCCCCCCCCA	CGCTCTCGAC	GGATCATACT	2040
TCTTGGGGAG	GATATGCTG	GGCTGGAGAG	CTGGGAACCT	GAGTTGCTGT	TGAAAATACC	2100
AGCGGCAGAG	GATTTTTCCG	AGAGTACACT	CCATTTGTAA	AAGTCCAAGC	TGTTTACTCG	2160
CGCCAAGATA	GCTTTGTTGA	ACTAGGAGCT	ATCAGTCGTG	ATTTTAGTGA	TTGCGACTCT	2220
TATAACCTTG	CGATTCTCT	TGGAATCAAG	TTAGAGAAAC	GGTTTGCAGA	GCAATATTAT	2280

CATGTTGTAG	CGATGTATTC	TCCAGATGTT	TGTCGTAGTA	ACCCCAAATG	TACGACTACC	2340
CTACTTTCCA	ACCAAGGGAG	TTGGAAGACC	AAAGGTTTCA	ACTTAGCAAG	ACAGGCTGGT	2400
ATTGTTTCAGG	CCTCAGGTTT	TCGATCTTTG	GGAGCTGCAG	CAGAGCTTTT	CGGGAACTTT	2460
GGCTTTGAAT	GGCGGGGATC	TTCTCGTAGC	TATAATGTAG	ATGCGGGTAG	CAAAATCAAA	2520
TTTTAG						2526

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 841 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met	Lys	Ile	Pro	Leu	Arg	Phe	Leu	Leu	Ile	Ser	Leu	Val	Pro	Thr	Leu	1	5	10	15
Ser	Met	Ser	Asn	Leu	Leu	Gly	Ala	Ala	Thr	Thr	Glu	Glu	Leu	Ser	Ala	20	25	30	
Ser	Asn	Ser	Phe	Asp	Gly	Thr	Thr	Ser	Thr	Thr	Ser	Phe	Ser	Ser	Lys	35	40	45	
Thr	Ser	Ser	Ala	Thr	Asp	Gly	Thr	Asn	Tyr	Val	Phe	Lys	Asp	Ser	Val	50	55	60	
Val	Ile	Glu	Asn	Val	Pro	Lys	Thr	Gly	Glu	Thr	Gln	Ser	Thr	Ser	Cys	65	70	75	80
Phe	Lys	Asn	Asp	Ala	Ala	Ala	Gly	Asp	Leu	Asn	Phe	Leu	Gly	Gly	Gly	85	90	95	
Phe	Ser	Phe	Thr	Phe	Ser	Asn	Ile	Asp	Ala	Thr	Thr	Ala	Ser	Gly	Ala	100	105	110	
Ala	Ile	Gly	Ser	Glu	Ala	Ala	Asn	Lys	Thr	Val	Thr	Leu	Ser	Gly	Phe	115	120	125	
Ser	Ala	Leu	Ser	Phe	Leu	Lys	Ser	Pro	Ala	Ser	Thr	Val	Thr	Asn	Gly	130	135	140	
Leu	Gly	Ala	Ile	Asn	Val	Lys	Gly	Asn	Leu	Ser	Leu	Leu	Asp	Asn	Asp	145	150	155	160
Lys	Val	Leu	Ile	Gln	Asp	Asn	Phe	Ser	Thr	Gly	Asp	Gly	Gly	Ala	Ile	165	170	175	
Asn	Cys	Ala	Gly	Ser	Leu	Lys	Ile	Ala	Asn	Asn	Lys	Ser	Leu	Ser	Phe	180	185	190	
Ile	Gly	Asn	Ser	Ser	Ser	Thr	Arg	Gly	Gly	Ala	Ile	His	Thr	Lys	Asn	195	200	205	
Leu	Thr	Leu	Ser	Ser	Gly	Gly	Glu	Thr	Leu	Phe	Gln	Gly	Asn	Thr	Ala	210	215	220	
Pro	Thr	Ala	Ala	Gly	Lys	Gly	Gly	Ala	Ile	Ala	Ile	Ala	Asp	Ser	Gly	225	230	235	240
Thr	Leu	Ser	Ile	Ser	Gly	Asp	Ser	Gly	Asp	Ile	Ile	Phe	Glu	Gly	Asn	245	250	255	
Thr	Ile	Gly	Ala	Thr	Gly	Thr	Val	Ser	His	Ser	Ala	Ile	Asp	Leu	Gly	260	265	270	
Thr	Ser	Ala	Lys	Ile	Thr	Ala	Leu	Arg	Ala	Ala	Gln	Gly	His	Thr	Ile	275	280	285	
Tyr	Phe	Tyr	Asp	Pro	Ile	Thr	Val	Thr	Gly	Ser	Thr	Ser	Val	Ala	Asp	290	295	300	
Ala	Leu	Asn	Ile	Asn	Ser	Pro	Asp	Thr	Gly	Asp	Asn	Lys	Glu	Tyr	Thr				

305		310		315		320
Gly Thr Ile Val	Phe Ser Gly Glu Lys Leu Thr Glu Ala Glu Ala Lys					
	325		330		335	
Asp Glu Lys Asn Arg Thr Ser Lys Leu Leu Gln Asn Val Ala Phe Lys						
	340		345		350	
Asn Gly Thr Val Val Leu Lys Gly Asp Val Val Leu Ser Ala Asn Gly						
	355		360		365	
Phe Ser Gln Asp Ala Asn Ser Lys Leu Ile Met Asp Leu Gly Thr Ser						
	370		375		380	
Leu Val Ala Asn Thr Glu Ser Ile Glu Leu Thr Asn Leu Glu Ile Asn						
	385		390		395	
Ile Asp Ser Leu Arg Asn Gly Lys Lys Ile Lys Leu Ser Ala Ala Thr						
	405		410		415	
Ala Gln Lys Asp Ile Arg Ile Asp Arg Pro Val Val Leu Ala Ile Ser						
	420		425		430	
Asp Glu Ser Phe Tyr Gln Asn Gly Phe Leu Asn Glu Asp His Ser Tyr						
	435		440		445	
Asp Gly Ile Leu Glu Leu Asp Ala Gly Lys Asp Ile Val Ile Ser Ala						
	450		455		460	
Asp Ser Arg Ser Ile Asn Ala Val Gln Ser Pro Tyr Gly Tyr Gln Gly						
	465		470		475	
Lys Trp Thr Ile Asn Trp Ser Thr Asp Asp Lys Lys Ala Thr Val Ser						
	485		490		495	
Trp Ala Lys Gln Ser Phe Asn Pro Thr Ala Glu Gln Glu Ala Pro Leu						
	500		505		510	
Val Pro Asn Leu Leu Trp Gly Ser Phe Ile Asp Val Arg Pro Phe Gln						
	515		520		525	
Asn Phe Ile Glu Leu Gly Thr Glu Gly Ala Pro Tyr Glu Lys Arg Phe						
	530		535		540	
Trp Val Ala Gly Ile Ser Asn Val Leu His Arg Ser Gly Arg Glu Asn						
	545		550		555	
Gln Arg Lys Phe Arg His Val Ser Gly Gly Ala Val Val Gly Ala Ser						
	565		570		575	
Thr Arg Met Pro Gly Gly Asp Thr Leu Ser Leu Gly Phe Ala Gln Leu						
	580		585		590	
Phe Ala Arg Asp Lys Asp Tyr Phe Met Asn Thr Asn Phe Ala Lys Thr						
	595		600		605	
Tyr Ala Gly Ser Leu Arg Leu Gln His Asp Ala Ser Leu Tyr Ser Val						
	610		615		620	
Val Ser Ile Leu Leu Gly Glu Gly Gly Leu Arg Glu Ile Leu Leu Pro						
	625		630		635	
Tyr Val Ser Lys Thr Leu Pro Cys Ser Phe Tyr Gly Gln Leu Ser Tyr						
	645		650		655	
Gly His Thr Asp His Arg Met Lys Thr Glu Ser Leu Pro Pro Pro Pro						
	660		665		670	
Pro Thr Leu Ser Thr Asp His Thr Ser Trp Gly Gly Tyr Val Trp Ala						
	675		680		685	
Gly Glu Leu Gly Thr Arg Val Ala Val Glu Asn Thr Ser Gly Arg Gly						
	690		695		700	
Phe Phe Arg Glu Tyr Thr Pro Phe Val Lys Val Gln Ala Val Tyr Ser						
	705		710		715	
Arg Gln Asp Ser Phe Val Glu Leu Gly Ala Ile Ser Arg Asp Phe Ser						
	725		730		735	
Asp Ser His Leu Tyr Asn Leu Ala Ile Pro Leu Gly Ile Lys Leu Glu						
	740		745		750	
Lys Arg Phe Ala Glu Gln Tyr Tyr His Val Val Ala Met Tyr Ser Pro						
	755		760		765	

Asp Val Cys Arg Ser Asn Pro Lys Cys Thr Thr Thr Leu Leu Ser Asn
 770 775 780
 Gln Gly Ser Trp Lys Thr Lys Gly Ser Asn Leu Ala Arg Gln Ala Gly
 785 790 795 800
 Ile Val Gln Ala Ser Gly Phe Arg Ser Leu Gly Ala Ala Ala Glu Leu
 805 810 815
 Phe Gly Asn Phe Gly Phe Glu Trp Arg Gly Ser Ser Arg Ser Tyr Asn
 820 825 830
 Val Asp Ala Gly Ser Lys Ile Lys Phe
 835 840

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2787 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATGAAGTCTT	CTTCCCCAA	GTTTGTATTT	TCTACATTTG	CTATTTTCCC	TTTGTCTATG	60
ATTGCTACCG	AGACAGTTTT	GGATTCAAGT	GCGAGTTTCG	ATGGGAATAA	AAATGGTAAT	120
TTTTCAGTTC	GTGAGAGTCA	GGAAGATGCT	GGAACACCT	ACCTATTTAA	GGGAAATGTC	180
ACTCTAGAAA	ATATTCTTGG	AACAGGCACA	GCAATCACAA	AAAGCTGTTT	TAACAACACT	240
AAGGGCGATT	TGACTTTTAC	AGGTAACGGG	AACCTCTCTAT	TGTTCCAAAC	GGTGGATGCA	300
GGGACTGTAG	CAGGGGCTGC	TGTTAACAGC	AGCGTGGTAG	ATAAATCTAC	CACGTTTATA	360
GGGTTTTCTT	CGCTATCTTT	TATTGCGTCT	CCTGGAAGTT	CGATAACTAC	CGGCAAAGGA	420
GCCGTTAGCT	GCTCTACGGG	TAGCTTGAAG	TTTGACAAAA	ATGTCAGTTT	GCTCTTCAGC	480
AAAACTTTTT	CAACGGATAA	TGGCGGTGCT	ATCACCGCAA	AAACTCTTTC	ATTAACAGGG	540
ACTACAATGT	CAGCTCTGTT	TTCTGAAAAT	ACCTCCTCAA	AGAAAGGCGG	AGCCATTTCAG	600
ACTTCCGATG	CCCTTACCAT	TACTGGAAC	CAAGGGGAAG	TCTCTTTTTC	TGACAATACT	660
TCTTCGGATT	CTGGAGCTGC	AATTTTACAA	GAAGCCTCGG	TGACTATTTT	TAATAATGCT	720
AAAGTTTCCT	TTATTGACAA	TAAGGTCACA	GGAGCGAGCT	CCTCAACAAC	GGGGGATATG	780
TCAGGAGGTG	CTATCTGTGC	TTATAAACT	AGTACAGATA	CTAAGGTCAC	CCTCACTGGA	840
AATCAGATGT	TACTCTTCAG	CAACAATACA	TCGACAACAG	CGGGAGGAGC	TATCTATGTG	900
AAAAAGCTCG	AACTGGCTTC	CGGAGGACTT	ACCCTATTCA	GTAGAAATAG	TGTCAATGGA	960
GGTACAGCTC	CTAAAGGTGG	AGCCATAGCT	ATCGAAGATA	GTGGGGAATT	GAGTTTATCC	1020
GCCGATAGTG	GTGACATTGT	CTTTTATAGG	AATACAGTCA	CTTCTACTAC	TCCTGGGACG	1080
AATAGAAGTA	GTATCGACTT	AGGAACGAGT	GCAAAGATGA	CAGCTTTGCG	TTCTGCTGCT	1140
GGTAGAGCCA	TCTACTTCTA	TGATCCCAT	ACTACAGGAT	CTTCCACAAC	AGTTACAGAT	1200
GTCTTAAAAG	TTAATGAGAC	TCCGGCAGAT	TCTGCACTAC	AATATACAGG	GAACATCATC	1260
TTCACAGGAG	AAAAGTTATC	AGAGACAGAG	GCCGCAGATT	CTAAAAATCT	TACTTCGAAG	1320
CTACTACAGC	CTGTAACCTT	TTCAGGAGGT	ACTCTATCTT	TAAAACATGG	AGTGACTCTG	1380
CAGACTCAGG	CATTCACTCA	ACAGGCAGAT	TCTCGTCTCG	AAATGGACGT	AGGAACTACT	1440
CTAGAACCTG	CTGATACTAG	CACCATAAAC	AATTTGGTCA	TTAACATCAG	TTCTATAGAC	1500
GGTGCAAAGA	AGGCAAAAAT	AGAAACCAAA	GCTACGTCAA	AAAATCTGAC	TTTATCTGGA	1560
ACCATCACTT	TATTGGACCC	GACGGGCACG	TTTTATGAAA	ATCATAGTTT	AAGAAATCCT	1620
CAGTCTACG	ACATCTTAGA	GCTCAAAGCT	TCTGGAACCT	TAACAAGCAC	CGCAGTGACT	1680
CCAGATCCTA	TAATGGGTGA	GAAATTCAT	TACGGCTATC	AGGGAACCTG	GGGCCCCAAT	1740
GTTTGGGGGA	CAGGGGCTTC	TACGACTGCA	ACCTTCAACT	GGACTAAAAC	TGGCTATATT	1800
CCTAATCCCG	AGCGTATCGG	CTCTTTAGTC	CCTAATAGCT	TATGGAATGC	ATTTATAGAT	1860
ATTAGCTCTC	TCCATTATCT	TATGGAGACT	GCAAACGAAG	GGTTGCAGGG	AGACCGTGCT	1920
TTTTGGTGTG	CTGGATTATC	TAACCTCTTC	CATAAGGATA	GTACAAAAAC	ACGACGCGGG	1980
TTTCGCCATT	TGAGTGGCGG	TTATGTCATA	GGAGGAAACC	TACATACTTG	TTCAGATAAG	2040

ATTCTTAGTG	CTGCATTTTG	TCAGCTCTTT	GGAAGAGATA	GAGACTACTT	TGTAGCTAAG	2100
AATCAAGGTA	CAGTCTACGG	AGGAACTCTC	TATTACCAGC	ACAACGAAAC	CTATATCTCT	2160
CTTCCTTGCA	AACTACGGCC	TTGTTTCGTTG	TCTTATGTTT	CTACAGAGAT	TCCTGTTCTC	2220
TTTTCAGGAA	ACCTTAGCTA	CACCCATACG	GATAACGATC	TGAAAACCAA	GTATACAACA	2280
TATCCTACTG	TTAAAGGAAG	CTGGGGGAAT	GATAGTTTCG	CTTTAGAATT	CGGTGGAAGA	2340
GCTCCGATTT	GCTTAGATGA	AAGTGCTCTA	TTTGAGCAGT	ACATGCCCTT	CATGAAATTG	2400
CAGTTTGTCT	ATGCACATCA	GGAAGGTTTT	AAAGAACAGG	GAACAGAAGC	TCGTGAATTT	2460
GGAAGTAGCC	GTCTTGTA	TCTTGCTTA	CCTATCGGGA	TCCGATTGA	TAAGGAATCA	2520
GACTGCCAAG	ATGCAACGTA	CAATCTAACT	CTTGGTTATA	CTGTGGATCT	TGTTTCGTAGT	2580
AACCCCGACT	GTACGACAAC	ACTGCGAATT	AGCGGTGATT	CTTGGAAAAC	CTTCGGTACG	2640
AATTGGCAA	GACAAGCTTT	AGTCCTTCGT	GCAGGGAACC	ATTTTGTGCTT	TAACCTCAAT	2700
TTTGAAGCCT	TTAGCCAATT	TTCTTTTGAA	TTGCGTGGGT	CATCTCGCAA	TTACAATGTA	2760
GACTTAGGAG	CAAAATACCA	ATTCTAA				2787

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 928 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met	Lys	Ser	Ser	Phe	Pro	Lys	Phe	Val	Phe	Ser	Thr	Phe	Ala	Ile	Phe
1				5				10						15	
Pro	Leu	Ser	Met	Ile	Ala	Thr	Glu	Thr	Val	Leu	Asp	Ser	Ser	Ala	Ser
			20					25					30		
Phe	Asp	Gly	Asn	Lys	Asn	Gly	Asn	Phe	Ser	Val	Arg	Glu	Ser	Gln	Glu
			35				40					45			
Asp	Ala	Gly	Thr	Thr	Tyr	Leu	Phe	Lys	Gly	Asn	Val	Thr	Leu	Glu	Asn
			50				55				60				
Ile	Pro	Gly	Thr	Gly	Thr	Ala	Ile	Thr	Lys	Ser	Cys	Phe	Asn	Asn	Thr
			65			70				75				80	
Lys	Gly	Asp	Leu	Thr	Phe	Thr	Gly	Asn	Gly	Asn	Ser	Leu	Leu	Phe	Gln
			85					90						95	
Thr	Val	Asp	Ala	Gly	Thr	Val	Ala	Gly	Ala	Ala	Val	Asn	Ser	Ser	Val
			100					105					110		
Val	Asp	Lys	Ser	Thr	Thr	Phe	Ile	Gly	Phe	Ser	Ser	Leu	Ser	Phe	Ile
			115				120						125		
Ala	Ser	Pro	Gly	Ser	Ser	Ile	Thr	Thr	Gly	Lys	Gly	Ala	Val	Ser	Cys
			130				135				140				
Ser	Thr	Gly	Ser	Leu	Lys	Phe	Asp	Lys	Asn	Val	Ser	Leu	Leu	Phe	Ser
			145			150				155				160	
Lys	Asn	Phe	Ser	Thr	Asp	Asn	Gly	Gly	Ala	Ile	Thr	Ala	Lys	Thr	Leu
			165					170						175	
Ser	Leu	Thr	Gly	Thr	Thr	Met	Ser	Ala	Leu	Phe	Ser	Glu	Asn	Thr	Ser
			180					185					190		
Ser	Lys	Lys	Gly	Gly	Ala	Ile	Gln	Thr	Ser	Asp	Ala	Leu	Thr	Ile	Thr
			195				200						205		
Gly	Asn	Gln	Gly	Glu	Val	Ser	Phe	Ser	Asp	Asn	Thr	Ser	Ser	Asp	Ser
			210				215				220				
Gly	Ala	Ala	Ile	Phe	Thr	Glu	Ala	Ser	Val	Thr	Ile	Ser	Asn	Asn	Ala
			225			230				235				240	
Lys	Val	Ser	Phe	Ile	Asp	Asn	Lys	Val	Thr	Gly	Ala	Ser	Ser	Ser	Thr

[illegible]

Val Tyr Gly Gly Thr Leu Tyr Tyr Gln His Asn Glu Thr Tyr Ile Ser
 705 710 715 720
 Leu Pro Cys Lys Leu Arg Pro Cys Ser Leu Ser Tyr Val Pro Thr Glu
 725 730 735
 Ile Pro Val Leu Phe Ser Gly Asn Leu Ser Tyr Thr His Thr Asp Asn
 740 745 750
 Asp Leu Lys Thr Lys Tyr Thr Thr Tyr Pro Thr Val Lys Gly Ser Trp
 755 760 765
 Gly Asn Asp Ser Phe Ala Leu Glu Phe Gly Gly Arg Ala Pro Ile Cys
 770 775 780
 Leu Asp Glu Ser Ala Leu Phe Glu Gln Tyr Met Pro Phe Met Lys Leu
 785 790 795 800
 Gln Phe Val Tyr Ala His Gln Glu Gly Phe Lys Glu Gln Gly Thr Glu
 805 810 815
 Ala Arg Glu Phe Gly Ser Ser Arg Leu Val Asn Leu Ala Leu Pro Ile
 820 825 830
 Gly Ile Arg Phe Asp Lys Glu Ser Asp Cys Gln Asp Ala Thr Tyr Asn
 835 840 845
 Leu Thr Leu Gly Tyr Thr Val Asp Leu Val Arg Ser Asn Pro Asp Cys
 850 855 860
 Thr Thr Thr Leu Arg Ile Ser Gly Asp Ser Trp Lys Thr Phe Gly Thr
 865 870 875 880
 Asn Leu Ala Arg Gln Ala Leu Val Leu Arg Ala Gly Asn His Phe Cys
 885 890 895
 Phe Asn Ser Asn Phe Glu Ala Phe Ser Gln Phe Ser Phe Glu Leu Arg
 900 905 910
 Gly Ser Ser Arg Asn Tyr Asn Val Asp Leu Gly Ala Lys Tyr Gln Phe
 915 920 925

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2757 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

ATGAGATCGT	CTTTTTCCTT	GTTATTAATA	TCTTCATCTC	TAGCCTTTCC	TCTCTTAATG	60
AGTGTTCCTG	CAGATGCTGC	CGATCTCACA	TTAGGGAGTC	GTGACAGTTA	TAATGGTGAT	120
ACAAGCACCA	CAGAATTTAC	TCCTAAAGCG	GCAACTTCTG	ATGCTAGTGG	CACGACCTAT	180
ATTCTCGATG	GGGATGTCTC	GATAAGCCAA	GCAGGGAAAC	AAACGAGCTT	AACCACAAGT	240
TGTTTTTCTA	ACACTGCAGG	AAATCTTACC	TTCTTAGGGA	ACGGATTTTC	TCTTCATTTT	300
GACAATATTA	TTTCGTCTAC	TGTTGCAGGT	GTTGTTGTTA	GCAATACAGC	AGCTTCTGGG	360
ATTACGAAAT	TCTCAGGATT	TTCAACTCTT	CGGATGCTTG	CAGCTCCTAG	GACCACAGGT	420
AAAGGAGCCA	TTAAAATTAC	CGATGGTCTG	GTGTTTGAGA	GTATAGGGAA	TCTTGACCAA	480
AATGAAAATG	CCTCTAGTGA	AAATGGGGGA	GCCATCAATA	CGAAGACTTT	GTCTTTGACT	540
GGGAGTACGC	GGTTTGTAGC	GTTCTTGGCC	AATAGCTCGT	CGCAACAAGG	GGGAGCGATC	600
TATGCTTCTG	GTGACTCTGT	GATTTCTGAG	AATGCAGGAA	TCTTGAGCTT	CGGAAACAAC	660
AGTGCGACAA	CATCAGGAGG	CGCGATCTCT	GCTGAAGGGA	ACCTTGATGAT	CTCCAATAAC	720
CAAAATATCT	TTTTCGATGG	CTGCAAAGCA	ACTACAAATG	GCGGAGCTAT	TGATTGTAAC	780
AAAGCAGGGG	CGAACCCAGA	CCCTATCTTG	ACTCTTTCAG	GAAATGAGAG	CCTGCATTTT	840
CTGAATAACA	CAGCAGGAAA	TAGTGGAGGT	GCGATTTATA	CCAAAAAATT	GGTGTTATCC	900
TCAGGACGAG	GAGGAGTGTT	ATTTTCTAAC	AACAAAGCTG	CGAATGCTAC	TCCTAAAGGA	960

```

GGGGCAATTG CGATTCTAGA TTCTGGAGAG ATTAGCATT CTGCAGATCT CGGCAATATC 1020
ATTTTCGAGG GCAATACTAC GAGCACTACA GGAAGTCCTG CGAGTGTGAC CAGAAATGCT 1080
ATAGATCTTG CATCGAATGC AAAATTTT TAATCTCCGAG CGACTCGGGG AAATAAAGTT 1140
ATTTTCTATG ATCCTATCAC GAGCTCAGGA GCTACTGATA AGCTCTCTTT GAATAAAGCT 1200
GACGCAGGAT CTGGAAATAC CTATGAAGGC TACATCGTTT TCTCTGGAGA GAAACTCTCA 1260
GAAGAGGAAC TTAAGAAACC TGACAATCTG AAGTCTACAT TTACACAGGC TGTAGAGCTT 1320
GCTGCAGGTG CCTTAGTATT GAAAGATGGA GTGACTGTAG TTGCAAATAC TATAACGCAG 1380
GTCGAGGGAT CGAAAGTCGT TATGGATGGA GGGACTACTT TTGAGGCAAG CGCTGAGGGG 1440
GTCACCTCTCA ATGGCCTAGC CATTAATATA GATTCCCTTAG ATGGGACAAA TAAAGCTATC 1500
ATTAAGGCGA CGGCAGCAAG TAAGGATGTT GCCTTATCAG GGCCTATCAT GCTTGTAGAT 1560
GCTCAGGGGA ACTATTATGA GCATCATAAT CTCAGTCAAC AGCAGGTCTT TCCTTTAATA 1620
GAGCTTTCTG CACAAGGAAC GATGACTACT ACAGATATCC CCGATACCCC AATTCTAAAT 1680
ACTACGAATC ACTATGGGTA TCAAGGAAC TGAATAATTG TTTGGGTCGA CGATGCAACT 1740
GCAAAAACAA AAAATGCTAC CTTAACCTGG ACTAAAACAG GATACAAGCC GAATCCAGAA 1800
CGTCAGGGAC CTTTGGTTCC TAATAGCGTG TGGGGTTCTT TTGTGATGT CCGCTCCATT 1860
CAGAGCCTCA TGGACCGGAG CACAAGTTCG TTATCTTCGT CAACAAATTT GTGGGTATCA 1920
GGAATCGCGG ACTTTTTCGA TGAAGATCAG AAAGGAAACC AACGTAGTTA TCGTCATTCT 1980
AGCGCGGGTT ATGCATTAGG AGGAGGATTC TTCACGGCTT CTGAAAATTT CTTTAATTTT 2040
GCTTTTTGTG AGCTTTTTTG CTACGACAAG GACCATCTTG TGGCTAAGAA CCATACCCAT 2100
GTATATGCAG GGGCAATGAG TTACCGACAC CTCGGAGAGT CTAAGACCCT CGCTAAGATT 2160
TTGTGAGGAA ATTCTGACTC CCTACCTTTT GTCTTCAATG CTCGGTTTGC TTATGGCCAT 2220
ACCGACAATA ACATGACCAC AAAGTACACT GGCTATTCTC CTGTTAAGGG AAGCTGGGGA 2280
AATGATGCCT TCGGTATAGA ATGTGGAGGA GCTATCCCGG TAGTTGCTTC AGGACGTCGG 2340
TCTTGGGTGG ATACCCACAC GCCATTTCTA AACCTAGAGA TGATCTATGC ACATCAGAAT 2400
GACTTTAAGG AAAACGGCAC AGAAGGCCGT TCTTTCCAAA GTGAAGACCT CTTCAATCTA 2460
GCGGTTCTTG TAGGGATAAA ATTTGAGAAA TTCTCCGATA AGTCTACGTA TGATCTCTCC 2520
ATAGCTTACG TTCCCGATGT GATTCGTAAT GATCCAGGCT GCACGACAAC TCTTATGGTT 2580
TCTGGGGATT CTGGGTCGAC ATGTGGTACA AGCTTGTCTA GACAAGCTCT TCTTGTACGT 2640
GCTGGAAATC ATCATGCCTT TGCTTCAAAC TTTGAAGTTT TCAGTCAGTT TGAAGTCGAG 2700
TTGCGAGGTT CTTCTCGTAG CTATGCTATC GATCTTGGAG GAAGATTCGG ATTTTAA 2757

```

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 918 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

```

Met Arg Ser Ser Phe Ser Leu Leu Leu Ile Ser Ser Ser Leu Ala Phe
 1           5           10           15
Pro Leu Leu Met Ser Val Ser Ala Asp Ala Ala Asp Leu Thr Leu Gly
 20           25           30
Ser Arg Asp Ser Tyr Asn Gly Asp Thr Ser Thr Thr Glu Phe Thr Pro
 35           40           45
Lys Ala Ala Thr Ser Asp Ala Ser Gly Thr Thr Tyr Ile Leu Asp Gly
 50           55           60
Asp Val Ser Ile Ser Gln Ala Gly Lys Gln Thr Ser Leu Thr Thr Ser
 65           70           75           80
Cys Phe Ser Asn Thr Ala Gly Asn Leu Thr Phe Leu Gly Asn Gly Phe
 85           90           95
Ser Leu His Phe Asp Asn Ile Ile Ser Ser Thr Val Ala Gly Val Val
100           105           110

```

Val	Ser	Asn	Thr	Ala	Ala	Ser	Gly	Ile	Thr	Lys	Phe	Ser	Gly	Phe	Ser	115	120	125
Thr	Leu	Arg	Met	Leu	Ala	Ala	Pro	Arg	Thr	Thr	Gly	Lys	Gly	Ala	Ile	130	135	140
Lys	Ile	Thr	Asp	Gly	Leu	Val	Phe	Glu	Ser	Ile	Gly	Asn	Leu	Asp	Gln	145	150	155
Asn	Glu	Asn	Ala	Ser	Ser	Glu	Asn	Gly	Gly	Ala	Ile	Asn	Thr	Lys	Thr	165	170	175
Leu	Ser	Leu	Thr	Gly	Ser	Thr	Arg	Phe	Val	Ala	Phe	Leu	Gly	Asn	Ser	180	185	190
Ser	Ser	Gln	Gln	Gly	Gly	Ala	Ile	Tyr	Ala	Ser	Gly	Asp	Ser	Val	Ile	195	200	205
Ser	Glu	Asn	Ala	Gly	Ile	Leu	Ser	Phe	Gly	Asn	Asn	Ser	Ala	Thr	Thr	210	215	220
Ser	Gly	Gly	Ala	Ile	Ser	Ala	Glu	Gly	Asn	Leu	Val	Ile	Ser	Asn	Asn	225	230	235
Gln	Asn	Ile	Phe	Phe	Asp	Gly	Cys	Lys	Ala	Thr	Thr	Asn	Gly	Gly	Ala	245	250	255
Ile	Asp	Cys	Asn	Lys	Ala	Gly	Ala	Asn	Pro	Asp	Pro	Ile	Leu	Thr	Leu	260	265	270
Ser	Gly	Asn	Glu	Ser	Leu	His	Phe	Leu	Asn	Asn	Thr	Ala	Gly	Asn	Ser	275	280	285
Gly	Gly	Ala	Ile	Tyr	Thr	Lys	Lys	Leu	Val	Leu	Ser	Ser	Gly	Arg	Gly	290	295	300
Gly	Val	Leu	Phe	Ser	Asn	Asn	Lys	Ala	Ala	Asn	Ala	Thr	Pro	Lys	Gly	305	310	315
Gly	Ala	Ile	Ala	Ile	Leu	Asp	Ser	Gly	Glu	Ile	Ser	Ile	Ser	Ala	Asp	325	330	335
Leu	Gly	Asn	Ile	Ile	Phe	Glu	Gly	Asn	Thr	Thr	Ser	Thr	Thr	Gly	Ser	340	345	350
Pro	Ala	Ser	Val	Thr	Arg	Asn	Ala	Ile	Asp	Leu	Ala	Ser	Asn	Ala	Lys	355	360	365
Phe	Leu	Asn	Leu	Arg	Ala	Thr	Arg	Gly	Asn	Lys	Val	Ile	Phe	Tyr	Asp	370	375	380
Pro	Ile	Thr	Ser	Ser	Gly	Ala	Thr	Asp	Lys	Leu	Ser	Leu	Asn	Lys	Ala	385	390	395
Asp	Ala	Gly	Ser	Gly	Asn	Thr	Tyr	Glu	Gly	Tyr	Ile	Val	Phe	Ser	Gly	405	410	415
Glu	Lys	Leu	Ser	Glu	Glu	Glu	Leu	Lys	Lys	Pro	Asp	Asn	Leu	Lys	Ser	420	425	430
Thr	Phe	Thr	Gln	Ala	Val	Glu	Leu	Ala	Ala	Gly	Ala	Leu	Val	Leu	Lys	435	440	445
Asp	Gly	Val	Thr	Val	Val	Ala	Asn	Thr	Ile	Thr	Gln	Val	Glu	Gly	Ser	450	455	460
Lys	Val	Val	Met	Asp	Gly	Gly	Thr	Thr	Phe	Glu	Ala	Ser	Ala	Glu	Gly	465	470	475
Val	Thr	Leu	Asn	Gly	Leu	Ala	Ile	Asn	Ile	Asp	Ser	Leu	Asp	Gly	Thr	485	490	495
Asn	Lys	Ala	Ile	Lys	Ala	Thr	Ala	Ala	Ser	Lys	Asp	Val	Ala	Leu		500	505	510
Ser	Gly	Pro	Ile	Met	Leu	Val	Asp	Ala	Gln	Gly	Asn	Tyr	Tyr	Glu	His	515	520	525
His	Asn	Leu	Ser	Gln	Gln	Gln	Val	Phe	Pro	Leu	Ile	Glu	Leu	Ser	Ala	530	535	540
Gln	Gly	Thr	Met	Thr	Thr	Thr	Asp	Ile	Pro	Asp	Thr	Pro	Ile	Leu	Asn	545	550	555
Thr	Thr	Asn	His	Tyr	Gly	Tyr	Gln	Gly	Thr	Gly	Ile	Ile	Val	Trp	Val	560		

565										570					575					
Asp	Asp	Ala	Thr	Ala	Lys	Thr	Lys	Asn	Ala	Thr	Leu	Thr	Trp	Thr	Lys					
580										585					590					
Thr	Gly	Tyr	Lys	Pro	Asn	Pro	Glu	Arg	Gln	Gly	Pro	Leu	Val	Pro	Asn					
595										600					605					
Ser	Leu	Trp	Gly	Ser	Phe	Val	Asp	Val	Arg	Ser	Ile	Gln	Ser	Leu	Met					
610										615					620					
Asp	Arg	Ser	Thr	Ser	Ser	Leu	Ser	Ser	Ser	Thr	Asn	Leu	Trp	Val	Ser					
625										630					635					
Gly	Ile	Ala	Asp	Phe	Leu	His	Glu	Asp	Gln	Lys	Gly	Asn	Gln	Arg	Ser					
645										650					655					
Tyr	Arg	His	Ser	Ser	Ala	Gly	Tyr	Ala	Leu	Gly	Gly	Gly	Phe	Phe	Thr					
660										665					670					
Ala	Ser	Glu	Asn	Phe	Phe	Asn	Phe	Ala	Phe	Cys	Gln	Leu	Phe	Gly	Tyr					
675										680					685					
Asp	Lys	Asp	His	Leu	Val	Ala	Lys	Asn	His	Thr	His	Val	Tyr	Ala	Gly					
690										695					700					
Ala	Met	Ser	Tyr	Arg	His	Leu	Gly	Glu	Ser	Lys	Thr	Leu	Ala	Lys	Ile					
705										710					715					
Leu	Ser	Gly	Asn	Ser	Asp	Ser	Leu	Pro	Phe	Val	Phe	Asn	Ala	Arg	Phe					
725										730					735					
Ala	Tyr	Gly	His	Thr	Asp	Asn	Asn	Met	Thr	Thr	Lys	Tyr	Thr	Gly	Tyr					
740										745					750					
Ser	Pro	Val	Lys	Gly	Ser	Trp	Gly	Asn	Asp	Ala	Phe	Gly	Ile	Glu	Cys					
755										760					765					
Gly	Gly	Ala	Ile	Pro	Val	Val	Ala	Ser	Gly	Arg	Arg	Ser	Trp	Val	Asp					
770										775					780					
Thr	His	Thr	Pro	Phe	Leu	Asn	Leu	Glu	Met	Ile	Tyr	Ala	His	Gln	Asn					
785										790					795					
Asp	Phe	Lys	Glu	Asn	Gly	Thr	Glu	Gly	Arg	Ser	Phe	Gln	Ser	Glu	Asp					
805										810					815					
Leu	Phe	Asn	Leu	Ala	Val	Pro	Val	Gly	Ile	Lys	Phe	Glu	Lys	Phe	Ser					
820										825					830					
Asp	Lys	Ser	Thr	Tyr	Asp	Leu	Ser	Ile	Ala	Tyr	Val	Pro	Asp	Val	Ile					
835										840					845					
Arg	Asn	Asp	Pro	Gly	Cys	Thr	Thr	Thr	Leu	Met	Val	Ser	Gly	Asp	Ser					
850										855					860					
Trp	Ser	Thr	Cys	Gly	Thr	Ser	Leu	Ser	Arg	Gln	Ala	Leu	Leu	Val	Arg					
865										870					875					
Ala	Gly	Asn	His	His	Ala	Phe	Ala	Ser	Asn	Phe	Glu	Val	Phe	Ser	Gln					
885										890					895					
Phe	Glu	Val	Glu	Leu	Arg	Gly	Ser	Ser	Arg	Ser	Tyr	Ala	Ile	Asp	Leu					
900										905					910					
Gly	Gly	Arg	Phe	Gly	Phe															
915																				

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2787 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

ATGAAATCCT	CTCTTCATTG	GTTTGTAAATC	TCGTCATCTT	TAGCACTTCC	CTTGTCACATA	60
AATTTCTCTG	CGTTTGCTGC	TGTTGTTGAA	ATCAATCTAG	GACCTACCAA	TAGCTTCTCT	120
GGACCAGGAA	CCTACACTCC	TCCAGCCCAA	ACAACAAATG	CAGATGGAAC	TATCTATAAT	180
CTAACAGGGG	ATGTCTCAAT	CACCAATGCA	GGATCTCCGA	CAGCTCTAAC	CGCTTCTCTGC	240
TTTAAAGAAA	CTACTGGGAA	TCTTTCTTTC	CAAGGCCACG	GCTACCAATT	TCTCCTACAA	300
AATATCGATG	CGGGAGCGAA	CTGTACCTTT	ACCAATACAG	CTGCAAATAA	GCTTCTCTCC	360
TTTTCAGGAT	TCTCTATT	GTCACATAA	CAAACCACGA	ATGCTACCAC	AGGAACAGGA	420
GCCATCAAGT	CCACAGGAGC	TTGTTCTATT	CAGTCGAACT	ATAGTTGCTA	CTTTGGCCAA	480
AACTTTTCTA	ATGACAATGG	AGGCGCCCTC	CAAGGCAGCT	CTATCAGTCT	ATCGCTAAAC	540
CCCAACCTAA	CGTTTGCCAA	AAACAAAGCA	ACGCAAAAAG	GGGGTGCCCT	CTATTCCACG	600
GGAGGGATTA	CAATTAACAA	TACGTTAAAC	TCAGCATCAT	TTTCTGAAAA	TACCGCGGCG	660
AACAATGGCG	GAGCCATTTA	CACGGAAGCT	AGCAGTTTTA	TTAGCAGCAA	CAAAGCAATT	720
AGCTTTATAA	ACAATAGTGT	GACCGCAACC	TCAGCTACAG	GGGGAGCCAT	TTACTGTAGT	780
AGTACATCAG	CCCCCAAACC	AGTCTTAACT	CTATCAGACA	ACGGGGAAC	GAACCTTTATA	840
GGAAATACAG	CAATTAAGTAG	TGGTGGGGEG	ATTTATACTG	ACAATCTAGT	TCTTTCTTCT	900
GGAGGACCTA	CGCTTTTAA	AAACAACCTCT	GCTATAGATA	CTGCAGCTCC	CTTAGGAGGA	960
GCAATTGCGA	TTGCTGACTC	TGGATCTTTG	AGTCTTTCGG	CTCTTGGTGG	AGACATCACT	1020
TTTGAAGGAA	ACACAGTAGT	CAAAGGAGCT	TCTTCGAGTC	AGACCACTAC	CAGAAATTCT	1080
ATTAACATCG	GAAACACCAA	TGCTAAGATT	GTACAGCTGC	GAGCCTCTCA	AGGCAATACT	1140
ATCTACTTCT	ATGATCCTAT	AACAATAAC	CATACTGCAG	CTCTCTCAGA	TGCTCTAAAC	1200
TTAAATGGTC	CTGACCTTGC	AGGGAATCCT	GCATATCAAG	GAACCATCGT	ATTTTCTGGA	1260
GAGAAGCTCT	CGGAAGCAGA	AGCTGCAGAA	GCTGATAATC	TCAAATCTAC	AATTTCAGCAA	1320
CCTCTAACTC	TTGCGGGAGG	GCAACTCTCT	CTTAAATCAG	GAGTCACTCT	AGTTGCTAAG	1380
TCCTTTTCGC	AATCTCCGGG	CTCTACCCTC	CTCATGGATG	CAGGGACCAC	ATTAGAAACC	1440
GCTGATGGGA	TCATATCAA	TAATCTTGTT	CTCAATGTAG	ATTCCTTAAA	AGAGACCAAG	1500
AAGGCTACGC	TAAAAGCAAC	ACAAGCAAGT	CAGACAGTCA	CTTTATCTGG	ATCGCTCTCT	1560
CTTGTAGATC	CTTCTGGAAA	TGTCTACGAA	GATGTCTCTT	GGAATAACCC	TCAAGTCTTT	1620
TCTTGTCTCA	CTCTTACTGC	TGACGACCCC	GCGAATATTC	ACATCACAGA	CTTAGCTGCT	1680
GATCCCCTAG	AAAAAATCC	TATCCATTGG	GGATACCAAG	GGAATTGGGC	ATTATCTTGG	1740
CAAGAGGATA	CTGCGACTAA	ATCCAAAGCA	GCGACTCTTA	CCTGGACAAA	AACAGGATAC	1800
AATCCGAATC	CTGAGCGTCG	TGGAACCTTA	GTTGCTAACA	CGCTATGGGG	ATCCTTTGTT	1860
GATGTGCGCT	CCATACAACA	GCTTGTAGCC	ACTAAAGTAC	GCCAATCTCA	AGAAACTCGC	1920
GGCATCTGGT	GTGAAGGGAT	CTCGAACTTC	TTCCATAAAG	ATAGCACGAA	GATAAATAAA	1980
GGTTTTCGCC	ACATAAGTGC	AGGTTATGTT	GTAGGAGCGA	CTACAACATT	AGCTTCTGAT	2040
AATCTTATCA	CTGCAGCCTT	CTGCCAATTA	TTGGGAAAG	ATAGAGATCA	CTTTATAAAT	2100
AAAAATAGAG	CTTCTGCCTA	TGCAGCTTCT	CTCCATCTCC	AGCATCTAGC	GACCTTGTCT	2160
TCTCCAAGCT	TGTTACGCTA	CCTTCTGGA	TCTGAAAGTG	AGCAGCCTGT	CCTCTTTGAT	2220
GCTCAGATCA	GCTATATCTA	TAGTAAAAAT	ACTATGAAAA	CCTATTACAC	CCAAGCACCA	2280
AAGGGAGAGA	GCTCGTGGTA	TAATGACGGT	TGCGCTCTGG	AACTTGCGAG	CTCCCTACCA	2340
CACACTGCTT	TAAGCCATGA	GGGTCTCTTC	CACGCGTATT	TTCTTTTCAT	CAAAGTAGAA	2400
GCTTCGTACA	TACACCAAGA	TAGCTTCAAA	GAACGTAATA	CTACCTTGGT	ACGATCTTTC	2460
GATAGCGGTG	ATTTAATTAA	CGTCTCTGTG	CCTATTGGAA	TTACCTTCGA	GAGATTCTCG	2520
AGAAACGAGC	GTGCGTCTTA	CGAAGCTACT	GTCATCTACG	TTGCCGATGT	CTATCGTAAG	2580
AATCCTGACT	GCACGACAGC	TCTCCTAATC	AACAATACCT	CGTGGAAAAC	TACAGGAACG	2640
AATCTCTCAA	GACAAGCTGG	TATCGGAAGA	GCAGGGATCT	TTTATGCCTT	CTCTCCAAAT	2700
CTTGAGGTCA	CAAGTAACCT	ATCTATGGAA	ATTCGTGGAT	CTTCACGCAG	CTACAATGCA	2760
GATCTTGGAG	GTAAGTTCCA	GTTCTAA				2787

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 928 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Met	Lys	Ser	Ser	Leu	His	Trp	Phe	Val	Ile	Ser	Ser	Ser	Leu	Ala	Leu
1				5				10						15	
Pro	Leu	Ser	Leu	Asn	Phe	Ser	Ala	Phe	Ala	Ala	Val	Val	Glu	Ile	Asn
			20					25					30		
Leu	Gly	Pro	Thr	Asn	Ser	Phe	Ser	Gly	Pro	Gly	Thr	Tyr	Thr	Pro	Pro
		35					40					45			
Ala	Gln	Thr	Thr	Asn	Ala	Asp	Gly	Thr	Ile	Tyr	Asn	Leu	Thr	Gly	Asp
	50					55				60					
Val	Ser	Ile	Thr	Asn	Ala	Gly	Ser	Pro	Thr	Ala	Leu	Thr	Ala	Ser	Cys
65					70					75					80
Phe	Lys	Glu	Thr	Thr	Gly	Asn	Leu	Ser	Phe	Gln	Gly	His	Gly	Tyr	Gln
			85						90					95	
Phe	Leu	Leu	Gln	Asn	Ile	Asp	Ala	Gly	Ala	Asn	Cys	Thr	Phe	Thr	Asn
			100					105					110		
Thr	Ala	Ala	Asn	Lys	Leu	Leu	Ser	Phe	Ser	Gly	Phe	Ser	Tyr	Leu	Ser
			115					120					125		
Leu	Ile	Gln	Thr	Thr	Asn	Ala	Thr	Thr	Gly	Thr	Gly	Ala	Ile	Lys	Ser
	130					135					140				
Thr	Gly	Ala	Cys	Ser	Ile	Gln	Ser	Asn	Tyr	Ser	Cys	Tyr	Phe	Gly	Gln
145					150					155					160
Asn	Phe	Ser	Asn	Asp	Asn	Gly	Gly	Ala	Leu	Gln	Gly	Ser	Ser	Ile	Ser
			165						170					175	
Leu	Ser	Leu	Asn	Pro	Asn	Leu	Thr	Phe	Ala	Lys	Asn	Lys	Ala	Thr	Gln
			180					185					190		
Lys	Gly	Gly	Ala	Leu	Tyr	Ser	Thr	Gly	Gly	Ile	Thr	Ile	Asn	Asn	Thr
		195					200						205		
Leu	Asn	Ser	Ala	Ser	Phe	Ser	Glu	Asn	Thr	Ala	Ala	Asn	Asn	Gly	Gly
	210					215				220					
Ala	Ile	Tyr	Thr	Glu	Ala	Ser	Ser	Phe	Ile	Ser	Ser	Asn	Lys	Ala	Ile
225					230					235					240
Ser	Phe	Ile	Asn	Asn	Ser	Val	Thr	Ala	Thr	Ser	Ala	Thr	Gly	Gly	Ala
			245						250					255	
Ile	Tyr	Cys	Ser	Ser	Thr	Ser	Ala	Pro	Lys	Pro	Val	Leu	Thr	Leu	Ser
		260					265						270		
Asp	Asn	Gly	Glu	Leu	Asn	Phe	Ile	Gly	Asn	Thr	Ala	Ile	Thr	Ser	Gly
		275					280					285			
Gly	Ala	Ile	Tyr	Thr	Asp	Asn	Leu	Val	Leu	Ser	Ser	Gly	Gly	Pro	Thr
	290					295					300				
Leu	Phe	Lys	Asn	Asn	Ser	Ala	Ile	Asp	Thr	Ala	Ala	Pro	Leu	Gly	Gly
305					310					315					320
Ala	Ile	Ala	Ile	Ala	Asp	Ser	Gly	Ser	Leu	Ser	Leu	Ser	Ala	Leu	Gly
			325						330					335	
Gly	Asp	Ile	Thr	Phe	Glu	Gly	Asn	Thr	Val	Val	Lys	Gly	Ala	Ser	Ser
		340						345					350		
Ser	Gln	Thr	Thr	Thr	Arg	Asn	Ser	Ile	Asn	Ile	Gly	Asn	Thr	Asn	Ala
		355					360					365			
Lys	Ile	Val	Gln	Leu	Arg	Ala	Ser	Gln	Gly	Asn	Thr	Ile	Tyr	Phe	Tyr
	370					375					380				
Asp	Pro	Ile	Thr	Thr	Asn	His	Thr	Ala	Ala	Leu	Ser	Asp	Ala	Leu	Asn
385					390					395					400
Leu	Asn	Gly	Pro	Asp	Leu	Ala	Gly	Asn	Pro	Ala	Tyr	Gln	Gly	Thr	Ile
			405					410					415		
Val	Phe	Ser	Gly	Glu	Lys	Leu	Ser	Glu	Ala	Glu	Ala	Ala	Glu	Ala	Asp
			420					425				430			
Asn	Leu	Lys	Ser	Thr	Ile	Gln	Gln	Pro	Leu	Thr	Leu	Ala	Gly	Gly	Gln

435	440	445
Leu Ser Leu Lys Ser Gly Val Thr Leu Val Ala Lys Ser Phe Ser Gln		
450	455	460
Ser Pro Gly Ser Thr Leu Leu Met Asp Ala Gly Thr Thr Leu Glu Thr		
465	470	475
Ala Asp Gly Ile Thr Ile Asn Asn Leu Val Leu Asn Val Asp Ser Leu		480
485	490	495
Lys Glu Thr Lys Lys Ala Thr Leu Lys Ala Thr Gln Ala Ser Gln Thr		
500	505	510
Val Thr Leu Ser Gly Ser Leu Ser Leu Val Asp Pro Ser Gly Asn Val		
515	520	525
Tyr Glu Asp Val Ser Trp Asn Asn Pro Gln Val Phe Ser Cys Leu Thr		
530	535	540
Leu Thr Ala Asp Asp Pro Ala Asn Ile His Ile Thr Asp Leu Ala Ala		
545	550	555
Asp Pro Leu Glu Lys Asn Pro Ile His Trp Gly Tyr Gln Gly Asn Trp		560
565	570	575
Ala Leu Ser Trp Gln Glu Asp Thr Ala Thr Lys Ser Lys Ala Ala Thr		
580	585	590
Leu Thr Trp Thr Lys Thr Gly Tyr Asn Pro Asn Pro Glu Arg Arg Gly		
595	600	605
Thr Leu Val Ala Asn Thr Leu Trp Gly Ser Phe Val Asp Val Arg Ser		
610	615	620
Ile Gln Gln Leu Val Ala Thr Lys Val Arg Gln Ser Gln Glu Thr Arg		
625	630	635
Gly Ile Trp Cys Glu Gly Ile Ser Asn Phe Phe His Lys Asp Ser Thr		640
645	650	655
Lys Ile Asn Lys Gly Phe Arg His Ile Ser Ala Gly Tyr Val Val Gly		
660	665	670
Ala Thr Thr Thr Leu Ala Ser Asp Asn Leu Ile Thr Ala Ala Phe Cys		
675	680	685
Gln Leu Phe Gly Lys Asp Arg Asp His Phe Ile Asn Lys Asn Arg Ala		
690	695	700
Ser Ala Tyr Ala Ala Ser Leu His Leu Gln His Leu Ala Thr Leu Ser		
705	710	715
Ser Pro Ser Leu Leu Arg Tyr Leu Pro Gly Ser Glu Ser Glu Gln Pro		720
725	730	735
Val Leu Phe Asp Ala Gln Ile Ser Tyr Ile Tyr Ser Lys Asn Thr Met		
740	745	750
Lys Thr Tyr Tyr Thr Gln Ala Pro Lys Gly Glu Ser Ser Trp Tyr Asn		
755	760	765
Asp Gly Cys Ala Leu Glu Leu Ala Ser Ser Leu Pro His Thr Ala Leu		
770	775	780
Ser His Glu Gly Leu Phe His Ala Tyr Phe Pro Phe Ile Lys Val Glu		
785	790	795
Ala Ser Tyr Ile His Gln Asp Ser Phe Lys Glu Arg Asn Thr Thr Leu		
805	810	815
Val Arg Ser Phe Asp Ser Gly Asp Leu Ile Asn Val Ser Val Pro Ile		
820	825	830
Gly Ile Thr Phe Glu Arg Phe Ser Arg Asn Glu Arg Ala Ser Tyr Glu		
835	840	845
Ala Thr Val Ile Tyr Val Ala Asp Val Tyr Arg Lys Asn Pro Asp Cys		
850	855	860
Thr Thr Ala Leu Leu Ile Asn Asn Thr Ser Trp Lys Thr Thr Gly Thr		
865	870	875
Asn Leu Ser Arg Gln Ala Gly Ile Gly Arg Ala Gly Ile Phe Tyr Ala		880
885	890	895

Phe Ser Pro Asn Leu Glu Val Thr Ser Asn Leu Ser Met Glu Ile Arg
 900 905 910
 Gly Ser Ser Arg Ser Tyr Asn Ala Asp Leu Gly Gly Lys Phe Gln Phe
 915 920 925

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2793 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

ATGAAAATAC	CCTTGCACAA	ACTCTGATC	TCTTCGACTC	TTGTCACTCC	CATTCTATTG	60
AGCATTGCAA	CTTACGGAGC	AGATGCTTCT	TTATCCCCTA	CAGATAGCTT	TGATGGAGCG	120
GGCGGCTCTA	CATTTACTCC	AAAATCTACA	GCAGATGCCA	ATGGAACGAA	CTATGTCTTA	180
TCAGGAAATG	TCTATATAAA	CGATGCTGGG	AAAGGCACAG	CATTAACAGG	CTGCTGCTTT	240
ACAGAACTA	CGGGTGATCT	GACATTTACT	GGAAGGGAT	ACTCATTTTC	ATTCAACACG	300
GTAGATGCGG	GTTTCAATGC	AGGAGCTGCG	GCAAGCACAA	CTGCTGATAA	AGCCCTAACA	360
TTCACAGGAT	TTTCTAACCT	TTCCTTCATT	GCAGCTCCTG	GAACCTACAGT	TGCTTCAGGA	420
AAAAGTACTT	TAAGTTCTGC	AGGAGCCTTA	AATCTTACCG	ATAATGGAAC	GATTCTCTTT	480
AGCCAAAACG	TCTCCAATGA	AGCTAATAAC	AATGGCGGAG	CGATCACCAC	AAAAACTCTT	540
TCTATTCTCG	GGAATACCTC	TTCTATAACC	TTCCTAGTA	ATAGCGCAAA	AAAATTAGGT	600
GGAGCGATCT	ATAGCTCTGC	GGCTGCAAGT	ATTTCAGGAA	ACACCGGCCA	GTTAGTCTTT	660
ATGAATAATA	AAGGAGAAAC	TGGGGGCGGG	GCTCTGGGCT	TTGAAGCCAG	CTCCTCGATT	720
ACTCAAAATA	GCTCCCTTTT	CTTCTCTGGA	AACACTGCAA	CAGATGCTGC	AGGCAAGGGC	780
GGGGCCATTT	ATTGTGAAAA	AACAGGAGAG	ACTCTACTC	TTACTATCTC	TGGAAATAAA	840
AGTCTGACCT	TCGCCGAGAA	CTCTTCAGTA	ACTCAAGGCG	GAGCAATCTG	TGCCCATGGT	900
CTAGATCTTT	CCGCTGCTGG	CCCTACCCTA	TTTTCAAATA	ATAGATGCGG	GAACACAGCT	960
GCAGGCAAGG	GCGGCGCTAT	TGCAATTGCC	GACTCTGGAT	CTTTAAGTCT	CTCTGCAAAT	1020
CAAGGAGACA	TCACGTTCTT	TGGCAACACT	CTAACCTCAA	CCTCCGCGCC	AACATCGACA	1080
CGGAATGCTA	TCTACCTGGG	ATCGTCAGCA	AAAATTACGA	ACTTAAGGGC	AGCCCAAGGC	1140
CAATCTATCT	ATTCTATAGA	TCCGATTGCA	TCTAACACCA	CAGGAGCTTC	AGACGTTCTG	1200
ACCATCAACC	AACCGGATAG	CAACTCGCCT	TTAGATTATT	CAGGAACGAT	TGTATTTTCT	1260
GGGGAAAAGC	TCTCTGCAGA	TGAAGCGAAA	GCTGCTGATA	ACTTCACATC	TATATTAAAG	1320
CAACCATTGG	CTCTAGCCTC	TGGAACCTTA	GCACTCAAAG	GAAATGTCGA	GTTAGATGTC	1380
AATGGTTTCA	CACAGACTGA	AGGCTCTACA	CTCCTCATGC	AACCAGGAAC	AAAGCTCAAA	1440
GCAGATACTG	AAGCTATCAG	TCTTACCAAA	CTTGTCTGTTG	ATCTTTCTGC	CTTAGAGGGA	1500
AATAAGAGTG	TGTCCATTGA	AACAGCAGGA	GCCAAACAAA	CTATAACTCT	AACCTCTCCT	1560
CTTGTTTTCC	AAGATAGTAG	CGGCAATTTT	TATGAAAGCC	ATACGATAAA	CCAAGCCTTC	1620
ACGCAGCCTT	TGGTGGTATT	CACTGCTGCT	ACTGCTGCTA	GCGATATTTA	TATCGATGCG	1680
CTTCTCACTT	CTCCAGTACA	AACTCCAGAA	CCTCATTACG	GGTATCAGGG	ACATTGGGAA	1740
GCCACTTGGG	CAGACACATC	AACTGCAAAA	TCAGGAACTA	TGACTTGGGT	AACTACGGGC	1800
TACAACCCTA	ATCCTGAGCG	TAGAGCTTCC	GTAGTTCCCG	ATTCAATTATG	GGCATCCTTT	1860
ACTGACATTC	GCACTCTACA	GCAGATCATG	ACATCTCAAG	CGAATAGTAT	CTATCAGCAA	1920
CGAGGACTCT	GGGCATCAGG	AACTGCGAAT	TTCTTCCATA	AGGATAAATC	AGGAACTAAC	1980
CAAGCATTCC	GACATAAAAG	CTACGGCTAT	ATTGTTGGAG	GAAGTGCTGA	AGATTTTCT	2040
GAAAATATCT	TCAGTGTAGC	TTTCTGCCAG	CTCTTCGGTA	AAGATAAAGA	CCTGTTTATA	2100
GTTGAAAATA	CCTCTCATAA	CTATTTAGCG	TCGCTATACC	TGCAACATCG	AGCATTCCCTA	2160
GGAGGACTTC	CCATGCCCTC	ATTTGGAAGT	ATCACCGACA	TGCTGAAAGA	TATTCCTCTC	2220
ATTTTGAATG	CCCAGCTAAG	CTACAGCTAC	ACTAAAAATG	ATATGGATAC	TCGCTATACT	2280
TCCTATCCTG	AAGCTCAAGG	TTCTTGGAAC	AATAATTCTG	GGGCTCTAGA	GCTCGGAGGA	2340
TCTCTGGCTC	TATATCTCCC	TAAAGAAGCA	CCGTTCTTCC	AGGGATATTT	CCCCTTCTTA	2400

```

AAGTTCAGG CAGTCTACAG CCGCCAACAA AACTTTAAAG AGAGTGGCGC TGAAGCCCGT 2460
GCTTTTGATG ATGGAGACCT AGTGAAGTGC TCTATCCCTG TCGGCATTTC GTTAGAAAAA 2520
ATCTCCGAAG ATGAAAAAAA TAATTTTCGAG ATTTCTCTAG CCAACATTGG TGATGTGTAT 2580
CGTAAAAATC CCCGTTTCGCG TACTTCTCTA ATGGTCAGTG GAGCCTCTTG GACTTCGCTA 2640
TGTA AAAACC TCGCACGACA AGCCTTCTTA GCAAGTGCTG GAAGCCATCT GACTCTCTCC 2700
CCTCATGTAG AACTCTCTGG GGAAGCTGCT TATGAGCTTC GTGGCTCAGC ACACATCTAC 2760
AATGTAGATT GTGGGCTAAG ATACTCATT TAG 2793

```

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 930 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

```

Met Lys Ile Pro Leu His Lys Leu Leu Ile Ser Ser Thr Leu Val Thr
 1           5           10           15
Pro Ile Leu Leu Ser Ile Ala Thr Tyr Gly Ala Asp Ala Ser Leu Ser
 20           25           30
Pro Thr Asp Ser Phe Asp Gly Ala Gly Gly Ser Thr Phe Thr Pro Lys
 35           40           45
Ser Thr Ala Asp Ala Asn Gly Thr Asn Tyr Val Leu Ser Gly Asn Val
 50           55           60
Tyr Ile Asn Asp Ala Gly Lys Gly Thr Ala Leu Thr Gly Cys Cys Phe
 65           70           75           80
Thr Glu Thr Thr Gly Asp Leu Thr Phe Thr Gly Lys Gly Tyr Ser Phe
 85           90           95
Ser Phe Asn Thr Val Asp Ala Gly Ser Asn Ala Gly Ala Ala Ala Ser
 100          105          110
Thr Thr Ala Asp Lys Ala Leu Thr Phe Thr Gly Phe Ser Asn Leu Ser
 115          120          125
Phe Ile Ala Ala Pro Gly Thr Thr Val Ala Ser Gly Lys Ser Thr Leu
 130          135          140
Ser Ser Ala Gly Ala Leu Asn Leu Thr Asp Asn Gly Thr Ile Leu Phe
 145          150          155          160
Ser Gln Asn Val Ser Asn Glu Ala Asn Asn Asn Gly Gly Ala Ile Thr
 165          170          175
Thr Lys Thr Leu Ser Ile Ser Gly Asn Thr Ser Ser Ile Thr Phe Thr
 180          185          190
Ser Asn Ser Ala Lys Lys Leu Gly Gly Ala Ile Tyr Ser Ser Ala Ala
 195          200          205
Ala Ser Ile Ser Gly Asn Thr Gly Gln Leu Val Phe Met Asn Asn Lys
 210          215          220
Gly Glu Thr Gly Gly Gly Ala Leu Gly Phe Glu Ala Ser Ser Ser Ile
 225          230          235          240
Thr Gln Asn Ser Ser Leu Phe Phe Ser Gly Asn Thr Ala Thr Asp Ala
 245          250          255
Ala Gly Lys Gly Gly Ala Ile Tyr Cys Glu Lys Thr Gly Glu Thr Pro
 260          265          270
Thr Leu Thr Ile Ser Gly Asn Lys Ser Leu Thr Phe Ala Glu Asn Ser
 275          280          285
Ser Val Thr Gln Gly Gly Ala Ile Cys Ala His Gly Leu Asp Leu Ser

```

290	295	300
Ala Ala Gly Pro Thr	Leu Phe Ser Asn Asn	Arg Cys Gly Asn Thr Ala
305	310	315
Ala Gly Lys Gly Gly	Ala Ile Ala Ile	Ala Asp Ser Gly Ser Leu Ser
325	330	335
Leu Ser Ala Asn Gln Gly	Asp Ile Thr Phe Leu Gly	Asn Thr Leu Thr
340	345	350
Ser Thr Ser Ala Pro Thr	Ser Thr Arg Asn Ala Ile	Tyr Leu Gly Ser
355	360	365
Ser Ala Lys Ile Thr	Asn Leu Arg Ala Ala	Gln Gly Gln Ser Ile Tyr
370	375	380
Phe Tyr Asp Pro Ile	Ala Ser Asn Thr Thr	Gly Ala Ser Asp Val Leu
385	390	395
Thr Ile Asn Gln Pro	Asp Ser Asn Ser Pro	Leu Asp Tyr Ser Gly Thr
405	410	415
Ile Val Phe Ser Gly	Glu Lys Leu Ser	Ala Asp Glu Ala Lys Ala Ala
420	425	430
Asp Asn Phe Thr Ser	Ile Leu Lys Gln	Pro Leu Ala Leu Ala Ser Gly
435	440	445
Thr Leu Ala Leu Lys	Gly Asn Val Glu Leu	Asp Val Asn Gly Phe Thr
450	455	460
Gln Thr Glu Gly Ser	Thr Leu Leu Met Gln	Pro Gly Thr Lys Leu Lys
465	470	475
Ala Asp Thr Glu Ala	Ile Ser Leu Thr Lys	Leu Val Val Asp Leu Ser
485	490	495
Ala Leu Glu Gly Asn	Lys Ser Val Ser	Ile Glu Thr Ala Gly Ala Asn
500	505	510
Lys Thr Ile Thr Leu	Thr Ser Pro Leu	Val Phe Gln Asp Ser Ser Gly
515	520	525
Asn Phe Tyr Glu Ser	His Thr Ile Asn	Gln Ala Phe Thr Gln Pro Leu
530	535	540
Val Val Phe Thr Ala	Ala Thr Ala Ala	Ser Asp Ile Tyr Ile Asp Ala
545	550	555
Leu Leu Thr Ser Pro	Val Gln Thr Pro	Glu Pro His Tyr Gly Tyr Gln
565	570	575
Gly His Trp Glu Ala	Thr Trp Ala Asp	Thr Ser Thr Ala Lys Ser Gly
580	585	590
Thr Met Thr Trp Val	Thr Thr Gly Tyr	Asn Pro Asn Pro Glu Arg Arg
595	600	605
Ala Ser Val Val Pro	Asp Ser Leu Trp	Ala Ser Phe Thr Asp Ile Arg
610	615	620
Thr Leu Gln Gln Ile	Met Thr Ser Gln	Ala Asn Ser Ile Tyr Gln Gln
625	630	635
Arg Gly Leu Trp Ala	Ser Gly Thr Ala	Asn Phe Phe His Lys Asp Lys
645	650	655
Ser Gly Thr Asn Gln	Ala Phe Arg His	Lys Ser Tyr Gly Tyr Ile Val
660	665	670
Gly Gly Ser Ala Glu	Asp Phe Ser Glu	Asn Ile Phe Ser Val Ala Phe
675	680	685
Cys Gln Leu Phe Gly	Lys Asp Lys Asp	Leu Phe Ile Val Glu Asn Thr
690	695	700
Ser His Asn Tyr Leu	Ala Ser Leu Tyr	Leu Gln His Arg Ala Phe Leu
705	710	715
Gly Gly Leu Pro Met	Pro Ser Phe Gly	Ser Ile Thr Asp Met Leu Lys
725	730	735
Asp Ile Pro Leu Ile	Leu Asn Ala Gln	Leu Ser Tyr Ser Tyr Thr Lys
740	745	750

Asn Asp Met Asp Thr Arg Tyr Thr Ser Tyr Pro Glu Ala Gln Gly Ser
 755 760 765
 Trp Thr Asn Asn Ser Gly Ala Leu Glu Leu Gly Gly Ser Leu Ala Leu
 770 775 780
 Tyr Leu Pro Lys Glu Ala Pro Phe Phe Gln Gly Tyr Phe Pro Phe Leu
 785 790 795 800
 Lys Phe Gln Ala Val Tyr Ser Arg Gln Gln Asn Phe Lys Glu Ser Gly
 805 810 815
 Ala Glu Ala Arg Ala Phe Asp Asp Gly Asp Leu Val Asn Cys Ser Ile
 820 825 830
 Pro Val Gly Ile Arg Leu Glu Lys Ile Ser Glu Asp Glu Lys Asn Asn
 835 840 845
 Phe Glu Ile Ser Leu Ala Asn Ile Gly Asp Val Tyr Arg Lys Asn Pro
 850 855 860
 Arg Ser Arg Thr Ser Leu Met Val Ser Gly Ala Ser Trp Thr Ser Leu
 865 870 875 880
 Cys Lys Asn Leu Ala Arg Gln Ala Phe Leu Ala Ser Ala Gly Ser His
 885 890 895
 Leu Thr Leu Ser Pro His Val Glu Leu Ser Gly Glu Ala Ala Tyr Glu
 900 905 910
 Leu Arg Gly Ser Ala His Ile Tyr Asn Val Asp Cys Gly Leu Arg Tyr
 915 920 925
 Ser Phe
 930

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 840 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GAAGACAATA	TAAGGTACCG	TCATAACAGC	GGGGGTTATG	CACTAGGGAT	CACAGCAACA	60
ACTCCTGCCG	AGGATCAGCT	TACTTTTGCC	TTCTGCCAGC	TCCTTGCTAG	AGATCGCAAT	120
CATATTACAG	GTAAGAACCA	CGGAGATACT	TACGGTGCCT	CTTTGTATT	CCACCATAACA	180
GAAGGGCTCT	TCGACATCGC	CAATTTCTCT	TGGGGAAAAG	CAACCCGAGC	TCCCTGGGTG	240
CTCTCTGAGA	TCTCCAGAT	CATTCCITTA	TCGTTTCGATG	CTAAATTCAG	TTATCTCCAT	300
ACAGACAACC	ACATGAAGAC	ATATTATACC	GATAACTCTA	TCATCAAGGG	TTCTTGGAGA	360
AACGATGCCT	TCTGTGCAGA	TCTTGGAGCT	AGCCTGCCTT	TTGTTATTTC	CGTTCCGTAT	420
CTTCTGAAAG	AAGTCGAACC	TTTTGTCAAA	GTACAGTATA	TCTATGCGCA	TCAGCAAGAC	480
TTCTACGAGC	GTCATGCTGA	AGGACGCGCT	TTCAATAAAA	GCGAGCTTAT	CAACGTCAGAG	540
ATTCTTATAG	GCGTCACCTT	CGAAAGAGAC	TCAAAATCAG	AAAAGGGAAC	TTACGATCTT	600
ACTCTTATGT	ATATACTCGA	TGCTTACCGA	CGCAATCCTA	AATGTCAAAC	TTCCCTAATA	660
GCTAGCGATG	CTAACTGGAT	GGCCTATGGT	ACCAACCTCG	CACGACAAGG	TTTTTCTGTT	720
CGTGCTGCGA	ACCATTTCCTA	AGTGAACCCC	CACATGGAAA	TCTTCGGTCA	ATTCGCTTTT	780
GAAGTACGAA	GTTCTTCACG	AAATTATAAT	ACAAACCTAG	GCTCTAAGTT	TTGTTTCTAG	840

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 279 amino acids
 (B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

```

Glu Asp Asn Ile Arg Tyr Arg His Asn Ser Gly Gly Tyr Ala Leu Gly
 1           5           10           15
Ile Thr Ala Thr Thr Pro Ala Glu Asp Gln Leu Thr Phe Ala Phe Cys
          20           25           30
Gln Leu Phe Ala Arg Asp Arg Asn His Ile Thr Gly Lys Asn His Gly
          35           40           45
Asp Thr Tyr Gly Ala Ser Leu Tyr Phe His His Thr Glu Gly Leu Phe
          50           55           60
Asp Ile Ala Asn Phe Leu Trp Gly Lys Ala Thr Arg Ala Pro Trp Val
          65           70           75           80
Leu Ser Glu Ile Ser Gln Ile Ile Pro Leu Ser Phe Asp Ala Lys Phe
          85           90           95
Ser Tyr Leu His Thr Asp Asn His Met Lys Thr Tyr Tyr Thr Asp Asn
          100          105          110
Ser Ile Ile Lys Gly Ser Trp Arg Asn Asp Ala Phe Cys Ala Asp Leu
          115          120          125
Gly Ala Ser Leu Pro Phe Val Ile Ser Val Pro Tyr Leu Leu Lys Glu
          130          135          140
Val Glu Pro Phe Val Lys Val Gln Tyr Ile Tyr Ala His Gln Gln Asp
          145          150          155          160
Phe Tyr Glu Arg His Ala Glu Gly Arg Ala Phe Asn Lys Ser Glu Leu
          165          170          175
Ile Asn Val Glu Ile Pro Ile Gly Val Thr Phe Glu Arg Asp Ser Lys
          180          185          190
Ser Glu Lys Gly Thr Tyr Asp Leu Thr Leu Met Tyr Ile Leu Asp Ala
          195          200          205
Tyr Arg Arg Asn Pro Lys Cys Gln Thr Ser Leu Ile Ala Ser Asp Ala
          210          215          220
Asn Trp Met Ala Tyr Gly Thr Asn Leu Ala Arg Gln Gly Phe Ser Val
          225          230          235          240
Arg Ala Ala Asn His Phe Gln Val Asn Pro His Met Glu Ile Phe Gly
          245          250          255
Gln Phe Ala Phe Glu Val Arg Ser Ser Ser Arg Asn Tyr Asn Thr Asn
          260          265          270
Leu Gly Ser Lys Phe Cys Phe
          275

```

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1545 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

ATGACCATAC TTCGAAATTT TCTTACCTGC TCGGCTTTAT TCCTCGCTCT CCCTGCAGCA

60

GCACAAGTTG	TATATCTTCA	TGAAAGTGAT	GGTTATAACG	GTGCTATCAA	TAATAAAAGC	120
TTAGAACCTA	AAATTACCTG	TTATCCAGAA	GGAACCTTCT	ACATCTTTCT	AGATGACGTG	180
AGGATTTCCTA	ACGTTAAGCA	TGATCAAGAA	GATGCTGGGG	TTTTTATAAA	TCGATCTGGG	240
AATCTTTTTT	TCATGGGCAA	CCGTTGCAAC	TTCACCTTTC	ACAACCTTAT	GACCGAGGGT	300
TTTGGCGCTG	CCATTTGAA	CCGCGTTGGA	GACACCACTC	TCACTCTCTC	TAATTTTTCT	360
TACTTAACGT	TCACCTCAGC	ACCTCTACTA	CCTCAAGGAC	AAGGAGCGAT	TTATAGTCTT	420
GGTTCCTGTA	TGATCGAAAA	TAGTGAGGAA	GTGACTTTCT	GTGGGAACCTA	CTCTTCGTGG	480
AGTGGAGCTG	CGATTTATAC	TCCCTACCTT	TTAGGTTCTA	AGGCGAGTCG	TCCTTCAGTA	540
AATCTCAGCG	GGAACCGCTA	CCTGGTGTTC	AGAGACTATG	TGAGCCAAGG	TTATGGCGGC	600
GCCGTATCTA	CCCACAATCT	CACACTCACG	ACTCGAGGAC	CTTCGTGTTC	TGAAAATAAT	660
CATGCTTATC	ATGACGTGAA	TAGTAATGGA	GGAGCCATTG	CCATTGCTCC	TGGAGGATCG	720
ATCTCTATAT	CCGTGAAAAG	CGGAGATCTC	ATCTTCAAAG	GAAATACAGC	ATCACAAGAC	780
GGAAATACAA	TACACAATCT	CATCCATCTG	CAATCTGGAG	CACAGTTTAA	GAACCTACGT	840
GCTGTTTCAG	AATCCGGAGT	TTATTTCTAT	GATCCTATAA	GCCATAGCGA	GTCGCATAAA	900
ATFACAGATC	TTGTAATCAA	TGCTCTGAA	GGAAAGGAAA	CTTATGAAGG	AACAATTAGC	960
TTCTCAGGAC	TATGCCTGGA	TGATCATGAA	GTTTGTGCGG	AAAATCTTAC	TTCCACAATC	1020
CTACAAGATG	TCACATTAGC	AGGAGGAACT	CTCTCTCTAT	CGGATGGGGT	TACCTTGCAA	1080
CTGCATTCTT	TTAAGCAGGA	AGCAAGCTCT	ACGCTTACTA	TGCTCTCAGG	AACCACTCTG	1140
CTCTGCTCAG	GAGATGCTCG	GGTTCAGAAT	CTGCACATCC	TGATTGAAGA	TACCGACAAC	1200
TTTGTTCCTG	TAAGGATTCG	CGCCGAGGAC	AAGGATGCTC	TTGTCTCATT	AGAAAACTT	1260
AAAGTTGCCT	TTGAGGCTTA	TTGGTCCGTC	TATGACTTTC	CTCAATTTAA	GGAAGCCTTT	1320
ACGATTCCTC	TTCTTGAACT	TCTAGGGCCT	TCTTTTGACA	GTCTTCTCCT	AGGGGAGACC	1380
ACTTTGGAGA	GAACCCAACT	CACAACAGAG	AATGACGCCG	TTGAGGTTT	CTGGTCCCTA	1440
AGCTGGGAAG	AGTACCCCC	TTCTCTGGAT	AAAGACAGAA	GGATCACACC	AACTAAGAAA	1500
ACTGTTTTCC	TCATTGGAA	TCCTGAGATC	ACTTCTACGC	CATAA		1545

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 514 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Met	Thr	Ile	Leu	Arg	Asn	Phe	Leu	Thr	Cys	Ser	Ala	Leu	Phe	Leu	Ala
1				5					10					15	
Leu	Pro	Ala	Ala	Ala	Gln	Val	Val	Tyr	Leu	His	Glu	Ser	Asp	Gly	Tyr
			20					25					30		
Asn	Gly	Ala	Ile	Asn	Asn	Lys	Ser	Leu	Glu	Pro	Lys	Ile	Thr	Cys	Tyr
		35				40					45				
Pro	Glu	Gly	Thr	Ser	Tyr	Ile	Phe	Leu	Asp	Asp	Val	Arg	Ile	Ser	Asn
	50				55						60				
Val	Lys	His	Asp	Gln	Glu	Asp	Ala	Gly	Val	Phe	Ile	Asn	Arg	Ser	Gly
65				70					75					80	
Asn	Leu	Phe	Phe	Met	Gly	Asn	Arg	Cys	Asn	Phe	Thr	Phe	His	Asn	Leu
		85						90					95		
Met	Thr	Glu	Gly	Phe	Gly	Ala	Ala	Ile	Ser	Asn	Arg	Val	Gly	Asp	Thr
		100						105					110		
Thr	Leu	Thr	Leu	Ser	Asn	Phe	Ser	Tyr	Leu	Thr	Phe	Thr	Ser	Ala	Pro
		115				120					125				
Leu	Leu	Pro	Gln	Gly	Gln	Gly	Ala	Ile	Tyr	Ser	Leu	Gly	Ser	Val	Met
	130					135					140				
Ile	Glu	Asn	Ser	Glu	Glu	Val	Thr	Phe	Cys	Gly	Asn	Tyr	Ser	Ser	Trp

145		150		155		160
Ser Gly Ala Ala Ile Tyr Thr Pro Tyr Leu Leu Gly Ser Lys Ala Ser						
	165		170		175	
Arg Pro Ser Val Asn Leu Ser Gly Asn Arg Tyr Leu Val Phe Arg Asp						
	180		185		190	
Tyr Val Ser Gln Gly Tyr Gly Gly Ala Val Ser Thr His Asn Leu Thr						
	195		200		205	
Leu Thr Thr Arg Gly Pro Ser Cys Phe Glu Asn Asn His Ala Tyr His						
	210		215		220	
Asp Val Asn Ser Asn Gly Gly Ala Ile Ala Ile Ala Pro Gly Gly Ser						
225		230		235		240
Ile Ser Ile Ser Val Lys Ser Gly Asp Leu Ile Phe Lys Gly Asn Thr						
	245		250		255	
Ala Ser Gln Asp Gly Asn Thr Ile His Asn Ser Ile His Leu Gln Ser						
	260		265		270	
Gly Ala Gln Phe Lys Asn Leu Arg Ala Val Ser Glu Ser Gly Val Tyr						
	275		280		285	
Phe Tyr Asp Pro Ile Ser His Ser Glu Ser His Lys Ile Thr Asp Leu						
	290		295		300	
Val Ile Asn Ala Pro Glu Gly Lys Glu Thr Tyr Glu Gly Thr Ile Ser						
305		310		315		320
Phe Ser Gly Leu Cys Leu Asp Asp His Glu Val Cys Ala Glu Asn Leu						
	325		330		335	
Thr Ser Thr Ile Leu Gln Asp Val Thr Leu Ala Gly Gly Thr Leu Ser						
	340		345		350	
Leu Ser Asp Gly Val Thr Leu Gln Leu His Ser Phe Lys Gln Glu Ala						
	355		360		365	
Ser Ser Thr Leu Thr Met Ser Pro Gly Thr Thr Leu Leu Cys Ser Gly						
	370		375		380	
Asp Ala Arg Val Gln Asn Leu His Ile Leu Ile Glu Asp Thr Asp Asn						
385		390		395		400
Phe Val Pro Val Arg Ile Arg Ala Glu Asp Lys Asp Ala Leu Val Ser						
	405		410		415	
Leu Glu Lys Leu Lys Val Ala Phe Glu Ala Tyr Trp Ser Val Tyr Asp						
	420		425		430	
Phe Pro Gln Phe Lys Glu Ala Phe Thr Ile Pro Leu Leu Glu Leu Leu						
	435		440		445	
Gly Pro Ser Phe Asp Ser Leu Leu Gly Glu Thr Thr Leu Glu Arg						
	450		455		460	
Thr Gln Val Thr Thr Glu Asn Asp Ala Val Arg Gly Phe Trp Ser Leu						
465		470		475		480
Ser Trp Glu Glu Tyr Pro Pro Ser Leu Asp Lys Asp Arg Arg Ile Thr						
	485		490		495	
Pro Thr Lys Lys Thr Val Phe Leu Thr Trp Asn Pro Glu Ile Thr Ser						
	500		505		510	
Thr Pro						

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 787 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

ATGAAAACGT	CTATTCGTAA	GTTCTTAATT	TCTACCACAC	TGGCGCCATG	TTTTGCTTCA	60
ACAGCGTTTA	CTGTAGAAGT	TATCATGCCT	TCCGAGAACT	TTGATGGATC	GAGTGGGAAG	120
ATTTTTCCTT	ACACAACACT	TTCTGATCCT	AGAGGGACAC	TCTGTATTTT	TTCAGGGGAT	180
CTCTACATTG	CGAATCTTGA	TAATGCCATA	TCCAGAACCT	CTTCCAGTTG	CTTTAGCAAT	240
AGGGCGGGAG	CACTACAAAT	CTTAGGAAAA	GGTGGGGTTT	TCTCCTTCTT	AAATATCCGT	300
TCTTCAGCTG	ACGGAGCCGC	GATTAGTAGT	GTAATCACCC	AAAATCCTGA	ACTATGTCCC	360
TTGAGTTTTT	CAGGATTTAG	TCAGATGATC	TTGATAACT	GTGAATCTTT	GACTTCAGAT	420
ACCTCAGCGA	GTAATGTCAT	ACCTCACGCA	TCGGCGATTT	ACGCTACAAC	GCCCATGCTC	480
TTTACAAACA	ATGACTCCAT	ACTATTCCAA	TACAACCGTT	CTGCAGGATT	TGGAGCTGCC	540
ATTCGAGGCA	CAAGCATCAC	AATAGAAAAT	ACGAAAAAGA	GCCTTCTCTT	TAATGGTAAT	600
GGATCCATCT	CTAATGGAGG	GGCCCTCACG	GGATCTGCAG	CGATCAACCT	CATCAACAAT	660
AGCGCTCCTG	TGATTTTCTC	AACGAATGCT	ACAGGGATCT	ATGGTGGGGC	TATTTACCTT	720
ACCGGAGGAT	CTATGCTCAC	CTCTGGGAAC	CTCTCAGGAG	TCTTGTTCGT	TTATAATAGC	780
TCGCGCT						787

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 262 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Met	Lys	Thr	Ser	Ile	Arg	Lys	Phe	Leu	Ile	Ser	Thr	Thr	Leu	Ala	Pro
1				5				10					15		
Cys	Phe	Ala	Ser	Thr	Ala	Phe	Thr	Val	Glu	Val	Ile	Met	Pro	Ser	Glu
			20					25					30		
Asn	Phe	Asp	Gly	Ser	Ser	Gly	Lys	Ile	Phe	Pro	Tyr	Thr	Thr	Leu	Ser
			35				40					45			
Asp	Pro	Arg	Gly	Thr	Leu	Cys	Ile	Phe	Ser	Gly	Asp	Leu	Tyr	Ile	Ala
			50			55					60				
Asn	Leu	Asp	Asn	Ala	Ile	Ser	Arg	Thr	Ser	Ser	Ser	Cys	Phe	Ser	Asn
					70					75					80
Arg	Ala	Gly	Ala	Leu	Gln	Ile	Leu	Gly	Lys	Gly	Gly	Val	Phe	Ser	Phe
				85				90						95	
Leu	Asn	Ile	Arg	Ser	Ser	Ala	Asp	Gly	Ala	Ala	Ile	Ser	Ser	Val	Ile
				100				105					110		
Thr	Gln	Asn	Pro	Glu	Leu	Cys	Pro	Leu	Ser	Phe	Ser	Gly	Phe	Ser	Gln
			115				120					125			
Met	Ile	Phe	Asp	Asn	Cys	Glu	Ser	Leu	Thr	Ser	Asp	Thr	Ser	Ala	Ser
			130			135					140				
Asn	Val	Ile	Pro	His	Ala	Ser	Ala	Ile	Tyr	Ala	Thr	Thr	Pro	Met	Leu
				150					155						160
Phe	Thr	Asn	Asn	Asp	Ser	Ile	Leu	Phe	Gln	Tyr	Asn	Arg	Ser	Ala	Gly
				165				170						175	
Phe	Gly	Ala	Ala	Ile	Arg	Gly	Thr	Ser	Ile	Thr	Ile	Glu	Asn	Thr	Lys
				180				185					190		
Lys	Ser	Leu	Leu	Phe	Asn	Gly	Asn	Gly	Ser	Ile	Ser	Asn	Gly	Gly	Ala
				195			200					205			
Leu	Thr	Gly	Ser	Ala	Ala	Ile	Asn	Leu	Ile	Asn	Asn	Ser	Ala	Pro	Val
			210			215					220				

Ile Phe Ser Thr Asn Ala Thr Gly Ile Tyr Gly Gly Ala Ile Tyr Leu
 225 230 235 240
 Thr Gly Gly Ser Met Leu Thr Ser Gly Asn Leu Ser Gly Val Leu Phe
 245 250 255
 Val Tyr Asn Ser Ser Arg
 260

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2838 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

ATGAAGACTT	CAGTTTCTAT	GTTGTTGGCC	CTGCTTTGCT	CGGGGGCTAG	CTCTATTGTA	60
CTCCATGCCG	CAACCACTCC	ACTAAATCCT	GAAGATGGGT	TTATTGGGGA	GGGCAATACA	120
AATACTTTTT	CTCCGAAATC	TACAACGGAT	GCTGCAGGAA	CTACCTACTC	TCTCACAGGA	180
GAGGTTCTGT	TTATAGATCC	GGGGAAAGGT	GGTTCAATTA	CAGGAACTTG	CTTTGTAGAA	240
ACTGCTGGCG	ATCTTACATT	TTTAGGTAAT	GGAAATACCC	TAAAGTTCCT	GTCGGTAGAT	300
GCAGGTGCTA	ATATCGCGGT	TGCTCATGTA	CAAGGAAAGTA	AGAATTTAAG	CTTCACAGAT	360
TTCTTTTCTC	TGGTGATCAC	AGAATCTCCA	AAATCCGCTG	TTAGTACAGG	AAAAGGTAGC	420
CTAGTCAGTT	CAGGTGCAGT	CCAACTGCAA	GATATAAACA	CTCTAGTTCT	TACAAGCAAT	480
GCCTCTGTCTG	AAGATGGTGG	CGTGATTAA	GGAACTCCT	GCTTGATTCA	GGGAATCAAA	540
AATAGTGC GA	TTTTTGGACA	AAATACATCT	TCGAAAAAAG	GAGGGGCGAT	CTCCACGACT	600
CAAGGACTCA	CCATAGAGAA	TAACCTAGGG	ACGCTAAAAGT	TCAATGAAAA	CAAAGCAGTG	660
ACCTCAGGAG	GCGCCTTAGA	TTTAGGAGCC	GCGTCTACAT	TCACTGCGAA	CCATGAGTTG	720
ATATTTTTCAC	AAAATAAGAC	TTCTGGGAAT	GCTGCAAAATG	GCGGAGCCAT	AAATTGCTCA	780
GGCGACCTAA	CATTTACTGA	TAACACTTCT	TTGTTACTTC	AAGAAAATAG	CACAATGCAG	840
GATGGTGGAG	CTTTGTGTAG	CACAGGAACC	ATAAGCATT	CCGGTAGTGA	TTCTATCAAT	900
GTGATAGGAA	ATACTTCAGG	ACAAAAAGGA	GGAGCGATTT	CTGCAGCTTC	TCTCAAGATT	960
TTGGGAGGGC	AGGGAGGCGC	TCTCTTTTCT	AATAACGTAG	TGACTCATGC	CACCCCTCTA	1020
GGAGGTGCCA	TTTTTATCAA	CACAGGAGGA	TCCTTGCGAGC	TCTTCACTCA	AGGAGGGGAT	1080
ATCGTATTTCG	AGGGGAATCA	GGTCACTACA	ACAGCTCCAA	ATGCTACCAC	TAAGAGAAAT	1140
GTAATTCACC	TCGAGAGCAC	CGCGAAGTGG	ACGGGACTTG	CTGCAAGTCA	AGGTAACGCT	1200
ATCTATTTCT	ATGATCCCAT	TACCACCAAC	GATACGGGAG	CAAGCGATAA	CTTACGTATC	1260
AATGAGGTCA	GTGCAAATCA	AAAGCTCTCG	GGATCTATAG	TATTTTCTGG	AGAGAGATTG	1320
TCGACAGCAG	AAGCTATAGC	TGAAAATCTT	ACTTCGAGGA	TCAACCAGCC	TGTCACTTTA	1380
GTAGAGGGGA	GCTTAGAACT	TAAACAGGGA	GTGACCTTGA	TCACACAAGG	ATTCTCGCAG	1440
GAGCCAGAAT	CCACGCTTCT	TTTGGATTG	GGGACCTCAT	TACAAGCTTC	TACAGAAGAT	1500
ATCGTCATCA	CAAATTCATC	TATAAATGCC	GATACCATT	ACGGAAAGAA	TCCAATCAAT	1560
ATTGTAGCTT	CAGCAGCGAA	TAAGAACATT	ACCCTAACAG	GAACCTTAGC	ACTTGTAAAT	1620
GCAGATGGAG	CTTTGTATGA	GAACCATACC	TTGCAAGACT	CTCAAGATTA	TAGCTTTGTA	1680
AAGTTATCTC	CAGGAGCGGG	AGGGACTATA	ATTACTCAAG	ATGCTTCTCA	GAAGCTTCTT	1740
GAAGTAGCTC	CTTCTAGACC	ACATTATGGC	TATCAAGGAC	ATTGGAATGT	GCAAGTCATC	1800
CCAGGAACGG	GAACCTCAACC	GAGCCAGGCA	AATTTAGAAT	GGGTGCGGAC	AGGATACCTT	1860
CCGAATCCCG	AACGGCAAGG	ATTTTGTAGT	CCCAATAGCC	TGTGGGGTTC	TTTTGTGTGAT	1920
CAGCGTGCTA	TCCAAGAAAT	CATGGTAAAT	AGTAGCCAAA	TCTTATGTCA	GGAACGGGGA	1980
GTCTGGGGAG	CTGGAATTGC	TAATTTCCCTA	CATAGAGATA	AAATTAATGA	GCACGGCTAT	2040
CGCCATAGCG	GTGTGGTTA	TCTTGTGGGA	GTTGGCACTC	ATGCTTTTTTC	TGATGCTACG	2100
ATAAATGCGG	CTTTTGTCCA	GCTCTTCAGT	AGAGATAAAG	ACTACGTAGT	ATCCAAAAAT	2160
CATGGAACCTA	GCTACTCAGG	GGTCGTATTT	CTTGAGGATA	CCCTAGAGTT	TAGAAGTCCA	2220
CAGGGATTCT	ATACTGATAG	CTCCTCAGAA	GCTTGCTGTA	ACCAAGTCGT	CACTATAGAT	2280

ATGCAGTTGT CTTACAGCCA TAGAAATAAT GATATGAAAA CCAAATACAC GACATATCCA	2340
GAAGCTCAGG GATCTTGGGC AAATGATGTT TTTGGTCTTG AGTTTGGAGC GACTACATAC	2400
TACTACCCTA ACAGTACTTT TTTATTTGAT TACTACTCTC CGTTTCTCAG GCTGCAGTGC	2460
ACCTATGCTC ACCAGGAAGA CTTCAAAGAG ACAGGAGGTG AGGTTCGTCA CTTTACTAGC	2520
GGAGATCTTT TCAATTAGC AGTTCCTATT GGCGTGAAGT TTGAGAGATT TTCAGACTGT	2580
AAAAGGGGAT CTTATGAACT TACCCTTGCT TATGTTCTCTG ATGTGATTCTG CAAAGATCCC	2640
AAGAGCACGG CAACATTGGC TAGTGGAGCT ACGTGGAGCA CCCACGGAAA CAATCTCTCC	2700
AGACAAGGAT TACAAC TGCG TTTAGGGAAC CACTGTCTCA TAAATCCTGG AATTGAGGTG	2760
TTCAGTCACG GAGCTATTGA ATTGCGGGGA TCCTCTCGTA ATTATAACAT CAATCTCGGG	2820
GGTAAATACC GATTTTAA	2838

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 946 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Met	Lys	Thr	Ser	Val	Ser	Met	Leu	Leu	Ala	Leu	Leu	Cys	Ser	Gly	Ala	1	5	10	15
Ser	Ser	Ile	Val	Leu	His	Ala	Ala	Thr	Thr	Pro	Leu	Asn	Pro	Glu	Asp	20	25	30	
Gly	Phe	Ile	Gly	Glu	Gly	Asn	Thr	Asn	Thr	Phe	Ser	Pro	Lys	Ser	Thr	35	40	45	
Thr	Asp	Ala	Ala	Gly	Thr	Thr	Tyr	Ser	Leu	Thr	Gly	Glu	Val	Leu	Phe	50	55	60	
Ile	Asp	Pro	Gly	Lys	Gly	Gly	Ser	Ile	Thr	Gly	Thr	Cys	Phe	Val	Glu	65	70	75	80
Thr	Ala	Gly	Asp	Leu	Thr	Phe	Leu	Gly	Asn	Gly	Asn	Thr	Leu	Lys	Phe	85	90	95	
Leu	Ser	Val	Asp	Ala	Gly	Ala	Asn	Ile	Ala	Val	Ala	His	Val	Gln	Gly	100	105	110	
Ser	Lys	Asn	Leu	Ser	Phe	Thr	Asp	Phe	Leu	Ser	Leu	Val	Ile	Thr	Glu	115	120	125	
Ser	Pro	Lys	Ser	Ala	Val	Ser	Thr	Gly	Lys	Gly	Ser	Leu	Val	Ser	Ser	130	135	140	
Gly	Ala	Val	Gln	Leu	Gln	Asp	Ile	Asn	Thr	Leu	Val	Leu	Thr	Ser	Asn	145	150	155	160
Ala	Ser	Val	Glu	Asp	Gly	Gly	Val	Ile	Lys	Gly	Asn	Ser	Cys	Leu	Ile	165	170	175	
Gln	Gly	Ile	Lys	Asn	Ser	Ala	Ile	Phe	Gly	Gln	Asn	Thr	Ser	Ser	Lys	180	185	190	
Lys	Gly	Gly	Ala	Ile	Ser	Thr	Thr	Gln	Gly	Leu	Thr	Ile	Glu	Asn	Asn	195	200	205	
Leu	Gly	Thr	Leu	Lys	Phe	Asn	Glu	Asn	Lys	Ala	Val	Thr	Ser	Gly	Gly	210	215	220	
Ala	Leu	Asp	Leu	Gly	Ala	Ala	Ser	Thr	Phe	Thr	Ala	Asn	His	Glu	Leu	225	230	235	240
Ile	Phe	Ser	Gln	Asn	Lys	Thr	Ser	Gly	Asn	Ala	Ala	Asn	Gly	Gly	Ala	245	250	255	
Ile	Asn	Cys	Ser	Gly	Asp	Leu	Thr	Phe	Thr	Asp	Asn	Thr	Ser	Leu	Leu	260	265	270	

Leu	Gln	Glu	Asn	Ser	Thr	Met	Gln	Asp	Gly	Gly	Ala	Leu	Cys	Ser	Thr	275	280	285
Gly	Thr	Ile	Ser	Ile	Thr	Gly	Ser	Asp	Ser	Ile	Asn	Val	Ile	Gly	Asn	290	295	300
Thr	Ser	Gly	Gln	Lys	Gly	Gly	Ala	Ile	Ser	Ala	Ala	Ser	Leu	Lys	Ile	305	310	315
Leu	Gly	Gly	Gln	Gly	Gly	Ala	Leu	Phe	Ser	Asn	Asn	Val	Val	Thr	His	325	330	335
Ala	Thr	Pro	Leu	Gly	Gly	Ala	Ile	Phe	Ile	Asn	Thr	Gly	Gly	Ser	Leu	340	345	350
Gln	Leu	Phe	Thr	Gln	Gly	Gly	Asp	Ile	Val	Phe	Glu	Gly	Asn	Gln	Val	355	360	365
Thr	Thr	Thr	Ala	Pro	Asn	Ala	Thr	Thr	Lys	Arg	Asn	Val	Ile	His	Leu	370	375	380
Glu	Ser	Thr	Ala	Lys	Trp	Thr	Gly	Leu	Ala	Ala	Ser	Gln	Gly	Asn	Ala	385	390	395
Ile	Tyr	Phe	Tyr	Asp	Pro	Ile	Thr	Thr	Asn	Asp	Thr	Gly	Ala	Ser	Asp	405	410	415
Asn	Leu	Arg	Ile	Asn	Glu	Val	Ser	Ala	Asn	Gln	Lys	Leu	Ser	Gly	Ser	420	425	430
Ile	Val	Phe	Ser	Gly	Glu	Arg	Leu	Ser	Thr	Ala	Glu	Ala	Ile	Ala	Glu	435	440	445
Asn	Leu	Thr	Ser	Arg	Ile	Asn	Gln	Pro	Val	Thr	Leu	Val	Glu	Gly	Ser	450	455	460
Leu	Glu	Leu	Lys	Gln	Gly	Val	Thr	Leu	Ile	Thr	Gln	Gly	Phe	Ser	Gln	465	470	475
Glu	Pro	Glu	Ser	Thr	Leu	Leu	Leu	Asp	Leu	Gly	Thr	Ser	Leu	Gln	Ala	485	490	495
Ser	Thr	Glu	Asp	Ile	Val	Ile	Thr	Asn	Ser	Ser	Ile	Asn	Ala	Asp	Thr	500	505	510
Ile	Tyr	Gly	Lys	Asn	Pro	Ile	Asn	Ile	Val	Ala	Ser	Ala	Ala	Asn	Lys	515	520	525
Asn	Ile	Thr	Leu	Thr	Gly	Thr	Leu	Ala	Leu	Val	Asn	Ala	Asp	Gly	Ala	530	535	540
Leu	Tyr	Glu	Asn	His	Thr	Leu	Gln	Asp	Ser	Gln	Asp	Tyr	Ser	Phe	Val	545	550	555
Lys	Leu	Ser	Pro	Gly	Ala	Gly	Gly	Thr	Ile	Ile	Thr	Gln	Asp	Ala	Ser	565	570	575
Gln	Lys	Leu	Leu	Glu	Val	Ala	Pro	Ser	Arg	Pro	His	Tyr	Gly	Tyr	Gln	580	585	590
Gly	His	Trp	Asn	Val	Gln	Val	Ile	Pro	Gly	Thr	Gly	Thr	Gln	Pro	Ser	595	600	605
Gln	Ala	Asn	Leu	Glu	Trp	Val	Arg	Thr	Gly	Tyr	Leu	Pro	Asn	Pro	Glu	610	615	620
Arg	Gln	Gly	Phe	Leu	Val	Pro	Asn	Ser	Leu	Trp	Gly	Ser	Phe	Val	Asp	625	630	635
Gln	Arg	Ala	Ile	Gln	Glu	Ile	Met	Val	Asn	Ser	Ser	Gln	Ile	Leu	Cys	645	650	655
Gln	Glu	Arg	Gly	Val	Trp	Gly	Ala	Gly	Ile	Ala	Asn	Phe	Leu	His	Arg	660	665	670
Asp	Lys	Ile	Asn	Glu	His	Gly	Tyr	Arg	His	Ser	Gly	Val	Gly	Tyr	Leu	675	680	685
Val	Gly	Val	Gly	Thr	His	Ala	Phe	Ser	Asp	Ala	Thr	Ile	Asn	Ala	Ala	690	695	700
Phe	Cys	Gln	Leu	Phe	Ser	Arg	Asp	Lys	Asp	Tyr	Val	Val	Ser	Lys	Asn	705	710	715
His	Gly	Thr	Ser	Tyr	Ser	Gly	Val	Val	Phe	Leu	Glu	Asp	Thr	Leu	Glu	720		

ATCAGGTGAT	AAAAGTTCCT	CGTTAGCTAG	TGACTGTAGG	TGACATGAGA	AAGCTAACAC	60
GGAGGAAACT	AAAACCCAAG	GAATCGAAGT	CTTCATGGTA	ATGCTTTTGT	TTTTTAGAGA	120
ACTATTCGCA	TCAATATAGA	AACAAAATAA	GTAAATCAAG	TTAAAGATGA	CAAAACAGCT	180
GTCAAGAATT	TTTATCTTGA	CTCTCTGAGT	TTTCTATTTT	ATATGACGCA	AGTAAGAATT	240
TAATAATAAA	GTGGGTTT	ATG AAA TCG	CAA TTT TCC	TGG TTA GTG	CTC TCT	291
		Met Lys Ser	Gln Phe Ser	Trp Leu Val	Leu Ser	
		1	5	10		

TCG ACA TTG GCA TGT TTT ACT AGT TGT TCC ACT GTT TTT GCT GCA ACT	339
Ser Thr Leu Ala Cys Phe Thr Ser Cys Ser Thr Val Phe Ala Ala Thr	
15 20 25	
GCT GAA AAT ATA GGC CCC TCT GAT AGC TTT GAC GGA AGT ACT AAC ACA	387
Ala Glu Asn Ile Gly Pro Ser Asp Ser Phe Asp Gly Ser Thr Asn Thr	
30 35 40	
GGC ACC TAT ACT CCT AAA AAT ACG ACT ACT GGA ATA GAC TAT ACT CTG	435
Gly Thr Tyr Thr Pro Lys Asn Thr Thr Thr Gly Ile Asp Tyr Thr Leu	
45 50 55	
ACA GGA GAT ATA ACT CTG CAA AAC CTT GGG GAT TCG GCA GCT TTA ACG	483
Thr Gly Asp Ile Thr Leu Gln Asn Leu Gly Asp Ser Ala Ala Leu Thr	
60 65 70 75	
AAG GGT TGT TTT TCT GAC ACT ACG GAA TCT TTA AGC TTT GCC GGT AAG	531
Lys Gly Cys Phe Ser Asp Thr Thr Glu Ser Leu Ser Phe Ala Gly Lys	
80 85 90	
GGG TAC TCA CTT TCT TTT TTA AAT ATT AAG TCT AGT GCT GAA GGC GCA	579
Gly Tyr Ser Leu Ser Phe Leu Asn Ile Lys Ser Ser Ala Glu Gly Ala	
95 100 105	
GCA CTT TCT GTT ACA ACT GAT AAA AAT CTG TCG CTA ACA GGA TTT TCG	627
Ala Leu Ser Val Thr Thr Asp Lys Asn Leu Ser Leu Thr Gly Phe Ser	
110 115 120	
AGT CTT ACT TTC TTA GCG GCC CCA TCA TCG GTA ATC ACA ACC CCC TCA	675
Ser Leu Thr Phe Leu Ala Ala Pro Ser Ser Val Ile Thr Thr Pro Ser	
125 130 135	
GGA AAA GGT GCA GTT AAA TGT GGA GGG GAT CTT ACA TTT GAT AAC AAT	723
Gly Lys Gly Ala Val Lys Cys Gly Gly Asp Leu Thr Phe Asp Asn Asn	
140 145 150 155	
GGA ACT ATT TTA TTT AAA CAA GAT TAC TGT GAG GAA AAT GGC GGA GCC	771
Gly Thr Ile Leu Phe Lys Gln Asp Tyr Cys Glu Glu Asn Gly Gly Ala	
160 165 170	
ATT TCT ACC AAG AAT CTT TCT TTG AAA AAC AGC ACG GGA TCG ATT TCT	819
Ile Ser Thr Lys Asn Leu Ser Leu Lys Asn Ser Thr Gly Ser Ile Ser	
175 180 185	
TTT GAA GGG AAT AAA TCG AGC GCA ACA GGG AAA AAA GGT GGG GCT ATT	867
Phe Glu Gly Asn Lys Ser Ser Ala Thr Gly Lys Lys Gly Gly Ala Ile	
190 195 200	
TGT GCT ACT GGT ACT GTA GAT ATT ACA AAT AAT ACG GCT CCT ACC CTC	915
Cys Ala Thr Gly Thr Val Asp Ile Thr Asn Asn Thr Ala Pro Thr Leu	
205 210 215	
TTC TCG AAC AAT ATT GCT GAA GCT GCA GGT GGA GCT ATA AAT AGC ACA	963
Phe Ser Asn Asn Ile Ala Glu Ala Ala Gly Gly Ala Ile Asn Ser Thr	
220 225 230 235	
GGA AAC TGT ACA ATT ACA GGG AAT ACG TCT CTT GTA TTT TCT GAA AAT	1011

Gly	Asn	Cys	Thr	Ile	Thr	Gly	Asn	Thr	Ser	Leu	Val	Phe	Ser	Glu	Asn	
				240					245					250		
AGT	GTG	ACA	GCG	ACC	GCA	GGA	AAT	GGA	GGA	GCT	CTT	TCT	GGA	GAT	GCC	1059
Ser	Val	Thr	Ala	Thr	Ala	Gly	Asn	Gly	Gly	Ala	Leu	Ser	Gly	Asp	Ala	
				255				260					265			
GAT	GTT	ACC	ATA	TCT	GGG	AAT	CAG	AGT	GTA	ACT	TTC	TCA	GGA	AAC	CAA	1107
Asp	Val	Thr	Ile	Ser	Gly	Asn	Gln	Ser	Val	Thr	Phe	Ser	Gly	Asn	Gln	
			270				275					280				
GCT	GTA	GCT	AAT	GGC	GGA	GCC	ATT	TAT	GCT	AAG	AAG	CTT	ACA	CTG	GCT	1155
Ala	Val	Ala	Asn	Gly	Gly	Ala	Ile	Tyr	Ala	Lys	Lys	Leu	Thr	Leu	Ala	
			285				290					295				
TCC	GGG	GGG	GGG	GGG	GGT	ATC	TCC	TTT	TCT	AAC	AAT	ATA	GTC	CAA	GGT	1203
Ser	Gly	Gly	Gly	Gly	Gly	Ile	Ser	Phe	Ser	Asn	Asn	Ile	Val	Gln	Gly	
300						305				310					315	
ACC	ACT	GCA	GGT	AAT	GGT	GGA	GCC	ATT	TCT	ATA	CTG	GCA	GCT	GGA	GAG	1251
Thr	Thr	Ala	Gly	Asn	Gly	Gly	Ala	Ile	Ser	Ile	Leu	Ala	Ala	Gly	Glu	
				320					325					330		
TGT	AGT	CTT	TCA	GCA	GAA	GCA	GGG	GAC	ATT	ACC	TTC	AAT	GGG	AAT	GCC	1299
Cys	Ser	Leu	Ser	Ala	Glu	Ala	Gly	Asp	Ile	Thr	Phe	Asn	Gly	Asn	Ala	
				335				340					345			
ATT	GTT	GCA	ACT	ACA	CCA	CAA	ACT	ACA	AAA	AGA	AAT	TCT	ATT	GAC	ATA	1347
Ile	Val	Ala	Thr	Thr	Pro	Gln	Thr	Thr	Lys	Arg	Asn	Ser	Ile	Asp	Ile	
			350				355					360				
GGA	TCT	ACT	GCA	AAG	ATC	ACG	AAT	TTA	CGT	GCA	ATA	TCT	GGG	CAT	AGC	1395
Gly	Ser	Thr	Ala	Lys	Ile	Thr	Asn	Leu	Arg	Ala	Ile	Ser	Gly	His	Ser	
			365				370				375					
ATC	TTT	TTC	TAC	GAT	CCG	ATT	ACT	GCT	AAT	ACG	GCT	GCG	GAT	TCT	ACA	1443
Ile	Phe	Phe	Tyr	Asp	Pro	Ile	Thr	Ala	Asn	Thr	Ala	Ala	Asp	Ser	Thr	
380					385					390					395	
GAT	ACT	TTA	AAT	CTC	AAT	AAG	GCT	GAT	GCA	GGT	AAT	AGT	ACA	GAT	TAT	1491
Asp	Thr	Leu	Asn	Leu	Asn	Lys	Ala	Asp	Ala	Gly	Asn	Ser	Thr	Asp	Tyr	
				400					405					410		
AGT	GGG	TCG	ATT	GTT	TTT	TCT	GGT	GAA	AAG	CTC	TCT	GAA	GAT	GAA	GCA	1539
Ser	Gly	Ser	Ile	Val	Phe	Ser	Gly	Glu	Lys	Leu	Ser	Glu	Asp	Glu	Ala	
			415					420					425			
AAA	GTT	GCA	GAC	AAC	CTC	ACT	TCT	ACG	CTG	AAG	CAG	CCT	GTA	ACT	CTA	1587
Lys	Val	Ala	Asp	Asn	Leu	Thr	Ser	Thr	Leu	Lys	Gln	Pro	Val	Thr	Leu	
			430				435					440				
ACT	GCA	GGA	AAT	TTA	GTA	CTT	AAA	CGT	GGT	GTC	ACT	CTC	GAT	ACG	AAA	1635
Thr	Ala	Gly	Asn	Leu	Val	Leu	Lys	Arg	Gly	Val	Thr	Leu	Asp	Thr	Lys	
			445				450				455					
GGC	TTT	ACT	CAG	ACC	GCG	GGT	TCC	TCT	GTT	ATT	ATG	GAT	GCG	GGC	ACA	1683
Gly	Phe	Thr	Gln	Thr	Ala	Gly	Ser	Ser	Val	Ile	Met	Asp	Ala	Gly	Thr	

460	465	470	475	
ACG TTA AAA GCA AGT ACA GAG GAG GTC ACT TTA ACA GGT CTT TCC ATT				1731
Thr Leu Lys Ala Ser Thr Glu Glu Val Thr Leu Thr Gly Leu Ser Ile	480	485	490	
CCT GTA GAC TCT TTA GGC GAG GGT AAG AAA GTT GTA ATT GCT GCT TCT				1779
Pro Val Asp Ser Leu Gly Glu Gly Lys Lys Val Val Ile Ala Ala Ser	495	500	505	
GCA GCA AGT AAA AAT GTA GCC CTT AGT GGT CCG ATT CTT CTT TTG GAT				1827
Ala Ala Ser Lys Asn Val Ala Leu Ser Gly Pro Ile Leu Leu Leu Asp	510	515	520	
AAC CAA GGG AAT GGT TAT GAA AAT CAC GAC TTA GGA AAA ACT CAA GAC				1875
Asn Gln Gly Asn Ala Tyr Glu Asn His Asp Leu Gly Lys Thr Gln Asp	525	530	535	
TTT TCA TTT GTG CAG CTC TCT GCT CTG GGT ACT GCA ACA ACT ACA GAT				1923
Phe Ser Phe Val Gln Leu Ser Ala Leu Gly Thr Ala Thr Thr Thr Asp	540	545	550	555
GTT CCA GCG GTT CCT ACA GTA GCA ACT CCT ACG CAC TAT GGG TAT CAA				1971
Val Pro Ala Val Pro Thr Val Ala Thr Pro Thr His Tyr Gly Tyr Gln	560	565	570	
GGT ACT TGG GGA ATG ACT TGG GTT GAT GAT ACC GCA AGC ACT CCA AAG				2019
Gly Thr Trp Gly Met Thr Trp Val Asp Asp Thr Ala Ser Thr Pro Lys	575	580	585	
ACT AAG ACA GCG ACA TTA GCT TGG ACC AAT ACA GGC TAC CTT CCG AAT				2067
Thr Lys Thr Ala Thr Leu Ala Trp Thr Asn Thr Gly Tyr Leu Pro Asn	590	595	600	
CCT GAG CGT CAA GGA CCT TTA GTT CCT AAT AGC CTT TGG GGA TCT TTT				2115
Pro Glu Arg Gln Gly Pro Leu Val Pro Asn Ser Leu Trp Gly Ser Phe	605	610	615	
TCA GAC ATC CAA GCG ATT CAA GGT GTC ATA GAG AGA AGT GCT TTG ACT				2163
Ser Asp Ile Gln Ala Ile Gln Gly Val Ile Glu Arg Ser Ala Leu Thr	620	625	630	635
CTT TGT TCA GAT CGA GGC TTC TGG GCT GCG GGA GTC GCC AAT TTC TTA				2211
Leu Cys Ser Asp Arg Gly Phe Trp Ala Ala Gly Val Ala Asn Phe Leu	640	645	650	
GAT AAA GAT AAG AAA GGG GAA AAA CGC AAA TAC CGT CAT AAA TCT GGT				2259
Asp Lys Asp Lys Lys Gly Glu Lys Arg Lys Tyr Arg His Lys Ser Gly	655	660	665	
GGA TAT GCT ATC GGA GGT GCA GCG CAA ACT TGT TCT GAA AAC TTA ATT				2307
Gly Tyr Ala Ile Gly Gly Ala Ala Gln Thr Cys Ser Glu Asn Leu Ile	670	675	680	
AGC TTT GCC TTT TGC CAA CTC TTT GGT AGC GAT AAA GAT TTC TTA GTC				2355
Ser Phe Ala Phe Cys Gln Leu Phe Gly Ser Asp Lys Asp Phe Leu Val	685	690	695	

GCT AAA AAT CAT ACT GAT ACC TAT GCA GGA GCC TTC TAT ATC CAA CAC Ala Lys Asn His Thr Asp Thr Tyr Ala Gly Ala Phe Tyr Ile Gln His 700 705 710 715	2403
ATT ACA GAA TGT AGT GGG TTC ATA GGT TGT CTC TTA GAT AAA CTT CCT Ile Thr Glu Cys Ser Gly Phe Ile Gly Cys Leu Leu Asp Lys Leu Pro 720 725 730	2451
GGC TCT TGG AGT CAT AAA CCC CTC GTT TTA GAA GGG CAG CTC GCT TAT Gly Ser Trp Ser His Lys Pro Leu Val Leu Glu Gly Gln Leu Ala Tyr 735 740 745	2499
AGC CAC GTC AGT AAT GAT CTG AAG ACA AAG TAT ACT GCG TAT CCT GAG Ser His Val Ser Asn Asp Leu Lys Thr Lys Tyr Thr Ala Tyr Pro Glu 750 755 760	2547
GTG AAA GGT TCT TGG GGG AAT AAT GCT TTT AAC ATG ATG TTG GGA GCT Val Lys Gly Ser Trp Gly Asn Asn Ala Phe Asn Met Met Leu Gly Ala 765 770 775	2595
TCT TCT CAT TCT TAT CCT GAA TAC CTG CAT TGT TTT GAT ACC TAT GCT Ser Ser His Ser Tyr Pro Glu Tyr Leu His Cys Phe Asp Thr Tyr Ala 780 785 790 795	2643
CCA TAC ATC AAA CTG AAT CTG ACC TAT ATA CGT CAG GAC AGC TTC TCG Pro Tyr Ile Lys Leu Asn Leu Thr Tyr Ile Arg Gln Asp Ser Phe Ser 800 805 810	2691
GAG AAA GGT ACA GAA GGA AGA TCT TTT GAT GAC AGC AAC CTC TTC AAT Glu Lys Gly Thr Glu Gly Arg Ser Phe Asp Asp Ser Asn Leu Phe Asn 815 820 825	2739
TTA TCT TTG CCT ATA GGG GTG AAG TTT GAG AAG TTC TCT GAT TGT AAT Leu Ser Leu Pro Ile Gly Val Lys Phe Glu Lys Phe Ser Asp Cys Asn 830 835 840	2787
GAC TTT TCT TAT GAT CTG ACT TTA TCC TAT GTT CCT GAT CTT ATC CGC Asp Phe Ser Tyr Asp Leu Thr Leu Ser Tyr Val Pro Asp Leu Ile Arg 845 850 855	2835
AAT GAT CCC AAA TGC ACT ACA GCA CTT GTA ATC AGC GGA GCC TCT TGG Asn Asp Pro Lys Cys Thr Thr Ala Leu Val Ile Ser Gly Ala Ser Trp 860 865 870 875	2883
GAA ACT TAT GCC AAT AAC TTA GCA CGA CAG GCC TTG CAA GTG CGT GCA Glu Thr Tyr Ala Asn Asn Leu Ala Arg Gln Ala Leu Gln Val Arg Ala 880 885 890	2931
GGC AGT CAC TAC GCC TTC TCT CCT ATG TTT GAA GTG CTC GGC CAG TTT Gly Ser His Tyr Ala Phe Ser Pro Met Phe Glu Val Leu Gly Gln Phe 895 900 905	2979
GTC TTT GAA GTT CGT GGA TCC Val Phe Glu Val Arg Gly Ser 910	3000

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 914 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

```

Met Lys Ser Gln Phe Ser Trp Leu Val Leu Ser Ser Thr Leu Ala Cys
 1           5           10           15
Phe Thr Ser Cys Ser Thr Val Phe Ala Ala Thr Ala Glu Asn Ile Gly
      20           25           30
Pro Ser Asp Ser Phe Asp Gly Ser Thr Asn Thr Gly Thr Tyr Thr Pro
      35           40           45
Lys Asn Thr Thr Thr Gly Ile Asp Tyr Thr Leu Thr Gly Asp Ile Thr
      50           55           60
Leu Gln Asn Leu Gly Asp Ser Ala Ala Leu Thr Lys Gly Cys Phe Ser
      65           70           75           80
Asp Thr Thr Glu Ser Leu Ser Phe Ala Gly Lys Gly Tyr Ser Leu Ser
      85           90           95
Phe Leu Asn Ile Lys Ser Ser Ala Glu Gly Ala Ala Leu Ser Val Thr
      100          105          110
Thr Asp Lys Asn Leu Ser Leu Thr Gly Phe Ser Ser Leu Thr Phe Leu
      115          120          125
Ala Ala Pro Ser Ser Val Ile Thr Thr Pro Ser Gly Lys Gly Ala Val
      130          135          140
Lys Cys Gly Gly Asp Leu Thr Phe Asp Asn Asn Gly Thr Ile Leu Phe
      145          150          155          160
Lys Gln Asp Tyr Cys Glu Glu Asn Gly Gly Ala Ile Ser Thr Lys Asn
      165          170          175
Leu Ser Leu Lys Asn Ser Thr Gly Ser Ile Ser Phe Glu Gly Asn Lys
      180          185          190
Ser Ser Ala Thr Gly Lys Lys Gly Gly Ala Ile Cys Ala Thr Gly Thr
      195          200          205
Val Asp Ile Thr Asn Asn Thr Ala Pro Thr Leu Phe Ser Asn Asn Ile
      210          215          220
Ala Glu Ala Ala Gly Gly Ala Ile Asn Ser Thr Gly Asn Cys Thr Ile
      225          230          235          240
Thr Gly Asn Thr Ser Leu Val Phe Ser Glu Asn Ser Val Thr Ala Thr
      245          250          255
Ala Gly Asn Gly Gly Ala Leu Ser Gly Asp Ala Asp Val Thr Ile Ser
      260          265          270
Gly Asn Gln Ser Val Thr Phe Ser Gly Asn Gln Ala Val Ala Asn Gly
      275          280          285
Gly Ala Ile Tyr Ala Lys Lys Leu Thr Leu Ala Ser Gly Gly Gly Gly
      290          295          300
Gly Ile Ser Phe Ser Asn Asn Ile Val Gln Gly Thr Thr Ala Gly Asn
      305          310          315          320
Gly Gly Ala Ile Ser Ile Leu Ala Ala Gly Glu Cys Ser Leu Ser Ala
      325          330          335
Glu Ala Gly Asp Ile Thr Phe Asn Gly Asn Ala Ile Val Ala Thr Thr
      340          345          350

```

Pro Gln Thr Thr Lys Arg Asn Ser Ile Asp Ile Gly Ser Thr Ala Lys
 355 360 365
 Ile Thr Asn Leu Arg Ala Ile Ser Gly His Ser Ile Phe Phe Tyr Asp
 370 375 380
 Pro Ile Thr Ala Asn Thr Ala Ala Asp Ser Thr Asp Thr Leu Asn Leu
 385 390 395 400
 Asn Lys Ala Asp Ala Gly Asn Ser Thr Asp Tyr Ser Gly Ser Ile Val
 405 410 415
 Phe Ser Gly Glu Lys Leu Ser Glu Asp Glu Ala Lys Val Ala Asp Asn
 420 425 430
 Leu Thr Ser Thr Leu Lys Gln Pro Val Thr Leu Thr Ala Gly Asn Leu
 435 440 445
 Val Leu Lys Arg Gly Val Thr Leu Asp Thr Lys Gly Phe Thr Gln Thr
 450 455 460
 Ala Gly Ser Ser Val Ile Met Asp Ala Gly Thr Thr Leu Lys Ala Ser
 465 470 475 480
 Thr Glu Glu Val Thr Leu Thr Gly Leu Ser Ile Pro Val Asp Ser Leu
 485 490 495
 Gly Glu Gly Lys Lys Val Val Ile Ala Ala Ser Ala Ala Ser Lys Asn
 500 505 510
 Val Ala Leu Ser Gly Pro Ile Leu Leu Leu Asp Asn Gln Gly Asn Ala
 515 520 525
 Tyr Glu Asn His Asp Leu Gly Lys Thr Gln Asp Phe Ser Phe Val Gln
 530 535 540
 Leu Ser Ala Leu Gly Thr Ala Thr Thr Thr Asp Val Pro Ala Val Pro
 545 550 555 560
 Thr Val Ala Thr Pro Thr His Tyr Gly Tyr Gln Gly Thr Trp Gly Met
 565 570 575
 Thr Trp Val Asp Asp Thr Ala Ser Thr Pro Lys Thr Lys Thr Ala Thr
 580 585 590
 Leu Ala Trp Thr Asn Thr Gly Tyr Leu Pro Asn Pro Glu Arg Gln Gly
 595 600 605
 Pro Leu Val Pro Asn Ser Leu Trp Gly Ser Phe Ser Asp Ile Gln Ala
 610 615 620
 Ile Gln Gly Val Ile Glu Arg Ser Ala Leu Thr Leu Cys Ser Asp Arg
 625 630 635 640
 Gly Phe Trp Ala Ala Gly Val Ala Asn Phe Leu Asp Lys Asp Lys Lys
 645 650 655
 Gly Glu Lys Arg Lys Tyr Arg His Lys Ser Gly Gly Tyr Ala Ile Gly
 660 665 670
 Gly Ala Ala Gln Thr Cys Ser Glu Asn Leu Ile Ser Phe Ala Phe Cys
 675 680 685
 Gln Leu Phe Gly Ser Asp Lys Asp Phe Leu Val Ala Lys Asn His Thr
 690 695 700
 Asp Thr Tyr Ala Gly Ala Phe Tyr Ile Gln His Ile Thr Glu Cys Ser
 705 710 715 720
 Gly Phe Ile Gly Cys Leu Leu Asp Lys Leu Pro Gly Ser Trp Ser His
 725 730 735
 Lys Pro Leu Val Leu Glu Gly Gln Leu Ala Tyr Ser His Val Ser Asn
 740 745 750
 Asp Leu Lys Thr Lys Tyr Thr Ala Tyr Pro Glu Val Lys Gly Ser Trp
 755 760 765
 Gly Asn Asn Ala Phe Asn Met Met Leu Gly Ala Ser Ser His Ser Tyr
 770 775 780
 Pro Glu Tyr Leu His Cys Phe Asp Thr Tyr Ala Pro Tyr Ile Lys Leu
 785 790 795 800
 Asn Leu Thr Tyr Ile Arg Gln Asp Ser Phe Ser Glu Lys Gly Thr Glu

				805						810					815
Gly	Arg	Ser	Phe	Asp	Asp	Ser	Asn	Leu	Phe	Asn	Leu	Ser	Leu	Pro	Ile
			820					825					830		
Gly	Val	Lys	Phe	Glu	Lys	Phe	Ser	Asp	Cys	Asn	Asp	Phe	Ser	Tyr	Asp
		835						840				845			
Leu	Thr	Leu	Ser	Tyr	Val	Pro	Asp	Leu	Ile	Arg	Asn	Asp	Pro	Lys	Cys
	850						855				860				
Thr	Thr	Ala	Leu	Val	Ile	Ser	Gly	Ala	Ser	Trp	Glu	Thr	Tyr	Ala	Asn
865					870					875				880	
Asn	Leu	Ala	Arg	Gln	Ala	Leu	Gln	Val	Arg	Ala	Gly	Ser	His	Tyr	Ala
			885						890				895		
Phe	Ser	Pro	Met	Phe	Glu	Val	Leu	Gly	Gln	Phe	Val	Phe	Glu	Val	Arg
			900					905					910		
Gly	Ser														

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1200 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION: 1...1200
- (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

GAT CCT AAA AAT AAA GAG TAC ACA GGG ACC ATA CTC TTT TCT GGA GAA	48
Asp Pro Lys Asn Lys Glu Tyr Thr Gly Thr Ile Leu Phe Ser Gly Glu	
1 5 10 15	
AAG AGT CTA GCA AAC GAT CCT AGG GAT TTT AAA TCT ACA ATC CCT CAG	96
Lys Ser Leu Ala Asn Asp Pro Arg Asp Phe Lys Ser Thr Ile Pro Gln	
20 25 30	
AAC GTC AAC CTG TCT GCA GGA TAC TTA GTT ATT AAA GAG GGG GCC GAA	144
Asn Val Asn Leu Ser Ala Gly Tyr Leu Val Ile Lys Glu Gly Ala Glu	
35 40 45	
GTC ACA GTT TCA AAA TTC ACG CAG TCT CCA GGA TCG CAT TTA GTT TTA	192
Val Thr Val Ser Lys Phe Thr Gln Ser Pro Gly Ser His Leu Val Leu	
50 55 60	
GAT TTA GGA ACC AAA CTG ATA GCC TCT AAG GAA GAC ATT GCC ATC ACA	240
Asp Leu Gly Thr Lys Leu Ile Ala Ser Lys Glu Asp Ile Ala Ile Thr	
65 70 75 80	
GGC CTC GCG ATA GAT ATA GAT AGC TTA AGC TCA TCC TCA ACA GCA GCT	288
Gly Leu Ala Ile Asp Ile Asp Ser Leu Ser Ser Ser Ser Thr Ala Ala	
85 90 95	

GTT ATT AAA GCA AAC ACC GCA AAT AAA CAG ATA TCC GTG ACG GAC TCT	336
Val Ile Lys Ala Asn Thr Ala Asn Lys Gln Ile Ser Val Thr Asp Ser	
100 105 110	
ATA GAA CTT ATC TCG CCT ACT GGC AAT GCC TAT GAA GAT CTC AGA ATG	384
Ile Glu Leu Ile Ser Pro Thr Gly Asn Ala Tyr Glu Asp Leu Arg Met	
115 120 125	
AGA AAT TCA CAG ACG TTC CCT CTG CTC TCT TTA GAG CCT GGA GCC GGG	432
Arg Asn Ser Gln Thr Phe Pro Leu Leu Ser Leu Glu Pro Gly Ala Gly	
130 135 140	
GGT AGT GTG ACT GTA ACT GCT GGA GAT TTC CTA CCG GTA AGT CCC CAT	480
Gly Ser Val Thr Val Thr Ala Gly Asp Phe Leu Pro Val Ser Pro His	
145 150 155 160	
TAT GGT TTT CAA GGC AAT TGG AAA TTA GCT TGG ACA GGA ACT GGA AAC	528
Tyr Gly Phe Gln Gly Asn Trp Lys Leu Ala Trp Thr Gly Thr Gly Asn	
165 170 175	
AAA GTT GGA GAA TTC TTC TGG GAT AAA ATA AAT TAT AAG CCT AGA CCT	576
Lys Val Gly Glu Phe Phe Trp Asp Lys Ile Asn Tyr Lys Pro Arg Pro	
180 185 190	
GAA AAA GAA GGA AAT TTA GTT CCT AAT ATC TTG TGG GGG AAT GCT GTA	624
Glu Lys Glu Gly Asn Leu Val Pro Asn Ile Leu Trp Gly Asn Ala Val	
195 200 205	
AAT GTC AGA TCC TTA ATG CAG GTT CAA GAG ACC CAT GCA TCG AGC TTA	672
Asn Val Arg Ser Leu Met Gln Val Gln Glu Thr His Ala Ser Ser Leu	
210 215 220	
CAG ACA GAT CGA GGG CTG TGG ATC GAT GGA ATT GGG AAT TTC TTC CAT	720
Gln Thr Asp Arg Gly Leu Trp Ile Asp Gly Ile Gly Asn Phe Phe His	
225 230 235 240	
GTA TCT GCC TCC GAA GAC AAT ATA AGG TAC CGT CAT AAC AGC GGT GGA	768
Val Ser Ala Ser Glu Asp Asn Ile Arg Tyr Arg His Asn Ser Gly Gly	
245 250 255	
TAT GTT CTA TCT GTA AAT AAT GAG ATC ACA CCT AAG CAC TAT ACT TCG	816
Tyr Val Leu Ser Val Asn Asn Glu Ile Thr Pro Lys His Tyr Thr Ser	
260 265 270	
ATG GCA TTT TCC CAA CTC TTT AGT AGA GAC AAA GAC TAT GCG GTT TCC	864
Met Ala Phe Ser Gln Leu Phe Ser Arg Asp Lys Asp Tyr Ala Val Ser	
275 280 285	
AAC AAC GAA TAC AGA ATG TAT TTA GGA TCG TAT CTC TAT CAA TAT ACA	912
Asn Asn Glu Tyr Arg Met Tyr Leu Gly Ser Tyr Leu Tyr Gln Tyr Thr	
290 295 300	
ACC TCC CTA GGG AAT ATT TTC CGT TAT GCT TCG CGT AAC CCT AAT GTA	960
Thr Ser Leu Gly Asn Ile Phe Arg Tyr Ala Ser Arg Asn Pro Asn Val	
305 310 315 320	
AAC GTC GGG ATT CTC TCA AGA AGG TTT CTT CAA AAT CCT CTT ATG ATT	1008

Asn Val Gly Ile Leu Ser Arg Arg Phe Leu Gln Asn Pro Leu Met Ile	
325 330 335	
TTT CAT TTT TTG TGT GCT TAT GGT CAT GCC ACC AAT GAT ATG AAA ACA	1056
Phe His Phe Leu Cys Ala Tyr Gly His Ala Thr Asn Asp Met Lys Thr	
340 345 350	
GAC TAC GCA AAT TTC CCT ATG GTG AAA AAC AGC TGG AGA AAC AAT TGT	1104
Asp Tyr Ala Asn Phe Pro Met Val Lys Asn Ser Trp Arg Asn Asn Cys	
355 360 365	
TGG GCT ATA AAA TGC GGA GGG AGC ATG CCT CTA TTG GTA TTT GAA AAC	1152
Trp Ala Ile Lys Cys Gly Gly Ser Met Pro Leu Leu Val Phe Glu Asn	
370 375 380	
GGA AAA CTT TTC CAA GGT GCC ATC CCA TTT ATG AAA CTA CAA TTA GTT	1200
Gly Lys Leu Phe Gln Gly Ala Ile Pro Phe Met Lys Leu Gln Leu Val	
385 390 395 400	

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 400 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Asp Pro Lys Asn Lys Glu Tyr Thr Gly Thr Ile Leu Phe Ser Gly Glu	
1 5 10 15	
Lys Ser Leu Ala Asn Asp Pro Arg Asp Phe Lys Ser Thr Ile Pro Gln	
20 25 30	
Asn Val Asn Leu Ser Ala Gly Tyr Leu Val Ile Lys Glu Gly Ala Glu	
35 40 45	
Val Thr Val Ser Lys Phe Thr Gln Ser Pro Gly Ser His Leu Val Leu	
50 55 60	
Asp Leu Gly Thr Lys Leu Ile Ala Ser Lys Glu Asp Ile Ala Ile Thr	
65 70 75 80	
Gly Leu Ala Ile Asp Ile Asp Ser Leu Ser Ser Ser Ser Thr Ala Ala	
85 90 95	
Val Ile Lys Ala Asn Thr Ala Asn Lys Gln Ile Ser Val Thr Asp Ser	
100 105 110	
Ile Glu Leu Ile Ser Pro Thr Gly Asn Ala Tyr Glu Asp Leu Arg Met	
115 120 125	
Arg Asn Ser Gln Thr Phe Pro Leu Leu Ser Leu Glu Pro Gly Ala Gly	
130 135 140	
Gly Ser Val Thr Val Thr Ala Gly Asp Phe Leu Pro Val Ser Pro His	
145 150 155 160	
Tyr Gly Phe Gln Gly Asn Trp Lys Leu Ala Trp Thr Gly Thr Gly Asn	
165 170 175	
Lys Val Gly Glu Phe Phe Trp Asp Lys Ile Asn Tyr Lys Pro Arg Pro	
180 185 190	

Glu Lys Glu Gly Asn Leu Val Pro Asn Ile Leu Trp Gly Asn Ala Val
 195 200 205
 Asn Val Arg Ser Leu Met Gln Val Gln Glu Thr His Ala Ser Ser Leu
 210 215 220
 Gln Thr Asp Arg Gly Leu Trp Ile Asp Gly Ile Gly Asn Phe Phe His
 225 230 235 240
 Val Ser Ala Ser Glu Asp Asn Ile Arg Tyr Arg His Asn Ser Gly Gly
 245 250 255
 Tyr Val Leu Ser Val Asn Asn Glu Ile Thr Pro Lys His Tyr Thr Ser
 260 265 270
 Met Ala Phe Ser Gln Leu Phe Ser Arg Asp Lys Asp Tyr Ala Val Ser
 275 280 285
 Asn Asn Glu Tyr Arg Met Tyr Leu Gly Ser Tyr Leu Tyr Gln Tyr Thr
 290 295 300
 Thr Ser Leu Gly Asn Ile Phe Arg Tyr Ala Ser Arg Asn Pro Asn Val
 305 310 315 320
 Asn Val Gly Ile Leu Ser Arg Arg Phe Leu Gln Asn Pro Leu Met Ile
 325 330 335
 Phe His Phe Leu Cys Ala Tyr Gly His Ala Thr Asn Asp Met Lys Thr
 340 345 350
 Asp Tyr Ala Asn Phe Pro Met Val Lys Asn Ser Trp Arg Asn Asn Cys
 355 360 365
 Trp Ala Ile Lys Cys Gly Gly Ser Met Pro Leu Leu Val Phe Glu Asn
 370 375 380
 Gly Lys Leu Phe Gln Gly Ala Ile Pro Phe Met Lys Leu Gln Leu Val
 385 390 395 400

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1830 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
 (B) LOCATION: 1...1830
 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GAT CTC ACA TTA GGG AGT CGT GAC AGT TAT AAT GGT GAT ACA AGC ACC	48
Asp Leu Thr Leu Gly Ser Arg Asp Ser Tyr Asn Gly Asp Thr Ser Thr	
1 5 10 15	
ACA GAA TTT ACT CCT AAA GCG GCA ACT TCT GAT GCT AGT GGC ACG ACC	96
Thr Glu Phe Thr Pro Lys Ala Ala Thr Ser Asp Ala Ser Gly Thr Thr	
20 25 30	
TAT ATT CTC GAT GGG GAT GTC TCG ATA AGC CAA GCA GGG AAA CAA ACG	144
Tyr Ile Leu Asp Gly Asp Val Ser Ile Ser Gln Ala Gly Lys Gln Thr	
35 40 45	

AGC	TTA	ACC	ACA	AGT	TGT	TTT	TCT	AAC	ACT	GCA	GGA	AAT	CTT	ACC	TTC	192
Ser	Leu	Thr	Thr	Ser	Cys	Phe	Ser	Asn	Thr	Ala	Gly	Asn	Leu	Thr	Phe	
50						55					60					
TTA	GGG	AAC	GGA	TTT	TCT	CTT	CAT	TTT	GAC	AAT	ATT	ATT	TCG	TCT	ACT	240
Leu	Gly	Asn	Gly	Phe	Ser	Leu	His	Phe	Asp	Asn	Ile	Ile	Ser	Ser	Thr	
65					70				75						80	
GTT	GCA	GGT	GTT	GTT	GTT	AGC	AAT	ACA	GCA	GCT	TCT	GGG	ATT	ACG	AAA	288
Val	Ala	Gly	Val	Val	Val	Ser	Asn	Thr	Ala	Ala	Ser	Gly	Ile	Thr	Lys	
				85					90					95		
TTC	TCA	GGA	TTT	TCA	ACT	CTT	CGG	ATG	CTT	GCA	GCT	CCT	AGG	ACC	ACA	336
Phe	Ser	Gly	Phe	Ser	Thr	Leu	Arg	Met	Leu	Ala	Ala	Pro	Arg	Thr	Thr	
			100					105					110			
GGT	AAA	GGA	GCC	ATT	AAA	ATT	ACC	GAT	GGT	CTG	GTG	TTT	GAG	AGT	ATA	384
Gly	Lys	Gly	Ala	Ile	Lys	Ile	Thr	Asp	Gly	Leu	Val	Phe	Glu	Ser	Ile	
	115						120					125				
GGG	AAT	CTT	GAT	CCG	ATT	ACT	GTA	ACA	GGA	TCG	ACA	TCT	GTT	GCT	GAT	432
Gly	Asn	Leu	Asp	Pro	Ile	Thr	Val	Thr	Gly	Ser	Thr	Ser	Val	Ala	Asp	
	130					135					140					
GCT	CTC	AAT	ATT	AAT	AGC	CCT	GAT	ACT	GGA	GAT	AAC	AAA	GAG	TAT	ACG	480
Ala	Leu	Asn	Ile	Asn	Ser	Pro	Asp	Thr	Gly	Asp	Asn	Lys	Glu	Tyr	Thr	
145					150					155					160	
GGA	ACC	ATA	GTC	TTT	TCT	GGA	GAG	AAG	CTC	ACG	GAG	GCA	GAA	GCT	AAA	528
Gly	Thr	Ile	Val	Phe	Ser	Gly	Glu	Lys	Leu	Thr	Glu	Ala	Glu	Ala	Lys	
				165					170					175		
GAT	GAG	AAG	AAC	CGC	ACT	TCT	AAA	TTA	CTT	CAA	AAT	GTT	GCT	TTT	AAA	576
Asp	Glu	Lys	Asn	Arg	Thr	Ser	Lys	Leu	Leu	Gln	Asn	Val	Ala	Phe	Lys	
			180					185					190			
AAT	GGG	ACT	GTA	GTT	TTA	AAA	GGT	GAT	GTC	GTT	TTA	AGT	GCG	AAC	GGT	624
Asn	Gly	Thr	Val	Val	Leu	Lys	Gly	Asp	Val	Val	Leu	Ser	Ala	Asn	Gly	
	195					200						205				
TTC	TCT	CAG	GAT	GCA	AAC	TCT	AAG	TTG	ATT	ATG	GAT	TTA	GGG	ACG	TCG	672
Phe	Ser	Gln	Asp	Ala	Asn	Ser	Lys	Leu	Ile	Met	Asp	Leu	Gly	Thr	Ser	
	210					215					220					
TTG	GTT	GCA	AAC	ACC	GAA	AGT	ATC	GAG	TTA	ACG	AAT	TTG	GAA	ATT	AAT	720
Leu	Val	Ala	Asn	Thr	Glu	Ser	Ile	Glu	Leu	Thr	Asn	Leu	Glu	Ile	Asn	
225					230					235					240	
ATA	GAC	TCT	CTC	AGG	AAC	GGG	AAA	AAG	ATA	AAA	CTC	AGT	GCT	GCC	ACA	768
Ile	Asp	Ser	Leu	Arg	Asn	Gly	Lys	Lys	Ile	Lys	Leu	Ser	Ala	Ala	Thr	
				245					250					255		
GCT	CAG	AAA	GAT	ATT	CGT	ATA	GAT	CGT	CCT	GTT	GTA	CTG	GCA	ATT	AGC	816
Ala	Gln	Lys	Asp	Ile	Arg	Ile	Asp	Arg	Pro	Val	Val	Leu	Ala	Ile	Ser	
			260				265					270				
GAT	GAG	AGT	TTT	TAT	CAA	AAT	GGC	TTT	TTG	AAT	GAG	GAC	CAT	TCC	TAT	864

Asp	Glu	Ser	Phe	Tyr	Gln	Asn	Gly	Phe	Leu	Asn	Glu	Asp	His	Ser	Tyr	
	275						280					285				
GAT	GGG	ATT	CTT	GAG	TTA	GAT	GCT	GGG	AAA	GAC	ATC	GTG	ATT	TCT	GCA	912
Asp	Gly	Ile	Leu	Glu	Leu	Asp	Ala	Gly	Lys	Asp	Ile	Val	Ile	Ser	Ala	
	290					295				300						
GAT	TCT	CGC	AGT	ATA	GAT	GCT	GTA	CAA	TCT	CCG	TAT	GGC	TAT	CAG	GGA	960
Asp	Ser	Arg	Ser	Ile	Asp	Ala	Val	Gln	Ser	Pro	Tyr	Gly	Tyr	Gln	Gly	
305					310					315					320	
AAG	TGG	ACG	ATC	AAT	TGG	TCT	ACT	GAT	GAT	AAG	AAA	GCT	ACG	GTT	TCT	1008
Lys	Trp	Thr	Ile	Asn	Trp	Ser	Thr	Asp	Asp	Lys	Lys	Ala	Thr	Val	Ser	
				325					330					335		
TGG	GCG	AAG	CAG	AGT	TTT	AAT	CCC	ACT	GCT	GAG	CAG	GAG	GCT	CCG	TTA	1056
Trp	Ala	Lys	Gln	Ser	Phe	Asn	Pro	Thr	Ala	Glu	Gln	Glu	Ala	Pro	Leu	
			340					345					350			
GTT	CCT	AAT	CTT	CTT	TGG	GGT	TCT	TTT	ATA	GAT	GTT	CGT	TCC	TTC	CAG	1104
Val	Pro	Asn	Leu	Leu	Trp	Gly	Ser	Phe	Ile	Asp	Val	Arg	Ser	Phe	Gln	
		355					360					365				
AAT	TTT	ATA	GAG	CTA	GGT	ACT	GAA	GGT	GCT	CCT	TAC	GAA	AAG	AGA	TTT	1152
Asn	Phe	Ile	Glu	Leu	Gly	Thr	Glu	Gly	Ala	Pro	Tyr	Glu	Lys	Arg	Phe	
	370					375					380					
TGG	GTT	GCA	GGC	ATT	TCC	AAT	GTT	TTG	CAT	AGG	AGC	GGT	CGT	GAA	AAT	1200
Trp	Val	Ala	Gly	Ile	Ser	Asn	Val	Leu	His	Arg	Ser	Gly	Arg	Glu	Asn	
385					390					395					400	
CAA	AGG	AAA	TTC	CGT	CAT	GTG	AGT	GGA	GGT	GCT	GTA	GTA	GGT	GCT	AGC	1248
Gln	Arg	Lys	Phe	Arg	His	Val	Ser	Gly	Gly	Ala	Val	Val	Gly	Ala	Ser	
				405					410					415		
ACG	AGG	ATG	CCG	GGT	GGT	GAT	ACC	TTG	TCT	CTG	GGT	TTT	GCT	CAG	CTC	1296
Thr	Arg	Met	Pro	Gly	Gly	Asp	Thr	Leu	Ser	Leu	Gly	Phe	Ala	Gln	Leu	
			420					425					430			
TTT	GCG	CGT	GAC	AAA	GAC	TAC	TTT	ATG	AAT	ACC	AAT	TTC	GCA	AAG	ACC	1344
Phe	Ala	Arg	Asp	Lys	Asp	Tyr	Phe	Met	Asn	Thr	Asn	Phe	Ala	Lys	Thr	
		435					440					445				
TAC	GCA	GGA	TCT	TTA	CGT	TTG	CAG	CAC	GAT	GCT	TCC	CTA	TAC	TCT	GTG	1392
Tyr	Ala	Gly	Ser	Leu	Arg	Leu	Gln	His	Asp	Ala	Ser	Leu	Tyr	Ser	Val	
	450					455					460					
GTG	AGT	ATC	CTT	TTA	GGA	GAG	GGA	GGA	CTC	CGC	GAG	ATC	CTG	TTG	CCT	1440
Val	Ser	Ile	Leu	Leu	Gly	Glu	Gly	Gly	Leu	Arg	Glu	Ile	Leu	Leu	Pro	
465					470					475					480	
TAT	GTT	TCC	AAT	ACT	CTG	CCG	TGC	TCT	TTC	TAT	GGG	CAG	CTT	AGC	TAC	1488
Tyr	Val	Ser	Asn	Thr	Leu	Pro	Cys	Ser	Phe	Tyr	Gly	Gln	Leu	Ser	Tyr	
				485					490					495		
GGC	CAT	ACG	GAT	CAT	CGC	ATG	AAG	ACC	GAG	TCT	CTA	CCC	CCC	CCC	CCC	1536
Gly	His	Thr	Asp	His	Arg	Met	Lys	Thr	Glu	Ser	Leu	Pro	Pro	Pro	Pro	

500	505	510	
CCG ACG CTC TCG ACG GAT CAT ACT TCT TGG GGA GGA TAT GTC TGG GCT			1584
Pro Thr Leu Ser Thr Asp His Thr Ser Trp Gly Gly Tyr Val Trp Ala			
515	520	525	
GGA GAG CTG GGA ACT CGA GTT GCT GTT GAA AAT ACC AGC GGC AGA GGA			1632
Gly Glu Leu Gly Thr Arg Val Ala Val Glu Asn Thr Ser Gly Arg Gly			
530	535	540	
TTT TTC CGA GAG TAC ACT CCA TTT GTA AAA GTC CAA GCT GTT TAC TCG			1680
Phe Phe Arg Glu Tyr Thr Pro Phe Val Lys Val Gln Ala Val Tyr Ser			
545	550	555	560
CGC CAA GAT AGC TTT GTT GAA CTA GGA GCT ATC AGT CGT GAT TTT AGT			1728
Arg Gln Asp Ser Phe Val Glu Leu Gly Ala Ile Ser Arg Asp Phe Ser			
565	570	575	
GAT TCG CAT CTT TAT AAC CTT GCG ATT CCT CTT GGA ATC AAG TTA GAG			1776
Asp Ser His Leu Tyr Asn Leu Ala Ile Pro Leu Gly Ile Lys Leu Glu			
580	585	590	
AAA CGG TTT GCA GAG CAA TAT TAT CAT GTT GTT GCG ATG TAT TCT CCA			1824
Lys Arg Phe Ala Glu Gln Tyr Tyr His Val Val Ala Met Tyr Ser Pro			
595	600	605	
GAT GTT			1830
Asp Val			
610			

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 610 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

```

Asp Leu Thr Leu Gly Ser Arg Asp Ser Tyr Asn Gly Asp Thr Ser Thr
 1           5           10           15
Thr Glu Phe Thr Pro Lys Ala Ala Thr Ser Asp Ala Ser Gly Thr Thr
 20           25           30
Tyr Ile Leu Asp Gly Asp Val Ser Ile Ser Gln Ala Gly Lys Gln Thr
 35           40           45
Ser Leu Thr Thr Ser Cys Phe Ser Asn Thr Ala Gly Asn Leu Thr Phe
 50           55           60
Leu Gly Asn Gly Phe Ser Leu His Phe Asp Asn Ile Ile Ser Ser Thr
 65           70           75           80
Val Ala Gly Val Val Val Ser Asn Thr Ala Ala Ser Gly Ile Thr Lys
 85           90           95
Phe Ser Gly Phe Ser Thr Leu Arg Met Leu Ala Ala Pro Arg Thr Thr

```

[illegible]

Arg Gln Asp Ser Phe Val Glu Leu Gly Ala Ile Ser Arg Asp Phe Ser
565 570 575
Asp Ser His Leu Tyr Asn Leu Ala Ile Pro Leu Gly Ile Lys Leu Glu
580 585 590
Lys Arg Phe Ala Glu Gln Tyr Tyr His Val Val Ala Met Tyr Ser Pro
595 600 605
Asp Val
610

Claims

1. Species specific diagnostic test for identifying infection of a mammal, such as a human, with *Chlamydia pneumoniae*, said test comprising detecting in a patient or in
5 a patient sample the presence of antibodies against one or more proteins from the outer membrane of *Chlamydia pneumoniae*, said proteins being of a molecular weight of 100.3-89.6 kDa or of 56.1 kDa, or detecting the presence of nucleic acid fragments encoding said outer membrane proteins.
- 10 2. Diagnostic test according to claim 1, wherein the outer membrane protein has the sequence as shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, or in SEQ ID NO: 24, or a variant
15 or subsequence thereof.
3. Diagnostic test according to claim 1, wherein the nucleic acid fragment has the sequence shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO:
20 19, SEQ ID NO: 21, or in SEQ ID NO: 23, or a variant or subsequence thereof.
4. Diagnostic test according to claim 3 wherein detection of nucleic acid fragments is obtained by using nucleic acid amplification.
- 25 5. Diagnostic test according to claim 4, wherein detection of nucleic acid fragments is obtained by using polymerase chain reaction.
6. A nucleic acid fragment derived from *Chlamydia pneumoniae* comprising the nucleotide sequence SEQ ID NO: 1, SEQ ID NO:
30 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23, or a variant or subsequence

of said nucleotide sequence which has a sequence homology of at least 50% with any of the sequences mentioned.

7. A protein derived from *Chlamydia pneumoniae* having the amino acid sequence shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, or SEQ ID NO: 24, or a variant or subsequence thereof having a sequence similarity of at least 50% and a similar biological function.
8. Polyclonal monospecific antibody against the protein with the sequence shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, or SEQ ID NO: 24, or a variant or subsequence thereof.
9. A diagnostic kit for the diagnosis of infection of a mammal, such as a human, with *Chlamydia pneumoniae*, said kit comprising a protein with the amino acid sequence SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, or SEQ ID NO: 24, or a variant or subsequence thereof.
10. A diagnostic kit for the diagnosis of infection of a mammal, such as a human, with *Chlamydia pneumoniae*, said kit comprising antibodies against a protein with the amino acid sequence SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, or SEQ ID NO: 24, or a variant or subsequence thereof.
11. A diagnostic kit for the diagnosis of infection of a mammal, such as a human, with *Chlamydia pneumoniae*, said kit comprising a nucleic acid fragment with the sequence SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO:

17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23, or a variant or subsequence thereof.

12. A composition for immunizing a mammal, such as a human, against *Chlamydia pneumoniae*, said composition
- 5 comprising a protein with the amino acid sequence shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, or SEQ ID NO: 24, or a variant or subsequence thereof.
- 10 13. Use of a protein with the sequence shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, or SEQ ID NO: 24, or a variant or subsequence thereof in diagnosis of infection of a
- 15 mammal, such as a human, with *Chlamydia pneumoniae*.
14. Use of the protein with the sequence shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, or SEQ ID NO: 24 or a
- 20 variant or subsequence thereof in an undenatured form, in diagnosis of infection of a mammal, such as a human, with *Chlamydia pneumoniae*.
15. Use of a protein with the sequence shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, or SEQ ID NO: 24, or a variant or subsequence thereof, for immunizing a mammal, such as a human, against *Chlamydia pneumoniae*.
- 25 16. Use of the protein with the sequence shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, or SEQ ID NO: 24, or a variant or subsequence thereof in an undenatured form, for
- 30

immunizing a mammal, such as a human, against *Chlamydia pneumoniae*.

17. Use of a nucleic acid fragment with the nucleotide sequence shown in SEQ ID NO: 1 SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23, or a variant or subsequence of said nucleotide sequence which has a sequence homology of at least 50% with any of the sequences mentioned for immunizing a mammal, such as a human, against *Chlamydia pneumoniae*.

1/21




Fig. 1

2/21




Fig. 2

3/21




Fig. 3

4/21




Fig. 4

5/21




Fig. 5

6/21





Fig. 6

7/21

C. pneumoniae omp4-15 gene clusters**Fig. 7**

8/21

[illegible][illegible]

Fig. 8A

9/21

[illegible][illegible]

Fig. 8B

13/21

omp12
 omp8
 omp5
 omp9
 omp11
 omp10
 omp4
 omp15
 omp6
 omp7
 omp13
 omp14

[illegible]

Fig. 8F

14/21

0	590	591	586	592	591	583	610	493	576	495	262		0	640	641	636	642	641	633	660	543	626	514	262
omp12	omp8	omp5	omp9	omp11	omp10	omp4	omp15	omp7	omp6	omp13	omp14		omp12	omp8	omp5	omp9	omp11	omp10	omp4	omp15	omp7	omp6	omp13	omp14
-	K	A	S	A	L	G	T	A	A	-	-	-	-	T	F	N	A	W	T	T	L	A	W	T
-	S	A	L	G	T	A	A	-	-	-	-	-	-	T	F	N	A	W	T	T	L	A	W	T
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A	D	V	D	A
-	T	V	D	A	D	V	D	A	D	V	D</													

Fig. 8G.

15/21

[illegible][illegible]

Fig. 8H

16/21

129	177
778	826
778	826
769	818
779	828
776	826
777	826
796	844
692	741
771	820
514	514
262	262

Fig. 81

17/21

[illegible]

omp12	277	Y	G	F	T	N	L	A	R	Q	G	F	S	V	R	A	G	S	N	H	F	E	A	I	F	G	Q	F	A	F	E	V	L	S	G	E	A	A	S	S	R	N	Y	N	T	N	L	G	A	G	K	F	277	
omp8	926	A	T	T	Y	A	N	L	A	R	Q	A	L	S	V	R	A	G	S	N	H	F	E	A	I	F	G	Q	F	A	F	E	V	L	S	G	E	A	A	S	S	R	N	Y	N	T	N	L	G	A	G	K	F	926
omp5	926	A	T	T	Y	A	N	L	A	R	Q	A	L	S	V	R	A	G	S	N	H	F	E	A	I	F	G	Q	F	A	F	E	V	L	S	G	E	A	A	S	S	R	N	Y	N	T	N	L	G	A	G	K	F	926
omp9	916	A	T	T	Y	A	N	L	A	R	Q	A	L	S	V	R	A	G	S	N	H	F	E	A	I	F	G	Q	F	A	F	E	V	L	S	G	E	A	A	S	S	R	N	Y	N	T	N	L	G	A	G	K	F	916
omp11	928	A	T	T	Y	A	N	L	A	R	Q	A	L	S	V	R	A	G	S	N	H	F	E	A	I	F	G	Q	F	A	F	E	V	L	S	G	E	A	A	S	S	R	N	Y	N	T	N	L	G	A	G	K	F	928
omp10	926	A	T	T	Y	A	N	L	A	R	Q	A	L	S	V	R	A	G	S	N	H	F	E	A	I	F	G	Q	F	A	F	E	V	L	S	G	E	A	A	S	S	R	N	Y	N	T	N	L	G	A	G	K	F	926
omp4	926	A	T	T	Y	A	N	L	A	R	Q	A	L	S	V	R	A	G	S	N	H	F	E	A	I	F	G	Q	F	A	F	E	V	L	S	G	E	A	A	S	S	R	N	Y	N	T	N	L	G	A	G	K	F	926
omp15	943	A	T	T	Y	A	N	L	A	R	Q	A	L	S	V	R	A	G	S	N	H	F	E	A	I	F	G	Q	F	A	F	E	V	L	S	G	E	A	A	S	S	R	N	Y	N	T	N	L	G	A	G	K	F	943
omp7	839	A	T	T	Y	A	N	L	A	R	Q	A	L	S	V	R	A	G	S	N	H	F	E	A	I	F	G	Q	F	A	F	E	V	L	S	G	E	A	A	S	S	R	N	Y	N	T	N	L	G	A	G	K	F	839
omp6	920	A	T	T	Y	A	N	L	A	R	Q	A	L	S	V	R	A	G	S	N	H	F	E	A	I	F	G	Q	F	A	F	E	V	L	S	G	E	A	A	S	S	R	N	Y	N	T	N	L	G	A	G	K	F	920
omp13	514	A	T	T	Y	A	N	L	A	R	Q	A	L	S	V	R	A	G	S	N	H	F	E	A	I	F	G	Q	F	A	F	E	V	L	S	G	E	A	A	S	S	R	N	Y	N	T	N	L	G	A	G	K	F	514
omp14	262	A	T	T	Y	A	N	L	A	R	Q	A	L	S	V	R	A	G	S	N	H	F	E	A	I	F	G	Q	F	A	F	E	V	L	S	G	E	A	A	S	S	R	N	Y	N	T	N	L	G	A	G	K	F	262

omp12	C	F	-	279
omp8	Q	F	-	928
omp5	Q	F	-	928
omp9	G	F	-	918
omp11	S	F	-	930
omp10	Q	F	-	928
omp4	R	F	-	928
omp15	R	F	-	945
omp7	K	F	-	841
omp6	R	F	-	922
omp13	-	-	-	514
omp14	-	-	-	262

Fig. 8J

18/21





Fig. 9

19/21



Immunoblotting of *C. pneumoniae* EB, lane 1-3 heated to 100°C in SDS-sample buffer, lane 4-6 unheated. Lane 1 reacted with rabbit anti *C. pneumoniae* OMC; lane 2 and 4 pre-serum; lane 3 and 5 polyclonal rabbit anti pEX1-1 fusion protein; lane 6 MAb 26.1.

Fig. 10

20/21




Fig. 11

21/21




Fig. 12